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Abstract 
Respiratory disease is the most common cause of both acute and chronic illness 
in children.  Optimal management of respiratory disease relies on accurate 
assessment of disease severity and response to interventions.  Current 
measures of pulmonary function are both unsuited to use in pre-school age 
children as well as poorly representing the range of pathophysiological changes 
occurring across the spectrum of lung diseases in children.  Electromyography 
of the parasternal intercostal muscles (EMGpara), as a marker of respiratory 
system load-capacity balance, may represent a novel, effort-independent 
method for assessment of respiratory disease in paediatric populations.   
 
The studies within this thesis assessed the application of EMGpara in evaluating 
response to clinical interventions in children with asthma and cystic fibrosis, as 
well as obtaining values of EMGpara values in healthy children, and comparing 
these measures of EMGpara to those obtained in the children with respiratory 
disease.  This thesis also further investigated the relationship between EMGpara 
and conventional measures of pulmonary function in both adult and paediatric 
subjects. 
 
Reductions in EMGpara activity were demonstrated following administration of 
bronchodilator in children with asthma, and with resolution of an infective 
exacerbation in children hospitalised for an acute exacerbation of cystic fibrosis 
lung disease.  Data from a large cohort of healthy children, as well as 
highlighting technical and developmental considerations relevant to clinical 
application of the EMGpara technique, also demonstrated higher levels of EMGpara 
in children with respiratory disease compared to healthy controls.  The absence 
of statistically significant correlations between EMGpara and standard pulmonary 
function variables from the studies conducted in both children with respiratory 
disease and in adult subjects undergoing incremental induced 
bronchoconstriction indicated the complex, multifactorial relationship between 
respiratory muscle activity and pulmonary function.  While EMGpara cannot be 
viewed as a substitute for conventional lung function techniques, the data from 
 5 
the studies contained within this thesis support further investigation and 
development of this novel method to assess of respiratory disease. 
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1. Chapter One: Introduction 
 
Chronic respiratory disease in childhood places a significant burden on 
healthcare systems both in the United Kingdom and internationally.  Optimal 
management of respiratory disease requires clinicians to be able to accurately 
assess disease severity, progression and response to treatment.  Current routine 
measures of pulmonary function such as spirometry require volitional 
manoeuvres from the subject and are therefore inappropriate for use in 
younger age groups.  Even in older age groups able to comply with the complex 
manoeuvres required, such tests also only assess individual aspects of 
respiratory function and may therefore underestimate the full impact of the 
range of pathophysiological changes.  Airway narrowing, distal airways collapse, 
hyperinflation and alterations in respiratory pattern serve not only to increase 
the respiratory load but also to decrease the capacity of the respiratory muscles, 
reducing their ability to respond to this load.  Electromyographic measurement 
of parasternal intercostal muscle (EMGpara) activity provides both a marker of 
load on the respiratory muscles as well as an index of capacity and therefore 
offers a potential non-invasive, effort-independent method to assess the 
respiratory load-capacity balance. 
 
1.1 Respiratory disease in childhood 
 
Respiratory disease is the most common cause of both acute and chronic illness 
in children in the United Kingdom, accounting for 14% of all hospital consultant 
appointments and 42% of all inpatient admissions [1].  While the majority of 
acute episodes of respiratory illness will resolve spontaneously with no long-
lasting effects [2], chronic disease places a substantial burden on healthcare 
systems worldwide and results in significant morbidity.  It is also well 
recognised that much of the burden of disease later in life has its origins in early 
childhood [3-6].  This thesis will examine the performance of a novel measure of 
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disease severity and control in three common lung diseases of childhood, 
namely asthma, pre-school wheeze and cystic fibrosis. 
 
1.1.1 Childhood asthma 
Asthma is the most common chronic disease in childhood, and the leading cause 
of morbidity in children [7].  Asthma is responsible for a significant burden on 
both primary and secondary care worldwide, and in many countries the 
prevalence is rising [7-9].  Asthma is characterised by the presence of increased 
airway smooth muscle activity and chronic airway inflammation, resulting in 
airway epithelial swelling, mucous hypersecretion, and airways obstruction. 
 
The diagnosis of asthma in children is principally clinical, and there exists no 
standardised definition of the type, severity or frequency of symptoms, nor of 
the investigative findings necessary for a formal diagnosis [10].  Nonetheless, 
there are common features to all definitions, namely the presence of more than 
one of wheezing, chest tightness, cough and breathlessness or difficulty 
breathing, as well as of variable airflow obstruction and bronchial 
hyperresponsiveness [7-9, 11, 12]. 
 
In older children, a detailed clinical history directly from the patient can 
ascertain the presence, frequency and severity of the symptoms of asthma.  In 
younger children, however, this is more challenging and relies on parental 
report.  Although cough can easily be noted by a caregiver, wheeze is commonly 
used by parents to describe any of a range of abnormal respiratory sounds, and 
thus the use of parent-reported wheeze may be poorly specific for asthma.  
Chest tightness and breathlessness are subjective sensations and obtaining an 
accurate indication of the presence of these symptoms is challenging in younger 
children [13]. 
 
Determining the presence of variable airflow obstruction requires objective 
assessment of pulmonary function.  In children over the age of five, spirometry 
or peak expiratory flow can be used to assess presence, severity, variability and 
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reversibility of airflow obstruction [11, 14], and consequently assist in diagnosis 
and guide treatment decisions.  International guidelines recognise that there 
may be little opportunity to obtain such measures in children under the age of 
five [7, 8, 11].  Management recommendations for children in this age group are 
therefore based on analysis of the probability of the child having asthma, taking 
into account factors such as family history, age, sex and presence or absence of 
atopy.  Suggested treatment options include either “watchful waiting”, which 
may result in delayed treatment for children later shown to be asthmatic, or a 
trial of treatment, which risks exposing children without asthma to the potential 
side effects of medication [10, 11]. 
 
1.1.2 Pre-school wheeze 
 
In the pre-school age group, recurrent wheeze is a commonly reported problem 
with a wide spectrum of presentations and proposed aetiologies.  Various large 
birth cohort studies have attempted to classify wheezing phenotypes.  Between 
three and six phenotypes of wheezing illness [15-19] have been identified based 
on factors such as coexisting conditions (such as atopy, allergic rhinitis and 
eczema), family history, age at onset and frequency and severity of symptoms.  
In practice, however, classification into these phenotypes is dependent on the 
child’s long-term outcome and hence can only be assigned retrospectively, 
making their clinical utility extremely limited.  In order to address this, the 
European Respiratory Society (ERS) Task Force on pre-school wheeze has 
proposed a symptom-based classification, which divides wheezing illnesses in 
this age group into two categories: episodic viral wheeze, occurring only with 
viral respiratory infections and with no interval symptoms, and multiple trigger 
wheeze, whereby triggers such as allergens, tobacco smoke and exercise, as well 
as viral illness, may result in wheeze [20].  While there is evidence that this 
classification is useful in predicting treatment response [13], it has been 
criticised due to the lack of evidence that these two phenotypes truly represent 
different pathological processes or result in different outcomes; indeed children 
have been shown to exhibit both phenotypes within a time course as short as 
one year [21].  It has also been noted that the absence of reliable objective 
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markers of pulmonary function for use in this age group may contribute to the 
difficulty in classifying wheezing phenotypes [13].  Due to the complexity of 
identifying aetiologies and subtypes of wheezing illness, the phrase “pre-school 
wheeze” will be used in this thesis to denote any chronic wheezing illness 
occurring in children under the age of five years.  
 
1.1.3 Cystic fibrosis 
 
Cystic fibrosis (CF) is the most common life-threatening inherited disease in the 
United Kingdom.  CF is caused by mutations in the CF transmembrane 
conductance regulator gene, resulting in disruption of sodium and chloride 
channels in secretory epithelial cells [22].  This causes multisystem dysfunction, 
including pancreatic insufficiency, liver disease, poor gut motility, elevated 
sweat electrolytes, and highly viscous mucous in the lungs.  The increased 
viscosity of pulmonary secretions leads to a tendency to pulmonary infections, 
resulting in a vicious cycle of endobronchial infection and concomitant 
inflammation of the small airways [23].  This results in progressive pulmonary 
destruction and eventual respiratory failure, which is the cause of death in the 
majority of patients with CF [24]. 
 
The substantial advances in CF diagnosis and care have resulted in significant 
improvements in maintenance of pulmonary function and associated increases 
in quality of life for patients with CF.  Life expectancy for a child diagnosed with 
CF at birth now extends into the fifth decade, and the majority of children with 
CF will experience long intervals between hospitalisations [25].  Nonetheless, 
structural changes have been shown to be present in the airways of infants with 
CF [26] and CF-related deaths continue to be reported in children prior to 
secondary school age [25].  Monitoring pulmonary function is essential in 
facilitating optimal management [27], with maintenance of good pulmonary 
function during childhood having been shown to be associated with improved 
outcomes later in life [28].   
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1.1.4 Pathophysiological changes in obstructive lung disease 
Obstructive lung disease may result in a wide variety of changes within the 
respiratory system.  The exact presentation will vary between diseases but all 
obstructive lung diseases can be said to share a number of common 
pathophysiological features. 
 
Airway narrowing is a predominant feature of all such diseases.  It may occur at 
any level within the bronchial tree, as a result of hyperactivity and hypertrophy 
of smooth muscle, airway oedema, chronic airway remodelling, and mucous 
hypersecretion [29].  Although much emphasis is placed on the obstructive 
defects seen in the larger proximal airways, small airway dysfunction is also of 
great significance.  It has been suggested that up to 90% of the airflow limitation 
present in asthma occurs beyond the 8th generation of the airways [30] and the 
earliest pathophysiological changes occurring in cystic fibrosis-related lung 
disease occur in the smaller, distal airways [31]. 
 
Obstruction of distal airways may result in their collapse during expiration.  
Such collapse leads to gas trapping within the lung and hyperinflation, defined 
as an abnormally high volume of air remaining in the lungs at the end of 
expiration.  Hyperinflation has been demonstrated both during acute 
exacerbations of respiratory disease and chronically, even in the absence of 
severe airflow limitation [32].  Hyperinflation imposes an elastic load on the 
respiratory muscles, due to the added stretch on the lung tissues as a result of 
the elevated lung volume.  Hyperinflation also leads to intrinsic positive end-
expiratory pressure (PEEPi) causing a threshold load which must be overcome 
before negative pressure can be generated and air can flow into the lungs [33]. 
 
An increase in end-expiratory lung volume also causes the diaphragm to 
operate at a mechanical disadvantage. As end expiratory lung volume increases, 
the diaphragm becomes progressively flattened and shortened, resulting in 
decreased force generating capacity [34].  At higher lung volumes, the zone of 
apposition is also reduced and the costal diaphragm fibres insert at a less acute 
angle, causing the costal portion of the diaphragm to have an expiratory, rather 
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than inspiratory, effect [34].  Other inspiratory muscles must therefore be 
recruited to effect the intrathoracic pressure change required for ventilation. 
 
The degree of expiratory airflow limitation seen in moderate to severe airways 
obstruction may alter the normal respiratory pattern, moving expiration from a 
passive process, mediated by the elastic recoil of the lung and chest wall, to one 
requiring active contraction of the expiratory muscles.  Recruitment of these 
muscles, particularly the large abdominal muscles, will increase the body’s 
metabolic requirements and consequently the demands on the respiratory 
system will be further increased. 
 
1.2 Structural anatomy of the respiratory system 
 
 
The lungs are a pair of passive distensible organs, located, with the heart, within 
the thoracic cage.  The thoracic cage is comprised of the thoracic portion of the 
vertebral column, the sternum, and twelve pairs of ribs, each articulating 
dorsally with a thoracic vertebral body and ventrally with the costal cartilage 
[35].  The orientation of the ribs in adults is such that the axis of rotation is 
orientated laterally, dorsally and caudally.  The ribs themselves are not 
horizontal, but slope inferiorly and anteriorly from their articulations with their 
respective vertebral bodies.  This combination results in lateral and anterior 
displacement of the anterior ends of the ribs occurring simultaneously with 
their elevation, as well as cranial and anterior movement of the sternum.  This 
results in increases in both the antero-posterior and lateral dimensions of the 
ribcage [36], often described as the ‘pump-‘ and ‘bucket-handle’ motions of the 
ribs respectively. 
 
The lungs are surrounded by a serous membrane (visceral pleura) which folds 
back on itself to form a two layered structure [35].  The outer pleural membrane 
(parietal pleura) is attached to the inside of the rib cage.  Surface tension of the 
small amount of fluid between the pleural membranes maintains close 
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apposition of the two pleurae, opposing the elastic recoil of the lung 
parenchyma, preventing lung collapse and maintaining lung inflation. 
 
1.2.1 Development and maturation of the respiratory system 
 
 
The data obtained from studies in paediatric populations must be placed into 
context with the substantial anatomical and physiological changes that occur 
throughout childhood.  As the studies contained within this thesis include 
children of less than a year of age, developmental changes from infancy have 
been considered.  At birth, the human infant has lungs that are structurally 
similar to the fully developed adult lung, with the adult number of airways and 
all components of the airway wall being present [37].  Development of the lungs 
is rapid in the first few months of life, but continues throughout childhood and 
adolescence.  At birth, up to 150 million alveoli are present [37].  It was until 
recently thought that alveolarisation was complete by seven to eight years of 
age, with alveolar numbers of between 200 and 600 million reported at this age 
[38-40].  More recent data has suggested, however, that alveolarisation 
continues throughout adolescence, with a combination of increases in both 
alveolar number and size proposed to be responsible for the near-quadrupling 
of lung volume from age seven to adulthood [41].  Gas exchange per unit of body 
mass also increases during childhood [42], mainly as a result of increases in the 
number of pulmonary capillaries [37].  The airways increase in size, resulting in 
decreased airways resistance [43-45], with an associated increase in lung 
compliance [46, 47]. 
 
Structural changes in the thoracic cage and torso also contribute to changes in 
respiratory system efficiency.  The infant ribcage is highly compliant, with a 
greater proportion of cartilage to mineralised bone [48]; ribcage ossification 
continues until as late as 25 years of age [35, 49].  Stiffening of the chest wall 
occurs during infancy as a result of both ribcage ossification [48] and increases 
in muscle mass.  Chest wall compliance in the infant is up to three times greater 
than that in the adult [50], which would result in a relaxed lung volume lower 
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than airway closing volume, potentially predisposing the infant to atelectasis 
and poor oxygenation.  Functional residual capacity (FRC) is actively maintained 
above closing volume in infants by initiating inspiration prior to reaching 
relaxed lung volume and by a combination of post-inspiratory action of the 
inspiratory muscles and expiratory “braking” by the upper airway muscles [48].  
Passive maintenance of FRC above closing volume is achieved by the end of the 
second year of life, and active efforts at maintaining appropriate end-expiratory 
lung volumes are no longer observed [51]. 
 
In infancy, the ribs are in a more perpendicular orientation relative to the 
vertebral column.  The rib cage is more circular than in adults [52] and the 
upper ribs are distinctly shorter than the lower ribs, giving a triangular shape to 
the thoracic cage, in contrast to the dome shape seen in adults [53].  Upon 
adoption of the upright posture at around six months [22] the ribs start to slope 
downward.  By the age of ten years, the inferior sloping of the ribcage has 
reached adult configuration [54].  As thoracic length increases with age, the 
height of the abdominal hydrostatic column increases, which results in a greater 
gravitational pull on the abdominal contents.  This augments the inspiratory 
action of the diaphragm, thus resulting in reductions in the required effort to 
effect volume change of the lungs [48].   
 
The horizontal orientation of the ribcage in infants and young children results in 
a flattened diaphragm with a corresponding smaller zone of apposition and less 
of the abdominal contents being encased by the lower ribcage.  The ‘bucket-‘ 
and ‘pump-handle’ effects of diaphragm contraction are therefore reduced in 
the infant [53], meaning that rib cage motion contributes little to tidal volume 
[55].  This deleterious effect is somewhat offset by the smaller radius of 
curvature of the diaphragm in infants and children, enhancing the force-
generating ability of the diaphragm through the law of Laplace [56].  The 
greater chest wall compliance results in less efficient translation of reductions 
in pleural pressure changes to lung volume changes, with discrepancies of up to 
sevenfold between diaphragm pressure-volume work and pulmonary work 
being reported [57].  
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1.2.2 The respiratory muscles 
 
Volume change of the lungs, and hence pulmonary ventilation, occurs as a result 
of contraction of the respiratory muscles [58] which work in concert to increase 
thoracic volume, expand the rib cage, lowering pleural and intrapulmonary 
pressure and causing air to flow into the lungs.  Effective function of the 
respiratory muscle pump is essential to maintain adequate gas exchange and 
comprises both inspiratory and expiratory muscles.  The inspiratory muscles 
include the diaphragm and external and parasternal intercostal muscles as well 
as accessory muscles of the upper chest and neck.  The expiratory muscles are 
comprised of the internal intercostal muscles and abdominal muscles (rectus 
abdominus, internal and external obliques, and transversus abdominus). 
 
 
1.2.2.1 Respiratory muscles: the diaphragm 
 
The diaphragm is the primary muscle of respiration performing approximately 
70% of the work of breathing in healthy adults [33].  It is a large dome shaped 
muscle that sits between the thoracic and abdominal compartments, innervated 
by the phrenic nerves, which originate from the third, fourth and fifth cervical 
segments [36].  The two halves of the diaphragm (left and right 
hemidiaphragms) are innervated by their respective phrenic nerves.  The fibres 
of the diaphragm originate from the postero-inferior portion of the sternum, the 
inner surfaces of the lower six ribs and costal cartilages, and the lumbar 
vertebrae and insert into a central tendon [35].  Contraction of the diaphragm 
results in flattening of the muscular sheet, compressing the abdominal contents 
and causing the volume of the thoracic cavity to be increased.  The increase in 
intra-abdominal pressure causes outward movement of the lower rib cage.  
Furthermore, the orientation of the fibres of the diaphragm where they attach 
to the lower rib cage (the ‘zone of apposition’) means that contraction of the 
muscle results in an upward and lateral movement of the lower ribs [59], thus 
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increasing the lateral and antero-posterior diameter of the rib cage.  It can thus 
be seen that the ‘bucket-handle’ motion of the ribs depends on the angle of 
insertion of the costal diaphragm muscle fibres (and thus the size of the zone of 





Figure 1 Diagram of the human diaphragm.  Reproduced from Gray, H. (1918) 




1.2.2.2 Respiratory muscles: intercostal muscles  
 
There are two layers of intercostal muscles: external and internal.  The external 
intercostal muscles are located superficially to the internal intercostal muscles 
[35].  The internal and external intercostal muscles between each pair of ribs 
are innervated by the corresponding intercostal nerve [35].  The fibre direction 
of each of the two muscle layers is shown in Figure 2. 
 
Figure 2 Fibre direction of the intercostal muscles [60]. 
 
Both groups of muscles play a significant role in respiratory function [61, 62].  
The internal intercostal muscles are orientated laterally and inferiorly from the 
cranial to the caudal rib, and have a predominantly expiratory action, 
contraction causing collapse of the rib cage.  The external intercostals extend 
medially and inferiorly from the superior to the inferior rib in each interspace, 
and act to raise the inferior rib, consequently having an inspiratory effect.  Both 
the internal and external intercostal muscles also have a postural role, being 
particularly active during rotation of the trunk [63, 64].  Between the sternum 
and costo-chondral junction in the first five interspaces ventrally, the external 
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intercostals are replaced by a fibrous aponeurosis.  The remaining internal 
intercostals in this area are termed the parasternal intercostal muscles.   
 
1.2.2.3 Respiratory muscles: the parasternal intercostal muscles 
 
The parasternal intercostal muscles are anatomically similar to the internal 
intercostal muscles, but are functionally distinct.  Unlike the internal intercostal 
muscles, the parasternal intercostals have an inspiratory role, and have been 
termed the ‘inspiratory intercostals’.  Similarly to the diaphragm, the 
parasternal intercostal muscles are composed of predominantly slow twitch, 
oxidative fibres, making them resistant to fatigue [65].  A number of studies in 
dogs and human subjects have resulted in a detailed understanding of the role 
of this muscle group.  Contraction of the parasternal intercostal muscles 
increases both the lateral and, to a lesser extent, the anteroposterior diameters 
of the chest wall [66].  Denervation or thoracic epidural block of these muscles 
in anaethetised dogs results in significant decreases in tidal volume, minute 
ventilation and increases in pCO2 [67, 68], with marked reductions in cranial rib 
displacement despite substantial compensatory increases in external intercostal 
muscle activity [69].  In contrast, severing of the canine external intercostal 
muscles in the presence of preserved parasternal intercostal muscle function 
results in only moderate reductions in tidal volume with no increase in 
parasternal intercostal activity [70].  Studies involving selective denervation of 
canine chest wall muscles suggest that the parasternal intercostal muscles are 
responsible for approximately 80% of rib motion during quiet breathing [69], 
though this may not be the case in humans.  
 
Wilson et al [71] applied the Maxwell reciprocity theorem to the human 
respiratory system in order to calculate indirectly the mechanical advantage of 
several rib cage muscles.  The authors state that the effect of a respiratory 
muscle’s contraction (airway pressure change, ΔPao) is related to the mass of 
the muscle (m), the maximum active muscle tension per unit cross sectional 
area (σ), and the fractional change in muscle length (ΔL/L) per unit volume 




Pao m(L /(LVL ))Rel  
 
The mechanical advantage of a basic lever is defined as the ratio of force 
delivered to the force applied, and when applied to the respiratory muscles can 
be defined as the change in airway pressure divided by the total respiratory 
muscle tension required to effect the change (ΔPao/mσ).  Using the above 
equation, the mechanical advantage can be calculated by measuring 
(ΔL/(LΔVL))Rel.  By assessing changes in intercostal muscle length induced by 
passive lung inflation during computed tomography scanning, together with 
cadaveric studies, these authors demonstrated that the parasternal intercostal 
muscles shorten during passive lung inflation and can therefore be said to have 
an inspiratory mechanical advantage, but that this is less than that of the 
external intercostal muscles [71, 72].  The mechanical advantage of the human 
parasternal intercostal muscles is fourfold greater in the second than in the fifth 
interchondral space [72]. 
 
While the parasternal intercostal muscles, when activated in isolation, do effect 
ribcage motion and volume change of the thoracic cavity, their role in the fully 
intact respiratory system is also dependent on their interaction with other 
muscle groups, particularly the external intercostal muscles and diaphragm 
[73].  It is noted that, while the parasternal intercostal muscles move the upper 
ribs laterally and cranially, and contraction of the external intercostal muscles 
results in cranial rib displacement, contraction of these two muscle groups 
enhances lateral rib motion, but with the additional effect of caudal 
displacement of the sternum [74]. 
 
Tetraplegic patients with preserved parasternal intercostal muscle activity 
demonstrate normal lung compliance, FRC and transpulmonary pressures.  By 
comparison, those with non-functional parasternal intercostal muscles 
demonstrate reductions in these parameters, supporting the premise that these 
muscles also assist in stabilising the upper chest wall against the potentially 
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deforming action of the diaphragm [75].  Studies in dogs have also 
demonstrated the stabilising role of the parasternal intercostal muscles, 
showing dorsal and caudal displacement of the ribs during inspiration in dogs 
with flail chest in whom the parasternal intercostal muscles had been 
denervated [76]. 
 
The parasternal intercostal muscles are consistently active during inspiration, 
only inactive when the inspired volume is minimal [62, 77-79].  They are 
activated in concert with the diaphragm [79, 80] and a strong agreement 
between both the amplitude and timing of peak diaphragm and parasternal 
intercostal electrical activity has been observed [81, 82].  
 
The neural drive to the parasternal intercostal muscles demonstrates a 
cephalocaudal gradient, with higher neural drive being delivered to those 
muscles with the greatest mechanical advantage [61, 80, 83, 84].  Timing of the 
activation of the parasternal intercostal muscles also shows a cephalocaudal 
gradient, with the muscles in the first to third interspaces being activated within 
the first 10% of inspiratory time, and those in the fourth and fifth interspaces 
commencing activity approximately one-third of the way through an inspiratory 
effort [80].  A mediolateral gradient of activation has been found in dogs [85], 
though this is not the case in human subjects [80]; it is suggested that these 
differences occur due to the differences in rib cage geometry and muscle fibre 
orientation between the two species.   
 
 
1.2.2.4 Respiratory muscles: sternocleidomastoid 
 
The sternocleidomastoid muscle is an accessory muscle of inspiration, 
originating from the lateral surface of the mastoid and occipital bones, and 
inserting via two heads into the upper part of the anterior surface of the 
manubrium sterni (sternal head) and the medial surface of the clavicle 
(clavicular head) [35].  Unilateral activation of the sternocleidomastoid acts to 
flex the head laterally and rotate it to the contralateral side, or bilateral 
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activation acts to flex the cervical spine.  If the head is fixed, however, 
contraction of the sternocleidomastoid muscles causes elevation of the sternum 
and upper ribs, and assists in stabilising the upper rib cage against the action of 
the diaphragm that, if unopposed, would deform the ribcage.  The 
sternocleidomastoid is only tonically active during resting breathing but is 
recruited when ventilatory requirements increase, such as during exercise or in 
the presence of lung disease [86]. 
 
 
Figure 3 Diagram of the human sternocleidomastoid muscle.  Reproduced from 







1.2.2.5 Respiratory muscles:  the scalenes 
 
The scalene group comprises three segments: anterior, medial and posterior.  
These muscles arise from the transverse processes of the second to the seventh 
cervical vertebrae and insert into the first and second ribs.  The scalenes act to 
elevate the first and second ribs and as such serve as inspiratory muscles [35].  
The scalenes have been shown to be consistently active during inspiration in 
humans, even when the inspired tidal volume is small [79, 87].  
 
 
Figure 4 Diagram of the human scalene muscles (anterior, medial and posterior 
segments indicated with arrows).  Adapted from Gray, H., (1918) Anatomy of the 





1.2.2.6 Respiratory muscles:  the abdominal muscles 
 
The abdominal muscles comprise a group of four separate muscles: transversus 
abdominus, internal and external oblique, and rectus abdominus [86].  
Transversus abdominus is a thin, flat, horizontally-orientated sheet of muscle, 
and is the deepest of the four abdominal muscles.  The internal oblique muscle 
sits superficial to transversus.  Both muscles originate from the lumbodorsal 
fascia, the inner lip of the iliac crest and the lateral aspect of the inguinal 
ligament, with transversus having fibres additionally originating from the inner 
surfaces of the cartilage of the lower six ribs.  Both muscles insert via an 
aponeurosis into the pubis, pectineal line and linea alba.  The internal oblique 
also has attachments into the seventh to twelfth ribs, with those fibres inserting 
into the lower three ribs being continuous with the internal intercostal muscles.  
The external oblique is the largest of the three flat abdominal muscles.  It arises 
from the external and inferior surfaces of the lower eight ribs, inserting via an 
aponeurosis into the linea alba and inguinal ligament.  Rectus abdominus is a 
long flat muscle, extending along the length of the front of the abdomen.  It 
originates from the crest of the pubis and the pubic symphysis, and inserts into 




Figure 5 Diagram of the human rectus abdominus and transversus abdominus 
muscles. Adapted from Gray, H., (1918) Anatomy of the human body, 




Contraction of the abdominal muscles pulls the abdominal wall inward, which 
acts on the abdominal contents, displacing the diaphragm upward, and also 
causing the lower ribs to move caudally [58].  The resultant increases in intra-
abdominal and intra-thoracic pressures causes air to move out of the lungs.  
Contraction of the abdominal muscles may also serve an accessory inspiratory 
role as active expiration to lung volumes below FRC augments the subsequent 






1.2.3 Respiratory muscle structure and function 
 
The respiratory muscles are skeletal muscles, demonstrating common 
structural and functional characteristics with peripheral muscles.  They are 
composed of individual motor units, each consisting of a group of muscle fibres 
innervated by a motor neurone [86].  Human skeletal muscle fibres are 
classified into type 1 (slow twitch) or type 2 (fast twitch) fibres on the basis of 
their functional properties.  Myosin is the protein responsible for conversion of 
chemical energy, in the form of adenosine triphosphate (ATP), into mechanical 
energy, and as such the myosin isoform that predominates in any given 
myofibril determines the functional properties of that myofibril.  Three myosin 
heavy chain (MyHC) isoforms are expressed in adult human skeletal muscle: 
slow (type 1), fast 2A and fast 2X [88].  In addition, a neonatal MyHC isoform is 
observed but rapidly differentiates into the adult forms after birth [89]. 
 
Slow fibres reach peak tension more slowly and have a slower maximum 
shortening velocity, as well as generally achieving lower tension during an 
isometric contraction, but demonstrate much greater resistance to fatigue than 
type 2A and 2X fibres.  These fibres consume relatively small amounts of ATP, 
with their consumption being matched by aerobic oxidative ATP production as a 
result of large numbers of mitochondria.  Type 1 fibres also show high capillary 
density, are typically small in diameter, and are supplied by motor neurones 
that fire at low frequency and have slower conduction velocities.  In contrast, 
type 2X fibres are large in size, have few mitochondria, and are supplied by 
large-diameter motor neurones that fire at high frequencies and have rapid 
conduction velocities.  Type 2X fibres demonstrate very high anaerobic 
metabolic power but, since they derive much of their ATP from anaerobic 
glycolysis, the cytosol rapidly becomes acidic due to lactate production, 
inhibiting the contractile response and leading to fatigue.  Type 2A fibres are 
intermediate to types 1 and 2X, able to derive ATP from both oxidative and 
glycolytic pathways, and hence are able to produce relatively high force over 
prolonged periods, demonstrating moderate fatigue resistance [86, 88, 90]. 
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Due to the requirement to contract rhythmically and repeatedly throughout life, 
the respiratory muscles must demonstrate high levels of resistance to fatigue.  
The human diaphragm is composed of approximately 55% type 1 fibres, 21% 
type 2A and 24% type 2X [91], with the intercostal muscles demonstrating a 
slightly higher ratio of slow oxidative fibres (greater than 60%) [92].  A lower 
proportion of slow oxidative fibres (25%) are present in the infant diaphragm 
at birth, reaching adult proportions within the second year after birth [93].  
During quiet breathing, mainly slow fibres are active, with a shift to fast twitch 
fibres observed as respiratory frequency increases [94, 95].  Diaphragm muscle 
fibres have also been shown to have a smaller cross-sectional area than limb 
muscle fibres, resulting in a smaller diffusion distance and increased efficiency 
of oxygen delivery to the contracting cells [96]. 
 
 
1.2.3.1 Physiology of muscle contraction 
 
An action potential arises in the motor neurone supplying the motor unit, 
resulting in release of acetylcholine into the neuromuscular junction and release 
of sodium ions at the motor end plate.  This depolarisation of the muscle fibre 
triggers a muscle action potential, which propagates along the sarcolemma and 
through the t-tubule system, resulting in release of calcium ions from the 
sarcoplasmic reticulum.  At rest, troponin-tropomyosin complexes are bound to 
the myosin receptor sites of the actin filament, preventing cross-bridge 
formation.  Hydrolysis of the ATP molecule into adenosine diphosphate (ADP) 
energises the myosin head.  Following the arrival of an action potential, the 
troponin-tropomyosin complexes bind with the released calcium ions, allowing 
the energised head of the myosin filament to attach to the actin filament and 
form a cross bridge.  The myosin head rotates, sliding the actin filament towards 
the centre of the sarcomere, and releasing the ADP molecule and the phosphate 
group.  Following this ‘power stroke’, a new ATP molecule binds to the myosin 
head, releasing it from its attachment to the actin filament.  If ATP remains 
available and calcium is still present in the sarcoplasm, myosin receptor sites of 
the actin filament will remain available for cross bridge formation and a further 
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contraction cycle will be initiated.  Although the motion of an individual myosin 
head effects only a very small change in sarcomere length, the repeated actions 
of many actin-myosin complexes results in large displacements of the filaments 
[86, 90, 97]. 
 
 
1.2.3.2 Factors affecting muscle contraction 
 
The force generated by an individual muscle during a contraction is dependent 
on the length of the muscle at the point of stimulation, the number of muscle 
fibres stimulated, the frequency at which they are stimulated, and the velocity of 
muscle fibre shortening.  These factors are also closely related with specific 
changes in muscle length, load, firing frequency or velocity of shortening rarely 
occurring in isolation. 
 
The length-tension relationship of skeletal muscle is a function of the degree of 
overlap of the actin and myosin filaments (Figure 6).  Under circumstances of 
excessive stretch, fewer myosin heads are able to make contact with actin 
filaments; once a muscle fibre reaches approximately 170% of its optimal 
length, no overlap occurs and no tension can be generated.  If a muscle is 
shortened to substantially below its resting length, the myosin heads become 
compressed against the Z discs at the end of the sarcomere, again reducing the 
number of myosin heads available for cross-bridge formation [90].  In 
respiratory muscles, this effect becomes apparent under circumstances of lung 
hyperinflation, whereby the respiratory muscles become shortened with a 
consequent reduction in force-generating ability [98].  Muscle length change in 
the human body is limited by the points to which the muscle is attached and 





Figure 6 Length-tension relationship in a skeletal muscle fibre.  Reproduced 
with permission and adapted from [90].  L0 = optimal muscle length. 
 
 
The frequency of stimulation also affects the force generated by the muscle 
through summation of isometric contractions [90].  Maximal force is generally 
achieved in response to 100Hz stimulation, though high frequencies are rarely 
seen during voluntary contractions, with motor neurone firing frequencies of 5-
30Hz observed during normal muscle activity [99].  The nature of the force-
frequency curve varies between different skeletal muscles [100], with muscles 
comprised predominantly of fast-twitch fibres requiring higher stimulation 
frequencies to achieve maximal force.   
 
The force and velocity of a muscle’s contraction demonstrate an inverse 
hyperbolic relationship, with maximal shortening velocity achieved under a 
condition of zero load.  The shortening velocity is determined by the rate of 
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1.3 Assessment of respiratory function 
 
It is well recognised that optimal treatment of respiratory disease requires 
accurate assessment of respiratory function, with maintenance of good 
pulmonary function in childhood being associated with improved outcomes into 
adulthood [27, 101, 102].  Early intervention is therefore recognised as being of 
major importance in childhood lung disease [103].  Many of the 
pharmacological treatments available to treat lung disease, while demonstrating 
good safety profiles, are not without side-effects and thus overtreatment must 
be avoided [11].  Management of respiratory disease also places a significant 
burden on patients and their families [104, 105], which further emphasises the 
importance of making treatment decisions with objective evidence of their 
efficacy in mind.   
 
Clinician opinion is a significant factor in assessment of lung disease, 
particularly in the younger age groups where objective measures are lacking.  
Physicians are often, through clinical assessment alone, able to identify an 
obstructive pattern of lung disease [106], but are generally unable to accurately 
quantify the severity of airflow obstruction [107].  Clinical signs, such as oxygen 
saturation, respiratory rate and asthma severity scores have been shown to 
correlate poorly with severity of airways obstruction and need for 
hospitalisation in children with asthma [108].  Equally, underestimation of 
disease severity by children, parents and carers has been implied to be a 
possible contributing factor in severe exacerbations [109, 110].  More detailed 









Spirometry is currently viewed as the cornerstone of pulmonary function 
testing in both adults and children.  The key parameters used are the forced 
vital capacity (FVC), and the expired volume in the first second of a forced 
exhalation (FEV1).  Other parameters may be of interest to clinicians or 
researchers but are not routinely used in clinical practice and hence will not be 
discussed in detail. 
 
While spirometry has long been recommended as the key tool with which to 
assess disease severity and guide treatment decisions in a wide range of lung 
diseases, it carries a number of drawbacks.  Chief among these in paediatric 
respiratory care is the level of cooperation and understanding required from 
the subject.  Some authors have suggested that reliable results may be obtained 
from children as young as three years old with appropriate coaching and 
encouragement [111], but in practice this is frequently not feasible [31].  
Reflecting this, national and international guidelines do not recommend the use 
of spirometric measures to guide treatment in children under the age of five 
years [7, 8, 11, 14, 112].  A major drawback associated with spirometry is the 
reliance of the technique on the subject’s own motivation and cooperation in 
order to obtain appropriate maximal efforts.  Factors such as fatigue, 
breathlessness and cough, frequently observed in patients with lung disease, 
may also impair patients’ ability or desire to comply with the demands of the 
test and hence result in values that are submaximal or of poor quality and 
technically unacceptable [14, 113].   
 
In addition to the volitional nature of spirometry, variability of the measure can 
impact on diagnostic accuracy.  Normal variability of spirometry is 
approximately 2-3% [114], but in the presence of obstructive airways disease 
has been shown to be two- to three-fold higher [113].  The greater variability of 
spirometric measures in diseased populations results in a reduced sensitivity of 
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the test to small changes in pulmonary function that can occur early in the 
disease process and may result in delays in commencing treatment. 
 
 
1.3.2 Peak expiratory flow 
 
Peak expiratory flow (PEF) can be derived from spirometry or can be measured 
independently using a small hand-held meter.  PEF is widely used in the home 
and primary care settings for ongoing monitoring of asthma in particular, and is 
recommended in national and international guidelines as an appropriate 
monitoring tool [8, 11].  However, PEF values have been shown to demonstrate 
little relationship to other spirometric parameters [115] and the values 
obtained from home measurement of PEF are potentially unreliable [116] and 
bear little relation to symptoms or disease severity [117]. 
 
 
1.3.3 Forced oscillation technique 
 
The forced oscillation technique (FOT) superimposes small oscillations of 
pressure over a range of frequencies onto tidal respiratory flow and uses the 
resultant pressure-flow responses to determine a range of pulmonary 
impedance characteristics [118], including resistive, inertive and elastic 
properties of the respiratory system. 
 
FOT requires only passive cooperation from the subject and thus is suitable for 
use in pre-school children.  Nonetheless, difficulties in cooperation have been 
reported, including refusal to breathe through a mouthpiece or wear a noseclip, 
inability to maintain a leak-free seal around the mouthpiece, or difficulty 
maintaining consistent tidal breathing in the presence of the imposed pressure 
signals [119].  Such difficulties may also be encountered when attempting to use 
this technique with patients who are breathless, coughing frequently or who are 
reliant on supplemental oxygen, with measurement success rates of as low as 
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20% reported in acutely unwell pre-school children [120].  FOT has also been 
shown to be unable to discriminate between healthy pre-school children and 
those with cystic fibrosis lung disease, bringing into question the ability of the 
technique to detect early, milder disease [121].  Without sedation, this 
technique is also unsuitable for use in infants. 
 
 
1.3.4 Body plethysmography 
 
Patients with obstructive lung disease have increased airways resistance, which 
in turn can lead to suboptimal lung emptying and gas trapping resulting in 
increases in end-expiratory lung volume.  Body plethysmography allows 
accurate measurement of intrathoracic gas volumes and airways resistance, 
which can be used to assess obstructive lung disease severity.  In order to 
satisfy the conditions of Boyle’s Law [122], which underpins the technique 
itself, the subject must remain in a sealed rigid chamber, such that changes in 
intrathoracic pressure can be inferred from changes in chamber pressure [123].  
Enclosure in a plethysmograph for several minutes, is often unacceptable to 
younger children [124] and the manoeuvres are complex, and therefore rarely 
successful in this age group.   
 
 
1.3.5 Respiratory interrupter resistance 
 
The respiratory interrupter resistance technique (Rint) is a non-invasive method 
for measuring respiratory system resistance.  It applies a brief (100msec) 
occlusion to airflow during inspiration or expiration during which mouth 
pressure equilibrates with alveolar pressure.  Respiratory system resistance is 
calculated by back extrapolation to obtain airway pressure at the point of 
occlusion and dividing this by the respiratory flow at that time [125-127].  The 
technique is effort-independent and requires only passive cooperation from the 
subject.  It does, however, require the subject to breathe through a mouthpiece 
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and wear a noseclip, which is unnatural for most children and is difficult during 
an acute exacerbation, particularly if the child is oxygen-dependent.  In addition, 
the child’s cheeks must be supported to prevent their influence on resistance 
measurements.  Rint can also underestimate airways resistance in severe 
airways obstruction [128] due to impaired pressure transmission across the 
airways to the mouth.  While studies have demonstrated good short-term 
repeatability, long-term variability of the measurement is much greater, limiting 
its application clinically [129]. 
 
 
1.3.6 Multiple breath washout 
 
Multiple breath washout (MBW) techniques use inert gases to measure FRC and 
have recently been further developed to assess gas mixing within the lung.  The 
lung clearance index (LCI) is the number of lung volume turnovers required to 
reduce the concentration of the test gas to one 40th of the equilibration 
concentration achieved during the test gas wash-in period.  Such measures of 
ventilation inhomogeneity have been suggested to provide a sensitive marker of 
airways disease [119].  These techniques can be performed using a facemask or 
mouthpiece and noseclip and require only tidal breathing.  Only passive 
cooperation is therefore required from the subject and as such the technique 
can be performed in children of any age, though infants may still require 
sedation [130].  Although requiring the subject to breathe through a mouthpiece 
or facemask, the major barrier to wider use of MBW techniques is the lack of 
agreement regarding standardisation of equipment and methodology and the 
relative lack of commercially available equipment [119].  Much research to date 
has focussed on the use of MBW techniques in cystic fibrosis but there is a lack 
of data in the literature regarding the utility of these techniques in other 
obstructive lung conditions [130].  Recent work has shown MBW to be of little 
use in assessing response to bronchodilator medication in pre-school children.  
Using this technique, it was not possible to discriminate between healthy 
children and those with recurrent wheeze, with ventilation inhomogeneity 
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increasing in some subjects, which the authors suggested was due to inability of 
the bronchodilator medication to permeate poorly ventilated lung areas [131]. 
 
 
1.3.7 Infant pulmonary function testing 
 
A variety of pulmonary function tests are available for use specifically in infants 
such as the rapid raised thoraco-abdominal compression technique and infant 
plethysmography.  However, both of these techniques are limited by the size 
and age of the child due to constraints imposed by the equipment used and the 
requirement that the child be sedated.  Such techniques are therefore not used 






Although a range of pulmonary function testing modalities have been developed 
that may be suitable for use in the paediatric population, few are suitable for 
routine use, particularly in pre-school children.   Infancy and early childhood is 
a critical time for lung development, and insults to the lung sustained during 
this period can have a significant impact on pulmonary function through later 
life.  The need for improved techniques to accurately assess lung function and 
allow both longitudinal monitoring to track disease progression and the effects 
of treatment interventions particularly during acute exacerbations of lung 
disease in this younger age group is therefore apparent.  Objective measures 
that are applicable across a wide range of ages and abilities in children in both 




1.3 Control of respiration 
 
Control of the respiratory cycle is mediated primarily by the respiratory centres 
in the medulla and pons of the brainstem.  These areas act to regulate 
ventilation and allow respiratory homeostasis to be maintained under varying 
conditions.  Axons from respiratory centres within the brain travel down the 
spinal cord to innervate the respiratory muscles via motor nerves. 
 
Breathing movements are produced by this spatially distributed ponto–
medullary respiratory network that generates rhythmic patterns of alternating 
inspiratory and expiratory activities that drive and coordinate the activity of 
spinal and cranial motoneurones.   The respiratory motor pattern originates and 
is controlled by inputs within interconnected bilateral columns of medullary 
neurons.  The functional role of the pons in the generation and control of 
respiratory rhythm and pattern has not been fully established, although pontine 
regions have been shown to interact with multiple medullary compartments 
which interact and provide strong modulation of medullary respiratory 
network activity and control respiratory phase transitions. 
 
 
1.3.1 Medullary respiratory centres 
 
Groups of cells demonstrating respiratory related activity are found throughout 
the medulla in number of different nuclei, however the major respiratory 
neurones are concentrated into four main nuclei: the dorsal respiratory group 
(DRG) within the nucleus tractus solitarius (NTS); the ventral respiratory group 
(VRG), containing the nucleus ambigualis (NA) and nucleus retroambigualis 
(NRA); the pre-Bötzinger complex; and the Bötzinger complex, located in and 
near the nucleus retrofacialis. 
 
The pre-Bötzinger complex is thought to be a key centre of respiratory 
rhythmogenesis, containing neurons with intrinsic pace-making capabilities 
that demonstrate cyclical firing in phase with respiratory activity without 
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additional synaptic input [134].  The Bötzinger complex lies rostral to the NA 
and is composed of expiratory neurones and vagal and glossopharyngeal motor 
neurones [135].  The NTS is the main site receiving input from lung and 
peripheral chemoreceptor afferents and provides sensory afferent input to the 
Bötzinger complex [136].  Both the Bötzinger and pre-Bötzinger complexes 
provide input to the VRG and DRG [137]. 
 
The DRG is located within the dorsomedial area of the medulla and comprises 
only inspiratory neurones, which fire immediately prior to the onset of 
inspiration and relay activity to the phrenic nerves to initiate diaphragm 
contraction [138].  This activity lasts for approximately two seconds in adults 
under resting conditions, before ceasing to allow passive expiration [36].  The 
DRG is responsive to afferent input from chemoreceptors and lung 
mechanoreceptors via the ninth and tenth cranial nerves and spinal cord, as 
well as descending afferents from higher brain centres.  The DRG inspiratory 
neurones inhibit the expiratory neurones of the VRG and pontine respiratory 
group (PRG) [136]. 
 
The VRG lies ventrolaterally in the medulla.  This area behaves similarly to the 
DRG, though contains both inspiratory and expiratory neurones, with the 
inspiratory and expiratory neurons demonstrating reciprocal inhibition [139].  
The NA contains premotor inspiratory neurones that supply the external and 
parasternal intercostals, accessory muscles of inspiration and the laryngeal 
motor neurones [140], as well as supplying parasympathetic input to the heart 
and bronchioles [141].  The rostral portion of the NRA contains inspiratory 
neurones, and the caudal portion expiratory neurones that activate expiratory 
muscles under conditions of active expiration, as well as sending inhibitory 






1.3.2 Pontine respiratory group 
 
The pontine respiratory group (PRG) has reciprocal connections with the 
respiratory centres within the medulla [137].  In the absence of any influence 
from the pons, the medullary respiratory centres generate a slow, rhythmic, 
gasping breathing pattern [142].  The PRG consists of expiratory neurones in 
the medial parabrachial nucleus and inspiratory neurones in the lateral 
parabrachial nucleus and Kölliker-Fuse nucleus [143].  Heightened activity in 
the PRG reduces the duration of activity of inspiratory neurones in the medulla, 
reducing inspiratory time and resulting in earlier initiation of expiration [86].  
This “phase-switching” allows respiratory frequency to increase.  Inferior areas 
of the pons exert an excitatory influence on inspiratory neurones, though the 
activity of this area is usually suppressed by the PRG.  In the absence of any 
input from the PRG or lung stretch receptors, breathing will cease in full 
inspiration [142].  
 
 
1.3.3 Cortical control of breathing 
 
Descending influences from the cerebral cortex to the medullary respiratory 
centres allow volitional control of breathing for tasks such as speech, laughter, 
defaecation and childbirth.  Impulses involved in the voluntary control of 
breathing bypass the medullary and pontine respiratory centres and synapse 
directly with spinal respiratory motor neurones [86].  This is demonstrated in 
the case of rare brainstem lesions in which cortical control of breathing remains 
intact with loss of autonomic control, such that patients are able to maintain 
adequate ventilation while awake but control is lost during sleep [144].  Pain, 
temperature and emotion also demonstrate an effect on ventilation, mediated 






1.3.3.1 Respiratory chemoreceptors 
 
The chemoreceptors involved in respiratory control respond to changes in pH, 
pO2 and pCO2.  The responses to changes in O2 and CO2 are quantitatively and 
qualitatively different.  Relatively minor increases in CO2 partial pressures 
result in significant and rapid alterations in ventilation [146].  In contrast, the 
ventilatory response to decreasing arterial oxygen pressures is hyperbolic 
under isocapnic conditions; large changes in pO2 are initially required to 
mediate a change in ventilation but thereafter the increase in ventilation is 
rapid [147]. 
 
Central chemoreceptors are found in several locations within the brain, 
including the ventrolateral medulla, NTS, VRG, the locus ceruleus, the caudal 
medullary raphé, and the fastigial nucleus of the cerebellum [146].  These 
receptors are located beyond the blood-brain barrier and therefore do not 
respond directly to changes in blood gas levels, but rather require changes in 
cerebrospinal fluid pH to occur (via changes in hydrogen ion concentration), 
which are subsequently sensed by the chemoreceptors [148]. 
 
Peripheral chemoreceptors are located within the carotid bodies at the 
bifurcation of the carotid arteries and in the aortic bodies above and below the 
aortic arch.  The carotid body receptors respond to change in arterial pH, PCO2 
and PO2, with the aortic chemoreceptors responding only to pH and CO2 levels.  
The carotid chemoreceptors exert a more potent influence over respiratory 
control than those in the aortic bodies.  Peripheral chemoreceptors are the only 
receptors mediating changes in ventilation in response to hypoxia, and 
complement the central chemoreceptors in responding to alterations in CO2 
levels [149].  Feedback to the respiratory centres from the carotid body 
receptors is via the glossopharyngeal (ninth cranial) nerves, and from the aortic 
body receptors is via the vagus nerve (tenth cranial nerve) [86].  Due to the high 
blood flow received by the peripheral chemoreceptors, they are able to respond 
rapidly to changes in blood gas concentrations, although their overall 
contribution to the response to changes in pCO2 is less than that from the 
central chemoreceptors [150]. 
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1.3.3.2 Respiratory system afferents 
 
Afferent feedback from receptors in the chest wall, respiratory muscles and 
lungs provide input to brainstem respiratory centres via the vagus nerve and 
thoracic and cervical nerve roots.  The receptors involved in the respiratory 
system can be divided into four principal types: stretch receptors, juxta-
pulmonary capillary (“J”) receptors, irritant receptors, and proprioceptors 
[151]. 
 
Both slowly- and rapidly-adapting stretch receptors (SARs and RARs) are 
located within the airway walls, with greater concentrations in the larger 
airways [152].   SARs are larger, myelinated fibres located within airway 
smooth muscle [153].  Stimulation of SARs by changes in lung volume and 
transpulmonary pressure plays a role in determining respiratory timing.  
Increased activity of SARs during inspiration is associated with reductions in 
tidal volume and inspiratory time in animal subjects [154], and the degree of 
both tonic and phasic SAR activity during expiration has been shown to assist in 
determining expiratory duration in dogs [155].  In humans, however, 
pulmonary stretch receptors appear to exert no influence on respiratory depth 
or timing at tidal volumes below approximately one litre [156, 157], despite 
clear activity being present [158].  SAR sensitivity may also be increased in the 
presence of bronchoconstriction, airway obstruction, or reduced lung 
compliance.  Increased SAR firing frequency has been demonstrated in the 
presence of bronchoconstriction, thought to be as a result of smooth muscle 
contraction stimulating SARs [159]. 
 
A deep inspiration (either passive or active) results in increased SAR activity, 
triggering the Hering-Breuer inflation reflex, whereby inhibitory impulses are 
sent via the vagus nerves to inspiratory respiratory centres in the brainstem, 
inhibiting further inspiratory muscle activity and prolonging expiratory time 
[151].  This reflex is particularly strong in infants, protecting against excessive 
lung distension due to the greater chest wall compliance [37], but is weak in 
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adults, being activated only at higher tidal volumes such as during exercise.  An 
increase in SAR activity is also thought to be involved, via a similar pathway, in 
the reflex bronchodilation occurring with deep inspiration in healthy 
individuals through reduction of parasympathetic tone to the airway [153, 160]. 
 
RARs are small-diameter, myelinated fibres and are widely distributed within 
and below the epithelium of the lower respiratory tract, with higher 
concentrations at the bifurcations of the trachea and bronchi [161].  Unlike 
SARs, these receptors demonstrate sensitivity to both mechanical (increases in 
tidal volume, respiratory frequency, or inspiratory and expiratory flows) and 
chemical (including cigarette smoke, dust, pro-inflammatory chemicals such as 
histamine and prostaglandin) stimuli, and may also be referred to as irritant 
receptors [162].  Stimulation of RARs results in cough, reflex laryngo- and 
broncho-constriction, airway vasodilatation, mucous hypersecretion, 
shortening of expiratory time and hyperpnoea, as well as cardiovascular 
responses, including tachycardia and hypertension [162].  They are also 
implicated in the deep augmented ‘sigh’ breaths that are seen every five to 
twenty minutes; RAR sensitivity increases as lung compliance decreases during 
tidal breathing, until a central nervous threshold is reached and an augmented 
breath triggered, reversing the reduction in lung compliance [163]. 
 
J receptors are unmyelinated fibres that respond to chemical changes in the 
bronchial and pulmonary circulations, and hence are also referred to as 
bronchial and pulmonary C-fibre receptors [151].  These receptors are 
stimulated primarily by chemical irritants such as capsaicin, histamine, 
bradykinin and prostaglandins, but also respond to increases in interstitial fluid 
in the alveolar wall and increased pulmonary blood flow [164].  Stimulation of 
these receptors results in increases in respiratory rate, constriction of the 
larynx and bronchi, and increased upper airway mucous secretion, in addition 
to reflex hypotension and bradycardia and a prolonged depression of spinal 
reflexes [165].  There is considerable overlap between the stimuli that activate 
the J and irritant receptors and between the reflex responses to the stimulation 
of both groups of endings. 
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Proprioceptors are located in the Golgi tendon organs and muscle spindles of 
the respiratory muscles, as well as in the joints of the thoracic cage, and are 
sensitive to changes in muscle tension and length respectively.  Activation of the 
mechanoreceptors within the costovertebral joints results in a reflex inhibition 
of inspiratory activity in response to rib elevation [166].  The diaphragm 
demonstrates a high ratio of Golgi tendon organs to muscle spindles, in contrast 
to the large number of muscle spindles in the intercostal muscles [167].  In 
combination, the sensory information projected to both brainstem respiratory 
centres as well as higher cortical areas provide information to facilitate 
modulation of respiratory drive, as well as to assist in accurate respiratory load 
perception.   
 
 
1.3.4 Respiratory control in childhood 
 
Maturation of respiratory control is relatively rapid and adult patterns of 
response to stimuli are seen at a relatively young age.  While there are some 
developmental changes in respiratory control during infancy, these will be 
discussed here in brief only as the children studied in this thesis were older 
than the age in which these changes are observed.  
 
The substantially greater metabolic rate in infants and young children results in 
a relatively limited respiratory reserve [168].  Reduced lung volume and lung 
compliance and an easily distorted chest wall characteristic of the infant chest, 
in combination with a less mature brainstem respiratory control centre, 
predispose the infant to irregular breathing.  Maintenance of lung volumes 
above closing volume is facilitated by active contraction of inspiratory muscles 
and laryngeal adduction during expiration [48], as well as initiation of 
inspiration prior to reaching a relaxed lung volume [37].  As a result of the 
absence during sleep of behavioural influences on respiratory pattern, 
chemoreceptor-mediated respiratory drive is of greater importance in the 
infant [168].  Beyond the immediate neonatal period, chemoreceptor influence 
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on respiratory behaviour shows relatively little difference to that seen in 
adulthood [169].  Other factors influencing respiratory control in infants include 
their greater sensitivity to environmental stress, particularly heat and cold, due 
to immature mechanisms of temperature regulation [170].  
 
1.4 Load: capacity balance of the respiratory muscles 
 
The mechanical action of any muscle is dependent on the imposed load and its 
capacity [58].  The load on the healthy human respiratory system during resting 
breathing is small.  Transdiaphragmatic pressures of approximately 5cmH20 are 
required to produce an adequate tidal volume.  The range of pathophysiological 
changes that occur in lung disease can substantially alter the balance between 
the load imposed on the respiratory muscles and their capacity.  In obstructive 
lung disease increased airways resistance, hyperinflation and intrinsic PEEP 
place an additional load on the respiratory system, while the inspiratory muscle 
shortening that occurs as a result of hyperinflation reduces the capacity of the 
inspiratory muscles to generate force [33] (Figure 7).  Neural respiratory drive 
(NRD) must therefore increase to compensate for this change in load-capacity 




Figure 7 Influence of pathophysiological changes seen in obstructive lung disease on respiratory system load and capacity, and the relationship with 
neural respiratory drive.
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1.4.1 Measurement of respiratory load 
 
The load on the respiratory muscles can be quantified in a number of ways.  
Standard pulmonary function tests can be used to assess the individual 
components of the overall respiratory load imposed by respiratory disease.  
Forced expiratory techniques in spirometry measure the degree of 
expiratory airflow limitation, while lung hyperinflation can be assessed by 
measurement of functional residual capacity using body plethysmography 
or gas dilution techniques.  These measures, however, only quantify a single 
aspect of disease pathology and correlate poorly with patient perception of 
disease. 
 
Respiratory load can also be assessed by measuring the pressures generated 
by the respiratory muscles to produce ventilation.  Intrathoracic 
(oesophageal (Poes)) and intra-abdominal (gastric (Pgas)) pressures can be 
measured using balloon catheters.  The pressure generated by the 
diaphragm, the transdiaphragmatic pressure (Pdi), can then be calculated by 
subtracting Poes from Pgas [171].  Mean or peak pressures generated during 
breathing can therefore be measured and used as an index of load on the 
respiratory system.  The integral of pressure changes with respect to time, 
the pressure-time product, can be used as a measure of the work of 
breathing to quantify respiratory load.  During tidal breathing in healthy 
individuals, the transduction of respiratory muscle pressure to respiratory 
flow and ventilation is highly efficient.  In severe airways obstruction, 
however, gas trapping leads to lung hyperinflation and intrinsic PEEP.  This 
positive resting intrathoracic pressure must be overcome before inspiratory 
flow will occur.  The change in pressure from baseline must therefore be 






1.4.2 Measurement of respiratory muscle capacity 
 
Muscle capacity or strength can be quantified simply and noninvasively by 
measuring the pressure at the mouth during a maximal volitional 
inspiratory effort against an occlusion (PI,max manoeuvre) or the maximum 
pressure in the nasopharynx during a maximal sniff (sniff nasal inspiratory 
pressure (SNIP)) [171].  The PI,max manoeuvre can be difficult to perform for 
some patients and as a result the values obtained can be submaximal and 
variable.  As a sniff is a natural manoeuvre, the SNIP measurement 
technique is more easily understood and performed by patients, and 
provides a robust measure of global inspiratory muscle strength [171].  Both 
measures are quick, simple, relatively easy to perform and non-invasive and 
therefore can be performed in routine clinical practice.  They do, however, 
rely on the subject being able to perform a maximal volitional effort.  The 
validity of the SNIP may also be compromised in severe airways obstruction 
due to poor pressure transmission across the lung to the airway opening.  In 
these instances, such measures may significantly underestimate true muscle 
strength. 
 
More detailed measurements of respiratory muscle strength may be 
obtained through the use of oesophageal and gastric balloon catheters to 
estimate maximum intrathoracic, intra-abdominal and transdiaphragmatic 
pressures during volitional manoeuvres.  In patients unable to reliably 
perform maximal voluntary efforts, the phrenic nerves can be stimulated 
using either magnetic or electrical stimulation techniques to generate a non-
volitional diaphragm contraction, and the resulting respiratory pressures 
measured. 
 
Invasive measures of inspiratory load and capacity are not without risk, and 
can be unpleasant for the patient.  Such measurements are unsuitable for 
use in routine clinical practice, particularly with young children.  Non-
invasive pressure-based measures of respiratory muscle strength are 
affected by patient cooperation and motivation as well as airways 
obstruction.  Alternative measures are therefore required to accurately 
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1.4.3 Neural respiratory drive 
 
Neural respiratory drive (NRD) is the electrical output from the respiratory 
centre in the brainstem to the respiratory muscles [33].  NRD varies in 
proportion to the loads placed on the respiratory system and any changes in 
the capacity of the respiratory muscles to respond to these loads [172].  The 
ideal method for quantifying NRD would be to measure the total brainstem 
respiratory neural output; however, such approaches are not possible in 
human subjects.  Pressure based measurements have been developed, but 
are subject to restrictions in their accuracy.  Measuring the neural input to 
selected important respiratory muscles would appear to overcome such 
limitations. 
 
1.4.3.1  Airway occlusion pressure 
 
The pressure generated in the first 100 milliseconds of inspiration against 
an occluded airway (P0.1) can be used as an index of respiratory drive.  
Unlike other measures of respiratory drive such as mean inspiratory flow 
(tidal volume divided by inspiratory time), P0.1 is independent of lung 
mechanics and does not elicit a conscious response from the subject due to 
the brief duration of the manoeuvre [173].  P0.1 is correlated with mean 
inspiratory flow in children [174].  To obtain an accurate measurement of 
P0.1, the airway must be occluded at end expiration, at the point of zero flow.  
Although a high value of P0.1 always indicates high respiratory drive, a low 
value can be difficult to interpret.  Respiratory muscle weakness and fatigue, 
the lung volume at the point of measurement, and any phase lag between 
pressure and flow (such as may occur in the presence of airways 
obstruction) will influence P0.1 [175].  Expressing P0.1 as a function of PI,max 
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has been used to overcome this [176].  The accuracy of P0.1 is also affected 
by dynamic hyperinflation and intrinsic PEEP, as P0.1 does not take account 
of the respiratory effort required to overcome PEEPi prior to generation of 
negative inspiratory pressure [177]. 
 
While the nature of this measure makes it applicable to a range of 
populations, including children [174] and mechanically ventilated patients 
[178], the effect of changes in lung volume on the pressure-generating 
capacity of the respiratory muscles results in measurements of P0.1 being 
poorly representative of true respiratory drive in patients with altered end 
expiratory lung volumes [179].  Additional physiological measurements may 
be required in order to fully interpret the values obtained from 
measurement of P0.1.  Practically the requirement for the subject to breathe 
through a mouthpiece in order to obtain the measurement makes the 
technique challenging in the paediatric age group, as well as the need to 
average many breaths in order to obtain precise results. 
 
 
1.4.3.2   Electromyography of the respiratory muscles 
 
Electromyography (EMG) is the technique used to record myoelectric 
signals, the electrical manifestation of the neural excitation process required 
for muscular contraction [180].  EMG measurements can be performed 
using surface electrodes placed over the muscle of interest, needle 
electrodes inserted into the relevant muscle or, in the case of crural 
diaphragm EMG, catheter-mounted electrodes in the oesophagus.  The EMG 
signal is representative of the electrical activity within the muscle [58] and 
represents motor unit recruitment.  The magnitude of the EMG signal is 
therefore directly related to the force generated by the muscle during an 
isometric contraction.  During an isotonic contraction when the muscle is 
also shortening, the EMG is related to both force generation and rate of 
change in muscle length [181, 182]. 
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As the principal inspiratory muscle, the diaphragm is the clear choice for 
measurement of NRD and EMG of the diaphragm (EMGdi) has been shown to 
be sensitive to changes in respiratory load-capacity balance [172, 183].  
EMGdi can be quantified using needle electrodes, though this technique 
carries a risk of pneumothorax and damage to internal organs and can be 
uncomfortable for the subject [184].  EMGdi can also be recorded 
transcutaneously using electrodes placed on the skin surface to measure the 
costal diaphragm EMG [185-187], or using an oesophageal electrode 
catheter to record crural diaphragm activity [172, 188, 189].  
Transcutaneous measurement techniques are prone to contamination from 
overlying musculature, particularly postural muscle activity [190].  In the 
presence of airways obstruction, pronounced abdominal muscle 
recruitment may be present in an effort to increase expiratory flow [191], 
resulting in greater contamination of the surface EMGdi signal.  
Measurements employing oesophageal electrodes provide high-quality, 
uncontaminated signals but the technique is invasive and hence impractical 
as a routine clinical tool, particularly in the paediatric population.  Other 
methods for quantification of NRD are therefore required.   
 
1.4.3.3   EMG of the parasternal intercostal muscles 
 
EMG of the parasternal intercostal muscles (EMGpara) has been used in a 
variety of laboratory and clinical studies, successfully demonstrating the 
ability of the measure to detect change in load in a number of patient 
populations.  In addition, studies in dogs have provided insight into the 
relationship between the mechanical and electrical behaviour of the 
parasternal intercostal muscles under a range of conditions.  The absence of 
overlying musculature results in the parasternal intercostal muscles being 
well suited to surface measurement of EMG, although needle techniques 
have also been used.  The obligate nature of the parasternal intercostal 
muscles’ recruitment, and their activation in tandem with the diaphragm 
[62, 77-80], indicates their suitability as an alternative method to quantify 
NRD.   
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The relationship between NRD measured using EMGdi and EMGpara has been 
examined and close agreement between the two measures observed [172, 
192, 193].  It is noted, however, that patterns of activity of the two muscles 
are not identical and the two measures cannot be viewed as 
interchangeable.  Parallel increases in EMGpara and crural EMGdi have been 
observed during incremental hypercapnic, inspiratory threshold loading, 
and incremental exercise to exhaustion though consistently higher levels of 
EMGdi were observed when compared to EMGpara [172, 192].  EMGpara and 
surface EMGdi of the costal diaphragm have also been shown to be closely 
related [194, 195], though a greater magnitude of increase in EMGpara than 
EMGdi activity was observed in these studies. 
 
The reproducibility of EMGpara measurements is well established, having 
been examined in a range of populations.  A study by Duiverman et al [187] 
examined the relationship between the increase in EMGpara recorded on two 
separate days in seven healthy subjects and seven patients with COPD 
undertaking a loaded breathing protocol, and reported a very strong 
correlation (r=0.89) in the COPD patients but a poorer relationship in 
healthy adults (r=0.63).  An earlier study [185] from the same group had 
demonstrated strong agreement between EMGpara measures recorded in 
both healthy adults and pre-school children (r=0.98 in both populations).  
The agreement in school-age children, both with and without asthma, was 
less strong (r=0.65 in both groups), though Bland-Altman analysis showed 
minimal bias and there was no significant difference between the measures 
on two occasions.  Reilly et al [172] and Murphy et al [196] assessed 
reproducibility of EMGpara in fifteen and ten healthy young adults 
respectively and reported values for inter-occasion coefficient of variation 
(CV) of 5-10%, with a strong correlation between the values obtained on the 
two occasions.  Murphy reported slightly poorer agreement between 
measures obtained on two occasions in ten stable COPD patients, with a 
mean CV of 15%.   
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Measurements of EMGpara can be used to discriminate between healthy 
subjects and those with respiratory disease, with greater levels of EMGpara 
observed in patients with cystic fibrosis [172], asthma [197] and COPD [78, 
198] in comparison to healthy subjects.  Different methods have been used 
to allow comparison of levels of EMGpara activity between subjects:  
Gandevia et al [78] utilised needle EMG techniques and compared motor 
unit firing frequencies, whereas other work using surface EMG has 
expressed the EMGpara signal as a percentage of that obtained during a 
maximal inspiratory effort (EMGpara%max) [172, 192, 197-199].  
EMGpara%max has been shown to relate to disease severity as quantified by 
FEV1 in both asthma [197] and cystic fibrosis [172].  Additionally, Reilly et al 
[172] demonstrated a positive relationship between EMGpara%max and end 
expiratory lung volume, and an inverse relationship with dynamic lung 
compliance.  EMGpara activity increases with the development of 
hyperinflation in asthmatic subjects, with strong relationships having been 
demonstrated between changes in thoracic gas volume and EMGpara activity 
following bronchoconstriction [32] and bronchodilation [200].  The 
parasternal muscles demonstrate less mechanical disadvantage than the 
diaphragm in the presence of lung hyperinflation [201], and  have greater 
mechanical efficiency  at total lung capacity (TLC) compared to FRC [202].  It 
is suggested, therefore, that the parasternal intercostal muscles may be 
preferentially recruited under conditions of increased end expiratory lung 
volume when compared to the diaphragm.   
 
The response of EMGpara to changes in respiratory load has been 
demonstrated under a number of circumstances.  Animal studies have 
shown increases in EMGpara activity during hypercapnia and histamine-
induced airway narrowing [203, 204].  A study by Duiverman et al [187] in 
adult human subjects examining diaphragm, parasternal intercostal and 
scalene muscle EMG showed different patterns of recruitment of the three 
muscle groups between COPD patients and healthy subjects.  Greater 
increases in EMGpara were observed in the COPD patients compared to 
healthy controls, with both groups exhibiting increases in EMGpara activity 
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when inspiratory resistive loads were applied.  Inspiratory activity of the 
parasternal intercostal muscles has also been shown to increase 
significantly above baseline values at the point of maximal histamine-
induced bronchoconstriction in both pre-school children and those over the 
age of five years, using clinical signs and spirometry respectively as 
reference points [190, 195].  A subsequent study by the same group 
suggested an exponential relationship between changes in FEV1 and EMGpara 
during a histamine challenge, with a return to baseline values following the 
administration of salbutamol [194].  The same authors also studied pre-
school children hospitalised with acute viral induced wheeze, and 
demonstrated reductions in EMGpara with resolution of the illness.  EMG 
activity was also shown to correlate with a clinical measure of illness 
severity in this cohort [186].  In these five studies, the logarithm of the EMG 
activity ratio (ratio of the recorded EMG signal to that obtained at baseline, 
logEMGAR) was used.  This method does not allow for comparison of levels 
of NRD between subjects, nor does it allow assessment of longitudinal 
change or quantification of disease severity from a single measurement, only 
of degree of change from an initial recording. 
 
To overcome the limitations of EMGAR, other authors have expressed 
EMGpara as a percentage of that obtained during a maximal inspiratory 
manoeuvre (EMGpara%max).  Utilising this measure, Steier et al [197] 
demonstrated greater diurnal variability of EMGpara%max in asthmatic 
subjects compared to healthy individuals, reflecting the patterns of 
variability seen in standard measures of pulmonary function.  During 
maximal incremental exercise, Reilly et al [172] showed EMGdi%max and 
EMGpara%max to be strongly correlated with patient reported 
breathlessness, both before and after the onset of neuromechanical 
dissociation (the point at which further increases in neural drive are no 
longer translated into increases in respiratory muscle pressure generation), 
indicating that measurement of respiratory muscle EMG is reflective of the 
subjective experience of respiratory disease.  This is further supported by a 
study in COPD patients during an acute exacerbation [198], in whom 
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reductions in EMGpara correlated strongly with improvements in 
breathlessness and could discriminate between patients deemed to have 
improved clinically and those who deteriorated.  In addition, EMGpara 
provided a potential index that could predict the likelihood of readmission 
within fourteen days, indicating the ability of the technique to track 
treatment response as well as to give prognostic information.  A further 
study demonstrated a significant reduction in EMGpara from hospital 
admission to discharge in a cohort of adult CF patients hospitalised for an 
acute exacerbation of CF lung disease [199]. 
 
The existing literature therefore supports the use of EMGpara as a marker of 
load on the respiratory system.  There has been relatively little work to date 
examining the applicability of this technique in paediatric populations.  Of 
these studies, the method used for expressing the EMGpara signal 
(logEMGAR) does not allow for the technique to be used as a measure of 
disease severity, nor does it permit inter-individual comparisons to be 
made.  There is a need for studies examining the use of EMGpara in children 
with a range of respiratory diseases and to evaluate the response of EMGpara 
to common clinical interventions.  The use of EMGpara%max, as has been 
used in previous studies in adult subjects, also places limitations on the 
populations in which the technique can be used; the utility of the raw EMG-




Childhood respiratory disease represents a substantial burden on 
healthcare systems worldwide.  The availability of objective measures of 
pulmonary function facilitates accurate diagnosis and optimal management 
of lung disease.  Existing measures have significant limitations in terms of 
both their ability to accurately represent the full range of pathophysiological 
changes occurring, as well as their applicability to all age groups.  
Measurement of neural respiratory drive via the parasternal intercostal 
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muscle electromyogram (EMGpara) represents a promising alternative for 
objective measurement of pulmonary function. 
 
EMGpara is feasible in both healthy subjects and patients with a range of lung 
disease, and is responsive to change in respiratory load-capacity balance.  
Much of the work to date, however, has been conducted in adult populations 
and therefore further assessment and validation of this technique is 
required to determine its value and efficacy in paediatric patient groups.  
The more recent work undertaken in adult patients has utilised the 
normalised signal (EMGpara%max) and while this approach has advantages 
over logarithmic transform of the ratio of a point measure of EMGpara to a 
baseline value (logEMGAR), as it allows comparison between individuals 
and therefore provides a quantifiable measure of disease severity, it does 
require a maximal inspiratory effort.  Volitional inspiratory and expiratory 
manoeuvres are the hallmark of many existing measures of pulmonary 
function and represent the major limitation of their applicability in younger 
age groups. Investigation of alternative methods for expressing the EMGpara 
signals is also therefore warranted. 
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1.6 Aims of thesis 
The work contained within this thesis aimed to explore the feasibility and 
utility of EMGpara in the assessment of paediatric respiratory disease.  The 
ability of the technique to detect changes in respiratory load has been 
explored.  Changes in EMGpara have also been related to change in 
conventional measures of pulmonary function, allowing the performance of 
EMGpara to be considered in the context of current clinical practice.  Studies 
have been conducted in healthy children to evaluate the effect of 
maturation, provide comparative data, and to allow investigation of 
technical considerations inherent in the measurement of EMGpara. 
 
 
Study One aimed to investigate the response of EMGpara following 
bronchodilator administration in asthmatic children, and to explore the 
relationship with conventional measures of pulmonary function. 
 
Study Two aimed to investigate the relationship between EMGpara and FEV1 
during incremental bronchoconstriction induced by methacholine challenge 
test. 
 
Study Three aimed to explore in greater depth the pathophysiological 
changes occurring in response to methacholine challenge testing and the 
relative influences of these changes on EMGpara. 
 
Study Four aimed to explore changes in EMGpara during a hospital 
admission for an acute respiratory exacerbation in children with cystic 
fibrosis, and the relationship of these changes with conventional lung 
function testing parameters. 
 
Study Five aimed to examine levels of EMGpara in a large cohort of healthy 
children, including maturational changes in EMGpara, and addressed 
technical concerns regarding normalisation and reproducibility.  The study 
 68 
also aimed to compare EMGpara values from healthy subjects to those 
obtained in children with asthma and cystic fibrosis from Studies One and 
Four. 
 69 
2. Chapter Two: Methods 
2.1 Ethical approval 
 
All studies contained within this thesis were granted ethical approval by the 
King’s College Hospital Research Ethics Committee (ref: 09/H0808/100).  
Informed, written consent was obtained from parents or guardians of all 





Height was measured using a wall-mounted stadiometer (Harpenden, 
Holtain Ltd, Crymych, UK) with a resolution of 1mm (range 600-2100mm).  
Subjects were asked to remove footwear and stand upright with heels, back 
and head against the stadiometer.  A 1kg weight was placed on the 
stadiometer carriage to improve accuracy. 
 
Weight was measured using an electronic medical scale (HR Person Scale, 
Marsden Ltd, Henley on Thames, UK) with a resolution of 50g (max weight: 
300kg).  Subjects were required to remove footwear and any heavy clothing 
and remain stationary on the scale until a steady reading to the nearest 
0.05kg was obtained. 
 
Accuracy of each device was checked daily, using a one-metre fixed bar for 
the stadiometer and validated five-kilogramme weights for the weighing 
scales. 
 
Body mass index (BMI) was calculated by dividing the individual’s weight in 
kilogrammes by the square of their height in metres.  World Health 
Organisation Anthro and Anthro Plus software (World Health Organization, 
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Geneva, Switzerland) was used to calculate weight-, height- and BMI-for-age 
percentiles based on WHO Child Growth standards [205]. 
 




Spirometric measurements were obtained using a Jaeger Masterscreen PFT 
system (Cardinal Health Ltd, Basingstoke, UK).  Flow was measured using a 
Lilly-type heated screen pneumotachograph and volume measurements 
obtained using a software-based integrator (JLAB software, version 4.0).  
Calibration of the system was performed daily in accordance with 
manufacturers’ instructions, using a 3L syringe discharged six times at a 
range of flows, as recommended by the ATS/ERS standards [14]. 
 
Spirometry was performed in accordance with ATS/ERS criteria [14].  The 
correct technique was explained and demonstrated to each subject prior to 
commencement of testing.  Subjects were seated upright with head and neck 
in a neutral or slightly extended position, fitted with a noseclip and asked to 
seal their lips tightly around a flanged mouthpiece.  The subject was then 
asked to inspire rapidly and fully to TLC and then, following a brief pause of 
less than one second, to perform a maximal forceful exhalation and to 
maintain expiratory flow until no more air could be expelled.  Subjects were 
encouraged to “blast”, rather than “blow”, the air from the lungs, and verbal 
encouragement was given throughout each manoeuvre to promote complete 
exhalation.  Software-based visual incentives were provided for all 
paediatric subjects to encourage maximal efforts.  Any traces showing 
evidence of incomplete expiration, cough, air leak or glottic closure were 
rejected.  Repeated efforts were performed until three acceptable maximal 
manoeuvres were obtained.  Acceptable repeatability was considered to 
have been obtained when the difference between the largest and next 
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largest manoeuvres was ≤0.150L or 5%.  Testing was ceased if any evidence 
of spirometry-induced bronchoconstriction was observed. 
 
2.2.2 Impulse oscillometry 
 
The impulse oscillometry technique uses small oscillatory forces imposed on 
an individual’s tidal breathing.   Through examination of the resulting 
pressure-flow relationship at the airway opening it is possible to ascertain 
the mechanical response of the tissues of the respiratory system [206].  Due 
to the use of externally-generated signals, this technique demonstrates more 
consistent results than other tests of pulmonary function, in particular those 
that rely on maximal efforts from the subject [207].  The overall response of 
the respiratory system to the imposed signals is termed impedance (Zrs), 
which is subsequently broken down into two components, each of which are 
then expressed in the frequency domain following Fast-Fourier 
Transformation (FFT).  The first is respiratory resistance (Rrs), representing 
the flow-resistive properties of the total respiratory system.  This can be 
split into the resistance occurring during inspiratory and expiratory phases, 
or can be expressed as a time-average of the entire respiratory cycle [206].  
The second component is reactance (Xrs), which is the degree to which the 
externally-imposed pressure leads flow and is the sum of the elastive and 
inertive properties of the respiratory system [118].  When elastic properties 
of the respiratory system predominate, flow occurs prior to an increase in 
pressure and thus reactance is negative.  When inertial forces are the major 
response to the pressure impulses, pressure occurs prior to the 
development of flow, and reactance is therefore positive.  The point at which 
elastic and inertive components are equal results in zero Xrs, and is termed 
the resonant frequency.  
 
The literature reports a number of changes in IOS parameters occurring as a 
result of the pathophysiological changes seen in obstructive lung disease.  It 
is well recognised that resistance is elevated in airways obstruction, 
primarily during expiration [208].  IOS provides measurement of both 
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inspiratory and expiratory resistance.  Expressing resistance in the 
frequency domain allows the frequency-dependence of resistance to be 
evaluated.  While the healthy respiratory system exhibits essentially 
frequency-independent resistance to the imposed oscillations, airways 
obstruction results in increased Rrs at lower frequencies [206].  Frequency-
dependence of Rrs, as expressed by the absolute difference or percentage 
change between Rrs at 5 and 15 or 20Hz, can also therefore be used as a 
marker of severity of airways obstruction.  In additional to changes in 
resistance, the reactance curve undergoes a rightward shift, that is, the 
elastic properties predominate and flow leads pressure to a greater extent, 
causing an increase in the resonant frequency. 
 
IOS was measured in accordance with ERS recommendations [207], using 
the Jaeger Masterscreen PFT system, operating JLAB software, version 4.0.  
The Jaeger system uses impulses of 45msec duration generated at 0.2-
second intervals; the impulses are comprised of frequencies of between 1 
and 35Hz.  IOS measurements were undertaken prior to spirometry, to 
avoid any effects on bronchomotor tone resulting from the maximal 
respiratory efforts involved in spirometry.  Subjects were seated with the 
head in a neutral or slightly extended position, with lips tightly sealed 
around the flanged mouthpiece and a noseclip in situ.  The subject was 
instructed to breathe quietly at the FRC level.  The volume-time trace 
displayed by the software was observed and recording was commenced 
once a regular tidal breathing pattern had been established.  Recording was 
continued for 90 seconds.  Verbal encouragement was given to ensure 
maintenance of a tight seal around the mouthpiece, regular tidal breathing 
and avoidance of tongue movement.  While international guidelines 
recommend manual support of cheeks [207], it has been suggested that this 
is not necessary [208].  Adding manual cheek support was found to distract 
many subjects and result in difficulty maintaining steady tidal breathing, 
and was therefore not used.  At least three recordings were undertaken and 
the volume-time and pressure-time traces of each examined for evidence of 
swallowing, coughing, air leak, glottal closure, irregular breathing or 
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improper noseclip seal.  If any evidence of the above was seen, or if 
coherence (a value used to evaluate the extent to which the obtained values 
may have been influenced by factors other than the characteristics of the 
respiratory system, used as a quality-assurance measure [209]) at any 
frequency was below 0.6, then the affected portion of the recording was 
eliminated, if at least 30 seconds of uncontaminated recording could still be 
preserved, or a further measurement was performed.  The mean of three 





2.3.1 Parasternal intercostal muscle electromyography 
 
Participants’ skin was prepared in accordance with international 
recommendations [210].  Skin was scrubbed with an abrasive gel (Nuprep, 
Weaver and Company, Aurora, Colorado, USA) to remove dead skin cells and 
excessive sebum in order to minimise electrode-skin impedance.  Any 
remaining gel and sebum was then removed with an alcohol-impregnated 
wipe before self-adhesive silver-silver-chloride electrodes were applied 
(Kendall Arbo, Tyco Healthcare, Neustadt/Donau, Germany).  Electrodes 
were applied in the second intercostal space bilaterally, directly adjacent to 
the lateral border of the sternum, with a reference electrode applied on the 
acromion process of the scapula.  While existing literature reports placing 
electrodes 3cm lateral to the sternal edge [172, 185, 198], this was felt to be 
inappropriate for the age range included in the studies contained within this 
thesis.  Data are not available regarding the dimensions of the parasternal 
intercostal muscles in children but 3cm constitutes a significant proportion 
of the overall rib length in younger children.  For example, the length of the 
second and third ribs are reported to be 100mm and 125mm respectively in 
one year-old children, and 140mm and 180mm in six year-olds [211].  
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Placing the electrodes directly adjacent to the sternal edge was felt to 
represent the best option for standardisation. 
 
Signals were amplified and band-pass filtered between 10 and 3,000Hz, 
with an additional analogue notch filter at 50Hz, to minimise mains 
frequency interference, using a PClab 3808 Biomedical Amplifier (Yinghui 
Medical Technology Co. Ltd, Guangzhou, China).  EMG signals were acquired 
(Powerlab 16SP, ADInstruments, Sydney, Australia), and displayed on a 
laptop computer (MacBook Pro, Apple, Cupertino, California, USA) running 
LabChart software (Version 7.2, ADInstruments Pty, Colorado Springs, 
Colorado, USA) with analogue to digital sampling of 10kHz.  This sample rate 
was chosen as it was the lowest sampling rate available that exceeded the 
Nyquist rate, which states that, in order to avoid aliasing and other signal 
distortion, the sampling rate must be greater than double the low-pass filter 
frequency [212].  Both amplifier and analogue-to-digital convertor were 
earthed to suitable points in the laboratory. 
 
A post-acquisition 20Hz high-pass digital filter was applied using the 
LabChart software to assist in the removal of ECG artefact.  Data were 
displayed both as raw EMG and as a rectified (root-mean-square (RMS)) 
trace, using a moving average window of 50ms [212].  
 
The EMG from the parasternal intercostal muscles was recorded during 
resting breathing.  Subjects were seated upright in a chair with their back 
supported, arms resting on armrests and feet flat on the floor.  In the case of 
younger children, arms were rested on thighs and additional foot support 
was provided to minimise trunk postural activity.  Subjects were instructed 
to remain still and not to speak throughout the recording period, with 
prompting given regularly for younger children.  Age-appropriate films were 
played for all paediatric subjects.  Three minutes of recording was allowed 
to achieve quasi homeostasis, thereafter a minimum of three minutes of 
uncontaminated EMGpara recording was obtained for all subjects.  In some 
subjects this necessitated a recording period of no more than three minutes 
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but in some paediatric subjects longer recording periods were required due 
to movement, speech or laughter causing artefact.  In order to obtain data 
regarding inter-minute variability of the measurement, recordings of up to 
fifteen minutes were undertaken, depending on the individual child’s 
attention span and ability to remain still. 
 
EMGpara recordings were undertaken prior to spirometry in all studies, with 
the exception of during methacholine challenge testing, in order to avoid 




2.3.2 Diaphragm electromyography 
 
Diaphragm EMG was recorded in adult subjects from the crural diaphragm 
using a multipair oesophageal catheter (Yinghui Medical Tech Ltd, 
Guangzhou, China), with an external diameter of 2mm.  The electrode 
catheter consists of nine consecutive electrode coils, each 10mm in length 





Figure 8 Diagram of diaphragm EMG electrode, showing electrode pairings. 
 
 
The catheter was introduced nasally, following administration of lidocaine 
topical anaesthetic spray  (Xylocaine, AstraZeneca UK Ltd, UK) into the nasal 
cavity and oropharynx.  The catheter was lubricated with gel (KY Jelly, 
Johnson & Johnson, New Brunswick, NJ, USA), passed into the nasopharnyx 
and swallowed into the oesophagus with small sips of water through a 
straw. 
 
The catheter was positioned with coil five close to the crus of the diaphragm, 
based on the EMG signal obtained from each of the electrode pairs.  
Optimum positioning of the catheter was indicated by high EMG activity 
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from electrode pairs one and five (electrodes one & five and five & nine 
respectively), and low EMG from electrode pair three (electrodes three & 
seven) during tidal breathing [213].  Once the catheter was satisfactorily 





2.3.3 EMG interpretation 
 





Figure 9 Section of raw EMGpara and root-mean-square (RMS) traces 
showing three breaths, with ECG also indicated.  Highlighted portion 
contains peak EMGpara.  
 
 
Periods of increased EMG activity characteristic of inspiration were 
identified.  Inspiratory activity located between ECG complexes was 
identified and highlighted. The peak RMS EMG activity per breath was 
calculated using the acquisition software.  For the purposes of data analysis, 
EMG was expressed in μV (EMG RMS per breath) and, where possible, as a 
ECG 
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percentage of that obtained during a maximal respiratory manoeuvre 
(EMGpara%max or EMGdi%max) obtained from an inspiration to TLC.  
Although previous studies utilising measurements of NRD have used a range 
of maximal respiratory efforts in order to normalise the resting EMG signal, 
including maximal inspiratory mouth pressures (PI,max), maximal sniff, 
maximal voluntary ventilation and inspiration to TLC [172, 196, 214], such 
manoeuvres may be difficult in younger children.  Laboratory studies with 
patients and healthy volunteers indicated that inspiration to TLC was the 
manoeuvre that could most consistently be performed by the widest age 
range of children without excessive contamination of the EMGpara signal 
from other muscle groups.  During the adult, laboratory-based methacholine 
challenge study, maxEMGpara and maxEMGdi activity was obtained from 
inspiratory capacity manoeuvres. 
 
During maximal inspiratory efforts, other muscles of the anterior chest wall 
may be recruited as accessory muscles of inspiration.  The contraction of 
these muscles may contaminate the EMGpara signal, significantly affecting the 
magnitude of the maxEMGpara signal and hence the accuracy of 
EMGpara%max as a standardised means of expressing the EMGpara signal.  
While needle EMG would have provided a method for identifying whether 
the electrical activity was originating from the parasternal intercostal 
muscles or elsewhere, this technique is unsuited to studies such as those 
contained within this thesis, nor indeed to routine clinical practice.  
Following discussion across the Respiratory Muscle Laboratories at King’s 
College, St Thomas’ and the Royal Brompton Hospitals, a consensus was 
reached regarding a qualitative method for determining whether the 
EMGpara signal recorded during a maximal inspiratory manoeuvre was 
considered to be contaminated; EMG interference patterns with very high 
amplitude or clearly visible individual spikes of EMG activity were rejected 










Figure 10  EMGpara recordings during maximal inspiratory efforts in two 
paediatric subjects. The upper trace demonstrates significant signal 
contamination, characterised by a much less dense pattern of EMG than the 
lower trace, which was deemed to contain EMGpara activity only. 
 
 
2.3.3.1 Calculation of significant change in EMGpara 
 
Although the relationship of EMGpara to other measures of pulmonary 
function has been studied [172, 185-187, 195, 198, 215, 216], the degree of 
change that can be defined as significant has not yet been described.  Such 
data are available for other pulmonary function tests, and are the focus of 
much study.  Early work to establish statistically significant changes in 
spirometric parameters [217-221] led to the now widely-recognised 
definition of 12% or greater increase in FEV1 constituting a clinically 
important bronchodilator response [222].  Such “cut-offs” are based on the 
known variability of the measurement.  By calculating the coefficient of 
variation (CV) of the measurement, and multiplying by 1.65, a cut-off value 
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above which only 5% of a normally-distributed population would be 
expected to lie can be defined [217].  Other authors have suggested the use 
of 95% confidence intervals to give a similar value [218-220]. 
 
Following the recent introduction of pulmonary function tests that can be 
used readily in younger children, such as impulse oscillometry and 
interrupter resistance, approaches to assess bronchodilator response in pre-
school children have been considered.  The use of 95% confidence intervals 
or two standard deviations from the mean of repeated measures have been 
suggested.  It is, however, also important to evaluate the intra-subject, intra-
occasion variability of the measure, and use these data to inform decisions 
regarding what should constitute a statistically significant change [223].  
Individually derived cut-offs are clearly less practical for implementation 
into clinical practice but may be more accurate in assessing an individual 
patient. 
 
Although previous work has suggested spirometric values to be more 
variable in diseased than in healthy populations [113, 217], many other 
physiological parameters have been shown to demonstrate reduced 
variability in diseased states [224].  Baseline variability of EMGpara 
measurements was therefore assessed in both healthy children and patient 
populations in this thesis.  Intra-individual change was evaluated both in the 
context of the individual’s own variability and that of the wider group.  To 
evaluate bronchodilator response, baseline CV of the EMGpara was calculated.  
Only negative changes (a reduction in NRD) were considered significant.  A 
reduction in NRD in excess of the CV multiplied by 1.65 was used as the 
threshold below which a significant change could be said to have occurred.  







2.4 Methacholine challenge testing 
 
Methacholine challenge testing was undertaken in accordance with ATS 
Guidelines [225].  Testing was performed in a well-ventilated room.  
Subjects were seated in a chair suitable for EMG recording, as described 
above.  Baseline pulmonary function testing was performed using a portable 
electronic spirometer (KoKo spirometer, Ferraris Respiratory, Louisville, 
CO, USA).  Repeated maximal efforts were performed until three acceptable 
FEV1 values within 5% of one another were obtained. 
 
The methacholine challenge was performed using a digidoser (KoKo USB 
Digidoser, Ferraris Respiratory, Louisville, CO, USA) and nebuliser 
(DeVilbiss 646 characterised nebuliser, Ferraris Respiratory, Louisville, CO, 
USA).  The KoKo software utilises an automatic triggering system and 
delivers nebulised solution for 600 milliseconds during the first second of 
inspiration via the digidoser.  The nebuliser had a certified output of 
between 1.019-1.134ml.min-1.  Use of a dosimeter and flow restrictor 
improve accuracy and repeatability of the dose delivered [225].  Subjects 
were required to wear a noseclip and inhale and exhale through the 
mouthpiece at a maximum flow of 0.5l.sec-1 imposed by a flow restrictor. 
Each inspiratory and expiratory breath was also fixed at 5 seconds in 
duration using verbal prompts.  Subjects were given verbal encouragement 
to maintain flow at the required rate and for sufficient duration.  The five-
breath dosimeter protocol was followed [225], with methacholine 
concentrations of 0.0625, 0.25, 1, 4, 8, 16 and 32mg.ml-1 (Acetyl-B-Methyl 
Choline, Nova Laboratories, Wigston, Leicestershire, UK).  A diluent (0.9% 
saline) step was also used.   
 
A single technically acceptable FEV1 manoeuvre was performed at both 30 
and 90 seconds following inhalation of each solution, and consecutive 
inhalations were performed at five minute intervals.  The lower of the two 
FEV1 manoeuvres was selected.  If the FEV1 remained within 20% of the 
post-diluent value, the next highest concentration was administered.  If a 
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20% or greater fall in FEV1 was elicited, 400μg of salbutamol was given via a 
metered-dose inhaler and spacer (Pocket Chamber, nSpire Health, Inc, 
Longmont, CO, USA).  Bronchodilator was not administered in individuals 
demonstrating a less than 20% fall in FEV1, unless specifically requested by 




2.4.1 Calculation of PC20 
 
PC20 is defined as the provocative concentration of methacholine inducing a 















C1 = penultimate methacholine concentration 
C2 = final methacholine concentration 
R1 = percent fall in FEV1 after C1 
R2 = percent fall in FEV1 after C2 
 
2.5 Measurement of respiratory flow and volume 
 
In adult subjects, respiratory flow during tidal breathing was measured 
using a Lilly-type pneumotachograph with a range of 0-800l.min-1 (Hans 
Rudolph model 4813, Hans Rudolph Inc, Kansas City, USA).  The pressure 
drop across the screen was measured using a differential pressure 
transducer (MP45-16, Validyne, Northridge, USA).  This signal was amplified 
by a carrier amplifier/demodulator (CD280, Validyne, Northridge, USA) and 
output to an analogue-to-digital converter (Powerlab 16SP, ADInstruments, 
Sydney, Australia).  Signals were displayed on a laptop computer (MacBook 
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Pro, Apple, Cupertino, California, USA) running LabChart software (Version 
7.2 ADInstruments Pty, Colorado Springs, Colorado, USA) with analogue to 
digital sampling of 100Hz.  Flow was calibrated prior to each study using a 
calibrated rotameter.  Volume was calculated via digital integration of the 
flow signal using LabChart software. 
 
Linearity of the pneumotachograph-transducer-amplifier system was 
confirmed by applying a range of flows (-200L.min-1 – 200L.min-1) to the 
pneumotachograph and plotting the amplified electrical output against 








The frequency response of the system was assessed using a balloon attached 
to the pneumotachograph via a three-way tap, which, while being allowed to 
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slowly deflate at a constant rate through the pneumotachograph, was then 
burst using a needle to provide an instantaneous cessation of flow.  The time 
taken for the signal to decay from 90% to 10% of full-scale (t10-90) was 8ms 








The Fourier transformation of the t10-90 allows the frequency response of the 
system to be calculated [227]: 
 
f3db = 1/(3*(0.008)) = 42Hz 
 
A frequency response of 42Hz is in accordance with ATS recommendations 
for equipment appropriate for the measurement of spontaneous respiratory 




Inspiratory capacity was obtained by asking the subject to perform a relaxed 
exhalation to FRC followed by a slow maximal inspiration.  The manoeuvre 
was performed a minimum of three times and the mean of the inspired 
volumes recorded. 
 
Linearity of the pneumotachograph-pressure transducer system and 
software-based digital integration for measuring inspired volume was 
assessed by passing known volumes of air (0.5L – 5.0L) through the 
pneumotachograph using a certified, adjustable 7 litre calibration syringe 
(Hans Rudolph Inc, Kansas City, USA).  The applied volume was plotted 
against the recorded volume from the LabChart software (Figure 13).  




Figure 13  Linearity of the integrated volume output of the 






2.6 Measurement of breathlessness 
 
Subjects were asked to rate their breathlessness using the modified Borg 
scale (mBorg, Figure 14) [228].  This is a twelve-point categorical scale that 
uses descriptors to anchor responses, ranging from 0 (“no breathlessness at 
all”) to 10 (“maximum breathlessness”).  The scale has been shown to be 
reliable and reproducible in subjects undergoing induced airways 
obstruction [229, 230]. 
 
 
0 Nothing at all 
0.5 Very, very slight (just noticeable) 
1 Very slight 
2 Slight 
3 Moderate 
4 Somewhat severe 
5 Severe 
6  
7 Very severe 
8  
9 Very, very severe (almost maximal) 
10 Maximal 
 










2.7 Statistical Analysis 
 
All data with n>30 were analysed for normality using the D’Agostino and 
Pearson omnibus test and if normally distributed expressed as mean (SD), 
otherwise as median (range).  Where n was <30, or in the case of ordinal 
data such as the mBorg score, data were expressed as median (range) and 
non-parametric testing used.  Paired t-tests were performed to assess the 
relationship between normally distributed within-subject variables, and 
Wilcoxon matched pairs tests for non-normally distributed data.  Normally 
and non-normally distributed unmatched data were analysed using 
unpaired t-tests and Mann-Whitney tests respectively to assess for 
differences between groups.  The relationship between variables was 
analysed using Pearson’s correlation in normally distributed data and 
Spearman’s rank correlation in non-normally distributed data.  Linear and 
non-linear regression analyses were performed to assess the strength of 
anthropometric variables in predicting EMGpara values.  Receiver-operator 
characteristic (ROC) analysis was used to assess the sensitivity, specificity, 
positive and negative predictive value of EMGpara to predict a significant 
change in FEV1.  Data analysis was performed using Prism version 6.0 
(GraphPad Software, Inc., San Diego, California, USA) software.   
 
Power calculations were undertaken using G*Power 3.1.3 (Heinrich Heine 
Universität, Düsseldorf, Germany) [232]. 
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3. Chapter Three: EMGpara to 
assess bronchodilator response 
in paediatric asthma  
3.1 Introduction 
 
Asthma is one of the most common chronic diseases of childhood, 
characterised by the presence of variable airflow obstruction, airway 
hyperresponsiveness, and airway inflammation, leading to symptoms 
including wheeze, chest tightness, cough, and difficulty in breathing [11].  
Mucosal oedema, mucous hypersecretion and smooth muscle spasm 
contribute to expiratory airflow limitation and may also lead to small airway 
collapse and hyperinflation [22].   
 
Although a clinical history can be sufficient in many cases to make a 
diagnosis, in children where a clinical history alone is inconclusive, objective 
testing is required [11].  A diagnosis of asthma in any age group is strongly 
supported by the reversibility of airways obstruction.  In older children and 
adults, this is determined by assessing the change in spirometry induced by 
inhaled β2 agonists.  An increase in FEV1 of 12% or greater is deemed a 
significant response [14].  It has been noted previously, however, that 
administration of a bronchodilator may induce changes in measures other 
than FEV1 in patients with obstructive lung disease [233], and hence 
evaluating this single measure may not fully represent the full response to 
β2 agonists.   EMGpara, as a measure of overall respiratory load, may more 
accurately represent the range of pathophysiological changes.  EMGpara has 
been shown to return to baseline levels when a bronchodilator is 
administered following airway challenge testing, though the specific 
relationship with spirometry following bronchodilator was not evaluated 
[194].  In addition, no objective measure is available to support the 
assessment of reversible airways obstruction in patients who are unable to 
reliably perform spirometry, including pre-school age children.  The aims of 
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this study were, therefore, to assess bronchodilator-induced changes in 
EMGpara in asthmatic children, including those unable to complete 
conventional pulmonary function tests, and to investigate the relationship 




Children from the paediatric chest and difficult asthma clinics at King’s 
College Hospital were recruited.  All children had a physician diagnosis of 
asthma or pre-school wheeze.  Ethical approval for the study was granted by 
the King’s College Hospital Research Ethics Committee (ref: 
09/H0808/100).  Informed, written consent was obtained from parents or 





Height was measured using a wall-mounted stadiometer (Harpenden, 
Holtain Ltd, Crymych, UK) and weight with an electronic medical scale (HR 
Person Scale, Marsden Ltd, Henley on Thames, UK). 
 
EMGpara, IOS and spirometry were measured as described in Chapter Two.  
Briefly, EMGpara was recorded using surface electrodes placed over the 
second intercostal space.  The signal was amplified (gain 1,000), band-pass 
filtered between 10 and 2,000Hz, and a 50Hz notch filter and a post-
acquisition 20Hz digital high-pass filter applied.  The signal was converted 
to root-mean-square (RMS) and mean peak RMS EMGpara per breath 
calculated.  IOS was performed in accordance with ERS guidelines [207], 
with the mean of three reproducible recordings being reported.  Spirometry 
was performed according to ATS/ERS recommendations [14], and the 






Anthropometric and demographic data were recorded.  Resting EMGpara was 
recorded for ten minutes with the child seated, at rest, and in children able 
to cooperate with the technique spirometry was performed.  A subset of 
children also underwent impulse oscillometry, which was performed prior 
to spirometry to avoid any effects on bronchomotor tone resulting from the 
maximal respiratory efforts involved in spirometry.  The bronchodilator 
salbutamol (400μg) was then administered via metered-dose inhaler and 
spacer.  EMGpara recording was repeated fifteen minutes later, at a time point 
corresponding to peak bronchodilator activity, after which IOS and 
spirometry were repeated. 
 
 
3.3.3 Statistical analysis 
 
All statistical testing was performed using Prism version 6.0 (GraphPad 
Software Inc., San Diego, USA).  On testing for normality, using the 
D’Agostino and Pearson omnibus test, no data were found to be normally 
distributed, hence all data were assessed using non-parametric statistical 
testing and expressed as median (range).  Within-subject changes were 
assessed using the Wilcoxon matched pairs test.  Differences between 
groups were assessed using the Mann-Whitney test. A p value <0.05 was 
taken as statistically significant.  Relationships between variables were 
assessed using Spearman’s correlation.  Receiver-operator characteristic 
analysis was used to assess the sensitivity, specificity, positive and negative 







EMGpara recordings of acceptable quality (as detailed in Chapter Two) were 
obtained in 53 children (Table 1).  Of those 53, technically acceptable 
spirometry was obtained in 33 children.  IOS, EMGpara and spirometry were 
obtained in 12 children.  Neither spirometry nor IOS were attempted in the 
20 children of pre-school age. 
 
 
3.4.1 Subject characteristics 
 
 




Age (years) 10.66 (3.67) 3.70 (0.65 – 5.12) 
Sex (male: female) 15: 18 12: 8 
Height (m) 1.448 (0.155) 
0.976 (0.732 – 
1.031) 
Weight (kg) 40.14 (13.01) 15.03 (8.50 – 19.70) 
BMI (kg m-2) 
17.75 
(13.35 - 27.25) 
15.9 (13.6 – 18.6) 
Ethnicity (n (%)) 
White: 13 (39.4%) 
Black: 15 (45.5%) 
Asian: 3 (9%) 
Other: 2 (6.1%) 
White: 13  (65%) 
Black: 4  (20%) 
Other:  3  (15%) 
Baseline FEV1 
(%predicted) 
85.6 (22.7) N/A 
Table 1 Anthropometric and demographic characteristics of subjects for 






3.4.2 Change in EMGpara 
 
In the cohort as a whole, there was a significant (p<0.0001) decrease in 
median (range) EMGpara following bronchodilator administration (8.36 (1.37 






Figure 15 Decrease in EMGpara following bronchodilator (BD) 




In the 33 school aged children who performed spirometry, a significant 
(p<0.001) decrease in median (range) EMGpara was observed (8.40 (1.37 – 
20.11)μV to 5.60 (1.42 – 20.57)μV), -11.06 (-58.4 – 13.9)%.  In the 20 pre-
school children in whom spirometry was not performed, median (range) 
EMGpara also decreased significantly from 8.20 (5.57 – 16.46)μV to 6.98 (4.99 
– 17.06)μV (p<0.01), -16.6 (-36.4 – 18.0)% (Figure 16). 
 
There was no statistically significant difference in baseline EMGpara or the 







Figure 16 Decrease in EMGpara following bronchodilator (BD) administration in 33 school age children and 20 pre-school children.  
Lines denote median and inter-quartile range. 
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3.4.3 Statistical power 
 
As no pre-existing data were available to support an a priori power 
calculation, retrospective power calculations were undertaken to assess the 
achieved power in detecting differences in EMGpara following 
bronchodilator.  For the cohort as a whole, 99.8% power at the 5% level was 
achieved to detect the change in mean (SD) EMGpara described above.  In the 
spirometry group (n=33), the power was 85.2% at the 5% level while in the 
no spirometry group (n=20), the achieved power was 65.8% at the 5% level. 
 
3.4.4 Determining significant change in EMGpara 
 
In 24 of the total cohort of patients, a sufficient duration of baseline (pre-
bronchodilator) EMGpara recording was available to allow the calculation of 
the inter-minute coefficient of variation (CV) of peak RMS EMGpara per 
breath.  This was used to determine a cut-off for the degree of change in 
EMGpara that would constitute a positive response to bronchodilator 
administration.  Cut-off values were calculated for the group as a whole. 
 
The group mean CV for the 24 children was 9.27%, which when multiplied 
by 1.65 (see Chapter Two) gave a cut-off value for change of 15.29%.  Using 
this group mean derived threshold, 27 of the 53 patients (50.9%) showed a 
significant reduction in NRD following bronchodilator administration.  
 
Median (range) baseline (pre-bronchodilator) EMGpara was significantly 
(p=0.017) higher in those children who demonstrated a reduction in 
EMGpara greater than the cut-off value compared to those who did not (9.38 







3.4.5 Changes in pulmonary function measures 
 
In the 33 school age children who underwent conventional measures of 
pulmonary function, significant changes were observed in all spirometry 
and impulse oscillometry parameters except R20Hz (Table 2). 
 
No significant relationships were observed between changes in spirometric 
and oscillometric results. 
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(38.2 – 126.0) 
97.0 










(0.26 – 0.89) 
0.49 




(0.27 – 0.80) 
0.45 




(0.23 – 0.47) 
0.33 




(0.0 – 62.3) 
28.2 




(8.04 – 31.97) 
16.71 




(0.18 – 4.93) 
0.86 
(0.10 – 1.72) 
0.005 
Table 2 Changes in pulmonary function following bronchodilator 
administration in asthmatic children (n=33 for FEV1, FVC and FEF25-75/FVC.  













3.4.6 Relationship with measures of pulmonary function 
 
The median (range) percentage changes in EMGpara and FEV1 (-11.06 (-58.4 
– 13.9)% versus 9.1 (-4.7 – 36.1)%) were not significantly different. 
 
No relationships were observed between percentage changes in EMGpara and 
any of the measures of pulmonary function.  No correlation was observed 
between baseline EMGpara and any baseline measures of pulmonary function. 
 
Of the 27 children in whom EMGpara exceeded the 15.29% group mean 
derived cut-off, 16 were over the age of five and had therefore also 
performed spirometry (lower segment of Figure 17).  Of the sixteen, six 
(37.5%) demonstrated a 12% or greater change in FEV1 (lower right 
quadrant of Figure 17).  Seven children from the cohort of 33 demonstrated 
an increase in FEV1 of greater than 12% without a significant decrease in 












Figure 17 Relative changes in EMGpara and FEV1 following bronchodilator 
administration in 33 school age children.  Horizontal dotted line represents 
the group mean CV*1.65 (15.29%); vertical dotted line a 12% increase in 




Table 3 details the sensitivity, specificity, positive and negative predictive 
values of the 15.29% cut-off value for change in EMGpara in predicting a 




























 Sensitivity: 46.2% Specificity: 50%  
Table 3 Group data derived cut-off for EMGpara.  Sensitivity, specificity, 
positive and negative predictive values for significant change in EMGpara to 





Due to the poor predictive ability of the 15.3% cutoff, further analyses were 
performed to explore alternative cutoff values for significant change in 
EMGpara.  A 16.94% decrease in EMGpara was found to offer the greatest 
ability to predict a 12% increase in FEV1; however, the values for 
sensitivity and specificity were 55.0% and 46.2% respectively and the area 







Figure 18 Receiver-operator characteristic curve using a value of -16.94% 
change in EMGpara to predict a 12% increase in FEV1.  Square symbols 
indicate line of identity. 
 
 
3.4.7 Determining significant change in EMGpara – individual 
subjects 
 
A significant change in EMGpara was also calculated based on an individual 
subject’s CV*1.65.  Of the 24 patients in whom a sufficient duration of 
baseline (pre-bronchodilator) recording was available to calculate their 
individual CV, 10 (47.5%) showed a change in EMGpara following 
bronchodilator administration that exceeded their own personal cut-off 
value. 
 
Seventeen of the 24 subjects had also performed spirometry.  Three 
demonstrated an increase in FEV1 greater than 12% as well as a decrease in 
EMGpara greater than their own cut-off.  Four patients demonstrated an 
increase in FEV1 of greater than 12% without a reduction in EMGpara in 
excess of their own CV*1.65.  Five patients demonstrated a significant 
decrease in EMGpara without a concomitant significant increase in FEV1.  The 
remaining five showed significant changes in neither EMGpara nor FEV1. 
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Table 4 details the sensitivity, specificity, positive and negative predictive 
values of subjects’ own CV*1.65 as a cut-off value for change in EMGpara to 

















 Sensitivity: 42.9% Specificity: 50%  
Table 4 Individual data derived cut-off for EMGpara.  Sensitivity, specificity, 
positive and negative predictive values for significant change in EMGpara to 








The results of this study show that EMGpara is a feasible technique for use in 
asthmatic children, and demonstrated the ability of EMGpara to detect change 
in NRD following administration of a bronchodilator.  Calculation of 
individual and group CVs allowed determination of a threshold for a 
statistically significant change in EMGpara from baseline values.  Significant 
changes were observed in conventional measures of pulmonary function, 
supporting the premise that changes in respiratory load occurred following 
bronchodilator administration.  The higher pre-bronchodilator NRD 
observed in those children demonstrating a significant change in EMGpara 
suggests that these children had greater levels of bronchoconstriction at 
baseline.  However, no relationship was found between the relative changes 
seen in EMGpara and conventional measures of pulmonary function 
(spirometry and impulse oscillometry). 
 
In children with asthma, the overall load on the respiratory system may be 
due to not only the changes in airway calibre, but also a result of lung 
hyperinflation and concomitant alterations in chest wall mechanics.  The 
numerically greater, though not statistically significant, mean percentage 
change observed in EMGpara compared to that in FEV1 following 
bronchodilator administration may be due to EMGpara reflecting the overall 
load on the respiratory system rather than a single component as with FEV1.  
This may also explain the individuals in whom a significant change was 
observed in EMGpara in the absence of a significant FEV1 change.  Spirometry 
primarily measures airways obstruction occurring in the larger proximal 
airways.  It has been suggested that 50-90% of the airways obstruction 
occurring in asthma may be present in distal airways [30].  Distal airway 
obstruction and collapse also contribute to hyperinflation and the 
development of intrinsic positive end-expiratory pressure (PEEPi).  This 
would impose an additional threshold load on the respiratory muscles, 
which would not be measured using spirometry but would cause NRD to be 
 105 
elevated.  Conversely, reducing airway narrowing through administration of 
a bronchodilator may have reduced expiratory airway collapse and 
therefore air trapping, hyperinflation and PEEPi which will not be reflected 
in the FEV1 but would result in a change in NRD, as shown by a decrease in 
EMGpara.  Changes in end-expiratory lung volumes may have contributed to 
changes in NRD [172] and have been observed in asthmatic subjects 
following bronchodilator administration [234].  Static lung volumes were 
not measured in this study, which represents a limitation of the protocol. 
 
In order to supplement the relatively limited information regarding overall 
respiratory system pathophysiology provided by FEV1 alone, a number of 
other indices were examined.  Mid-expiratory airflows (FEF25-75) can be 
used to assess smaller airways function, and have been reported to change 
in asthmatics following bronchodilator administration [221] as occurred in 
this study.  Such measurements, however, are affected by changes in vital 
capacity.  The ratio of FEF25-75 to FVC has been used to account for this [235].  
As with FEF25-75, FEF25-75:FVC changed significantly following 
bronchodilation, but no correlation with EMGpara was observed. 
 
Impulse oscillometry (IOS) was also performed in a subset of 12 subjects.  
This measurement was performed in a limited number of subjects only due 
to practical considerations – the addition of IOS lengthened the protocol, 
and as much of the testing was performed prior to a clinic appointment 
sufficient time was not available in many cases to perform IOS in addition to 
spirometry and EMGpara.  A number of indices were examined, as 
recommended by a recent American Thoracic Society consensus publication 
[236].  Z5Hz is a composite measure of the resistance and reactance 
components that comprise the impedance of the respiratory system.  Lower 
frequency components of the oscillometry signal have been shown to be 
discriminative between healthy and asthmatic children [207].  Measures of 
resistance at 5Hz and 20Hz reflect primarily the contributions of smaller 
and larger airways respectively to overall respiratory system resistance.  
The percentage difference between these two indices (ΔR5-R20) assesses 
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the frequency-dependence of respiratory system resistance.  In health, 
respiratory system resistance is essentially frequency-independent, but in 
airways obstruction, increases in smaller airways resistance lead to greater 
discrepancy between the Rrs values at lower and higher frequencies.  ΔR5-
R20 hence provides a measure of smaller airways dysfunction.  Reactance 
parameters (RF and AX) represent the interaction of elastic and inertial 
properties of the respiratory system and have been shown to demonstrate 
the greatest changes with disease and following treatment [118].  It has 
been suggested that composite measures (such as AX and ΔR5-R20) 
including measurements at a number of frequencies offer an improved 
signal-to-noise ratio and thus are better able to detect clinically relevant 
changes [118]. 
 
It was anticipated that the FEF25-75/FVC and IOS data could have provided 
further information regarding small airways function.  The significant 
changes in FEF25-75/FVC, R5 and ΔR5-R20 indicate that an increase in smaller 
airways calibre did occur in this cohort; however, there was still no 
relationship with the relative changes in these parameters and EMGpara. 
 
It is widely recognised that there is significant heterogeneity in the 
pathophysiological changes that occur in patients with asthma [237].  It is 
possible that airway obstruction was present in both the large and small 
airways in the patients in this study and may explain the absence of a 
correlation between flow- or pressure-based measures of pulmonary 
function (spirometry and IOS) and EMGpara.  Similarly, for a given change in 
EMGpara the changes in larger and smaller airway calibre may have been 
different in each individual patient, resulting in an absence of relationships 
between EMGpara and spirometric or IOS variables.  This premise is 
supported by the absence of significant relationships between oscillometric 
and spirometric parameters. 
 
In addition to this, the fact that many of the subjects included in this study 
were receiving inhaled corticosteroid therapy (or other ‘controller’ 
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medication) and would therefore be expected to have a diminished or even 
absent response to β2 agonists, may make the detection of relationships 
between variables more challenging.  While the second aim of this study – to 
investigate the relationship between relative changes in EMGpara and 
conventional measures of pulmonary function – does not theoretically 
require significant changes in each parameter to be achieved, smaller 
changes may well lie within the natural variability of each measure; the 
signal to noise ratio may therefore not be sufficient to allow relationships to 
be detected. 
 
Previous studies examining the use of EMGpara in adults with CF and COPD 
have demonstrated relationships between disease severity (measured by 
spirometry) and EMGpara [172, 196, 197].  It should be noted, however, that 
the patients in these studies had more severe lung disease, facilitating the 
detection of relationships between variables. 
  
Recruiting patients likely to demonstrate a marked bronchodilator response 
would be difficult in this patient population as the majority of children 
studied were receiving inhaled corticosteroid therapy (or other ‘preventer’ 
medication) and would therefore be expected to have a diminished or even 
absent response to β2 agonists.  Steroid-naïve patients may have been a 
more appropriate population to study; however, many children referred to 
King’s College Hospital have an established diagnosis of asthma and are 
already receiving treatment.  Asthma management in primary care settings 
is undertaken according to national and international guidelines, and 
referral to a secondary or tertiary centre is not recommended without a trial 
of inhaled steroids [11].  Recruitment of newly diagnosed asthmatic children 
not yet commenced on long-term treatment, although potentially presenting 
a greater logistical challenge and thus resulting in a smaller sample size, 
may have shown relationships between EMGpara and lung function.  
 
While there were no significant correlations found between conventional 
measures of pulmonary function and EMGpara, it was anticipated that there 
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would have been a stronger agreement between the changes in FEV1 and 
EMGpara when examined using a binary outcome (significant versus non-
significant changes).  In approximately half of patients (16 of 33 (48.5%)), 
EMGpara reflected the change in FEV1.  In the subjects in whom a significant 
change was observed in EMGpara but not in FEV1, it could be hypothesised 
that the EMGpara reflected changes additional to those occurring in larger 
airways.  The presence, however, of significant changes in FEV1 in the 
absence of reciprocal changes in EMGpara is more challenging to explain. 
 
An increase in FEV1 in the absence of a fall in EMGpara may be explained in 
some patients by increased effort in the FEV1 manoeuvre following 
bronchodilator.  By evaluating the shape of the flow-volume loops and 
ensuring at least three reproducible FEV1 efforts were produced, the 
likelihood of submaximal efforts was minimised [14].  Other authors have 
suggested, however, that submaximal efforts, both in skeletal muscle 
strength [238] and pulmonary function testing [219], may still be 
reproducible.  It is conceivable that some subjects in the current study may 
have produced submaximal efforts prior to bronchodilator administration 
and, following salbutamol, a combination of the small improvement in 
pulmonary function together with a ‘true’ maximal effort produced a 12% or 
greater increase in FEV1. 
 
Acute administration of salbutamol has also been shown to increase resting 
metabolic rate and oxygen consumption in adult subjects [239].  An increase 
in oxygen consumption and CO2 production would result in an increase in 
ventilation and hence NRD to maintain blood gas homeostasis.  Increases in 
metabolism were, however, only observed in subjects who were salbutamol-
naïve [239],  not in those chronically exposed to  the medication [240] and 
were only observed following dosages of inhaled salbutamol of 800μg or 
greater, double the dose used in the current study.  It is possible that lower 
doses in children may result in similar effects on metabolism.  Many of the 
children studied regularly used β2 agonists, although a precise history of 
medication use was not taken.  It is possible, therefore that some children 
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whose asthma was well controlled may not have been using inhaled 
salbutamol regularly.  It is not possible to determine from the current data 
whether the reduction in EMGpara represented solely salbutamol-mediated 
bronchodilation reducing the load on the respiratory system or whether this 
was attenuated by a concomitant rise in NRD mediated by an increase in 
metabolism.  It is feasible that this may explain why in some patients there 
was an increase in FEV1 without an associated reduction in EMGpara. 
 
Measurement of mean peak RMS EMGpara per breath does not take account 
of other factors such as inspiratory time or the rate of rise of muscle activity 
during inspiration.  A decrease in total parasternal intercostal muscle 
activity (i.e. the area under the RMS EMGpara curve) may occur in the absence 
of a fall in peak EMGpara, and would not be seen by using the current method 
of analysis.  Measurement of respiratory flow and timing  (inspiratory, 
expiratory and total breath time) can be obtained using a 
pneumotachograph attached to a mouthpiece, but such techniques were 
found to be too distracting for younger subjects and resulted in marked 
alterations in the tidal breathing pattern.  Technological limitations in EMG 
signal processing currently preclude the use of other analysis methods.  
Further developments in filtering algorithms should allow removal of ECG 
artefact and consequently more detailed analysis of the EMGpara signal. 
 
Contamination of the EMG signal by cardiac artefact is a recognised 
limitation of the technique.  Reliable methods for ECG removal that do not 
also remove a significant proportion of the EMG signal are not currently 
available.  As a result the data from eleven children were excluded from 
analysis.  Electrical interference from external sources resulted in a further 
four cases being excluded from analysis.  External interference was 
encountered despite appropriate signal conditioning with electronic and 
digital filtering and grounding of equipment.  In a further two cases a stable 
respiratory pattern that would allow analysis of one minute of EMGpara 
activity was not established.  Further technological developments are likely 
to reduce the number of data sets that are rejected and improved filtering 
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algorithms may allow complete removal of the ECG signal.  This study was 
also undertaken first and investigator inexperience when recording EMGpara 
may have resulted in a number of traces being unacceptable for analysis.  
For seventeen of 70 traces to be rejected could indicate that the technique 
may have limited utility, but it should be noted that such issues were not 
encountered in the studies contained within Chapters Four to Seven.  The 
difficulties in obtaining optimal signals within this study do, however, 
highlight the need for experienced investigators when undertaking 
measurements of EMGpara using currently available systems. 
 
The appropriateness of the use of the individual versus group CV to 
determine the threshold for a significant change cannot be determined from 
these data.  The sensitivity and specificity of each method (group and 
individual CV*1.65) is very similar.  Calculating a patient’s individual CV 
from a baseline recording would not currently be possible in clinical 
practice due to the technological limitations of the technique and the 
current reliance on manual analysis, though further software advances may 
allow this in future.  The sample size is small from which to develop a 
threshold for the group mean CV but the agreement with the CV from 
Chapter Seven (examining EMGpara in healthy children) indicates that this 
threshold may be appropriate and that a change in EMGpara of 15.3% could 
be viewed as significant. 
 
 
3.5.1 Relationship with previous literature 
 
There are few data currently available on the use of parasternal intercostal 
muscle EMG in children.  The EMGpara response of paediatric subjects to 
bronchodilator administration has previously been assessed only following 
induced airways obstruction.  Maarsingh et al demonstrated a return of 
EMGpara to baseline levels when salbutamol was administered to asthmatic 
children following a histamine challenge, in both children over the age of 
five years [194] and in pre-school children [195].  Maarsingh et al [194] did 
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not report the agreement between changes in FEV1 and EMGpara following 
bronchodilator administration, although an exponential relationship 
between changes in FEV1 and EMGpara was observed during the histamine 
challenge. 
 
Reductions in EMGpara, recorded using fine-wire electrodes, have previously 
been shown in patients with severe COPD following inhalation of a 
combined β2 agonist and corticosteroid (salmeterol fluticasone propionate) 
[241].  The subjects demonstrated minimal changes in FEV1 and end-
expiratory lung volumes, yet pronounced reductions in EMGpara activity.  In 
keeping with the current results, these data suggested that relationships 
between changes in conventional measures of pulmonary function may not 
be seen.  The authors speculated that this might have been due to a 
combination of improvements in respiratory mechanics and increases in 
skeletal muscle contractility, which enhanced the efficiency of respiratory 
muscle contraction.  The same authors previously demonstrated increases 
in parasternal intercostal muscle contractility in dogs when high doses of 
intravenous salbutamol were administered [242].  Data obtained in a severe 
COPD cohort must, however, be used with caution when interpreting the 
data from this group of paediatric patients with relatively mild asthma, 
particularly in view of the methodological differences of using needle EMG 
versus surface techniques. 
 
3.5.2 Relevance to clinical practice 
 
While these data demonstrate that EMGpara changes in response to β2 
agonist administration in both pre-school and school-aged asthmatic 
children, suggesting that the technique may act as a marker of respiratory 
load in these populations, the lack of relationship with conventional 
measures of pulmonary function indicates that EMGpara cannot be viewed as 
a direct substitute for spirometry.  In older children able to perform 
spirometry, the data from this study are unlikely to be sufficiently 
convincing to warrant the introduction of EMGpara in place of FEV1 as a 
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determinant of reversibility of airways obstruction.  The relationship 
between EMGpara and other aspects of pulmonary pathophysiology require 
further exploration in order to more fully understand the determinants of 
reductions in NRD following bronchodilator administration, which would 
facilitate translation into clinical practice.  
 
The determination of a threshold for a statistically significant reduction in 
EMGpara activity, however, provides an important step towards the 
development of EMGpara as a clinical test.  Although future studies will need 
to address the question of what constitutes a clinically significant change in 
EMGpara, the data presented from this study suggest that a reduction in 
EMGpara activity of greater than 15.3% constitutes a change that is unlikely 
to occur simply as a result of the natural variability of the measure.  This 
may be more useful in wheezy pre-school children where other measures of 
reversibility of airways obstruction are lacking, and may provide objective 





In conclusion, these data demonstrate that EMGpara can detect change in 
NRD following administration of bronchodilator in asthmatic children.  The 
magnitude of change observed was greater than that seen in FEV1.  There 
was poor agreement between the changes observed in EMGpara and 
conventional measures of pulmonary function.  Using the coefficient of 
variation provided a method for determining a significant change in 
respiratory load, but there remained a number of children in whom the 
EMGpara did not change significantly despite an increase in FEV1. 
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4. Chapter Four: EMGpara in 
assessing response to 




Data from studies using EMGpara in adult patients with cystic fibrosis [172] 
and using EMGdi in patients with COPD [189] have indicated a direct 
relationship between neural respiratory drive (NRD) and FEV1 when 
measured on a single occasion.  The relationship between dynamic changes 
in NRD and lung function is, however, unclear.  Previous studies have shown 
no relationship between changes in FEV1 and EMGpara [198, 199] in patients 
hospitalised with acute exacerbations of cystic fibrosis and COPD 
respectively.  A study by Maarsingh et al [194] indicated that a linear 
relationship existed between changes in FEV1 and the logarithm of the 
EMGpara activity ratio (EMGpara activity related to baseline, EMGAR) during a 
histamine challenge in asthmatic children.  No such relationship has, 
however, been observed between FEV1 and EMGpara in the data presented in 
Chapter Three.  Bronchial hyperresponsiveness testing involves repeated 
inhalation of gradually increasing concentrations of a provocant agent 
resulting in controlled, incremental changes in lung function.  Such a 
repeated-measures design allows relative changes in FEV1 and EMGpara to be 
investigated without the potential confounding factors inherent in a 
longitudinal clinical study, though it is important to recognise that this may 
not be entirely representative of the spontaneous bronchoconstriction and 
hyperinflation occurring in asthma.  The current study was undertaken to 
further elucidate the nature of the relationship between FEV1 and EMGpara 
during incremental changes in airway calibre.  As chemical challenge testing 
is not routinely undertaken clinically in children, the study was performed 




We hypothesised that: 
 EMGpara would increase in a stepwise manner reflecting the 
decrement in lung function in response to the incremental dose of the 
chemical bronchoconstrictor agent. 
 The magnitude of increase in EMGpara would be greater than the 
decrease in FEV1 due to greater sensitivity of EMGpara to the range of 




Adult patients attending the Chest Unit of King’s College Hospital following 
physician referral for methacholine challenge testing, and staff and students 
of King’s College Hospital and King’s College London were recruited.  Ethical 
approval was granted by the King’s College Hospital Research Ethics 
Committee (ref: 09/H0808/100).  Informed, written consent was obtained 






Height was measured using a wall-mounted stadiometer (Harpenden, 
Holtain Ltd, Crymych, UK) and weight with an electronic medical scale (HR 
Person Scale, Marsden Ltd, Henley on Thames, UK). 
 
EMGpara was measured as described in Chapter Two (Methods).  Briefly, 
EMGpara was recorded using surface electrodes placed over the second 
intercostal space.  The signal was amplified (gain 1,000), band-pass filtered 
between 10 and 2,000Hz, and a 50Hz notch filter and a post-acquisition 
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20Hz digital high-pass filter applied.  The signal was converted to root-
mean-square (RMS) and mean peak RMS EMGpara per breath calculated. 
 
The methacholine challenge test was performed using a portable electronic 
spirometer-digidoser system (KoKo USB spirometer and digidoser, Ferraris 
Respiratory, Louisville, CO, USA) and nebuliser (DeVilbiss 646 characterised 
nebuliser, Ferraris Respiratory, Louisville, CO, USA).  A five-breath 
dosimeter protocol was followed [226], with the duration of both 
inspiration and expiration fixed at five seconds and inspiratory flow limited 
to 0.5L.sec-1.  A 0.9% saline diluent step was followed by methacholine 
concentrations of 0.0625, 0.25, 1, 4, 8, 16 and 32mg.ml-1 (Acetyl-B-Methyl 





EMGpara was recorded for three minutes prior to commencement of the 
challenge protocol to provide a measure of baseline NRD.  Baseline 
measurements of FVC and FEV1 were then performed.  As per standard 
practice the first inhalation of the challenge test was saline, to screen for 
reaction to the diluent, which was followed by methacholine solutions of 
gradually increasing concentration (as stated above), administered at five-
minute intervals.  A single, technically acceptable FEV1 manoeuvre was 
performed at both 30 and 90 seconds following each inhalation, with the 
lowest FEV1 value recorded.  Following the second FEV1 manoeuvre, EMGpara 
was recorded for the remaining 3.5 minutes prior to the next methacholine 
dose, with the final minute of the recording used for analysis.  The challenge 
test was terminated either when the subject demonstrated a 20% or greater 
fall in FEV1, considered a positive response, or when the maximal dose of 
32mg.ml-1 methacholine was reached.  In subjects demonstrating a positive 
response or reporting a sensation of respiratory discomfort, 400μg 
salbutamol was administered via a metered-dose inhaler and spacer.  If 
salbutamol was administered, one further FEV1 manoeuvre was performed 
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after 15 minutes to ensure the subject had regained their baseline level of 
pulmonary function.  The changes in EMGpara and FEV1 from those obtained 
following saline inhalation were calculated [226]. 
 
Changes in FEV1 from the post-diluent stage were plotted against the log-
transformed methacholine concentration.  The provocative concentration of 
methacholine that induced a 20% fall in FEV1 (PC20) was calculated using 
the following equation [226]: 
 
PC20 =  
 
Where: 
C1 = penultimate methacholine concentration 
C2 = final methacholine concentration 
R1 = percent fall in FEV1 after C1 
R2 = percent fall in FEV1 after C2 
 
Percentage changes in EMGpara were also plotted against log methacholine 
concentration.  Linear interpolation of the EMGpara–log methacholine dose 
curve was used to calculate the percentage change in EMGpara at PC20. 
 
 
4.3.3 Additional analyses 
 
Area under the dose-response curve and the slope of the dose-response 
regression line have been used previously to evaluate bronchial 
hyperresponsiveness [243, 244].  These methods have the benefit of 
including the response at each stage of the challenge test, not only baseline 
and end of test.  Area under the curve was calculated by plotting percentage 
change in FEV1 or EMGpara against methacholine concentration.  Due to the 
non-linear nature of the methacholine concentrations, doses were 
numbered to give a linear scale along the x-axis (with saline assigned zero, 

antilog logC1 









0.0625mg.ml-1 one, and so on).  Linear regression was performed to 
determine the slopes of the dose-response lines of EMGpara and FEV1 
percentage changes in response to increasing methacholine concentrations, 





4.3.4 Statistical analysis 
 
Data were tested for normality using the D’Agostino and Pearson omnibus 
test, although where n<30, data were always treated as non-normally 
distributed and non-parametric statistical testing was used.  Within-subject 
changes were assessed using the paired t-test or Wilcoxon matched pairs 
test for normally and non-normally distributed data respectively.  
Differences between group medians of non-normally distributed data were 
assessed with the Mann-Whitney test.  Unpaired t-tests were used to assess 
differences between group means in normally distributed data.  
Relationships between variables were assessed using Spearman’s rank 
correlation, as no variables in which correlations were assessed fitted a 
Gaussian distribution.  A p value <0.05 was taken as statistically significant.  
When comparing the relative magnitudes of changes in FEV1 and EMGpara, 




4.3.4.1 Sample size calculation 
 
We hypothesised that the increase in EMGpara observed in a positive test 
would be greater than the 20% reduction in FEV1 that defines a positive 
methacholine challenge test [226].  Assuming a baseline mean (SD) raw 
EMGpara of 4.8 (2.0)µV as reported by Reilly et al [172], 25 subjects were 
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A total of 32 subjects were studied in order to obtain the minimum sample 
of 25 subjects in whom a significant response to methacholine was observed 
(defined by a 20% or greater decrease in FEV1 [226]).  The demographic and 
anthropometric characteristics are shown in Table 5.  Subjects’ diagnoses 
(reason for inclusion in the study) are shown in Table 6. 
 
 
Age (years) 29.2 (22.0 – 50.8) 
Sex (male: female) 12: 20 
Height (m) 1.70 (1.51 – 1.90) 
Weight (kg) 68.4 (51.6 – 105.9)  
BMI (kg m-2) 24.4 (20.2 – 32.1) 
Ethnicity (n (%)) White 26 (81.25%) 
Black: 1 (3.13%) 
Asian: 4 (12.5%) 
Other: 1 (3.13%) 
Baseline FEV1 (%predicted) 97.1 (80.0 – 122.3) 
Table 5 Anthropometric and demographic characteristics of participants in 
























Asthma (taking medication) 





















Asthma (taking medication) 
Self-reported atopy/allergies 









Both EMGpara and FEV1 changed significantly from baseline to end of test in 
the whole cohort (Table 7, Figure 19) as well as the ‘responder’ subset 
(Table 7).  Despite being below the threshold to be considered a positive 
response, the change in FEV1 from baseline in the ‘non-responder’ group 
was also statistically significant.  The corresponding change in EMGpara was 












(2.00 – 8.92) 
5.86 







(80.00 – 122.30) 
70.95 









(2.25 – 8.92) 
6.27 
(3.37 – 19.60) 
<0.0001 
31.6 




(80.00 – 122.30) 
67.80 
(37.98 – 92.27) 
<0.0001 
-27.8 






(2.00 – 5.01) 
4.49 
(2.37 – 9.32) 
ns 
23.0 




(84.91 – 105.8) 
91.43 
(72.98 – 100.70) 
0.031 
-7.2 
(-14.2 – -2.2) 




Figure 19  Decrease in FEV1 and increase in EMGpara in 32 adults undergoing methacholine challenge test. 
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Although the median (range) percentage change in EMGpara was numerically 
greater than that observed in FEV1 from baseline to end of test (EOT) this 
did not reach statistical significance for the cohort as a whole (p=0.091), the 
responder (p=0.22) or non-responder (p=0.2188) groups. 
 
A one-sample t-test was used to compare the changes in EMGpara at the 
concentration of methacholine inducing a 20% fall in FEV1 (PC20) to those 
in FEV1.  The median (range) change in EMGpara (28.4 (-33.7 – 141.7) %) was 
not significantly different to the 20% change in FEV1 (p=0.2).  Similarly, 
there was no significant difference between the median (range) area under 
the curve (AUC) of FEV1 (41.8 (19.3 – 71.2) arbitrary units (AU)) and 
EMGpara (29.35 (-228.8 – 289.1) AU) responses to methacholine (p=0.7). 
 
Correlation analysis indicated there was no relationship between the 
baseline to EOT changes in EMGpara and FEV1 in the cohort as a whole or in 
either the responder or non-responder subsets (Figure 20). 
 
The median (range) slope of the individual subjects’ relationships between 
EMGpara and methacholine dose number was significantly greater than that 
for FEV1 against dose number in the entire cohort (7.13 (-4.36 – 35.70) 
versus 4.68 (-0.10 – 17.20), p=0.0125).  This was also the case in the 
responder subset (11.17 (-0.86 – 35.70) versus 5.09 (2.64 – 17.18), 
p=0.0451), though not in the non-responder group.  The greater slopes 
indicate that changes in EMGpara are greater and occur more rapidly than 
those in FEV1. 
 
In the whole cohort, a weak correlation approaching statistical significance 
was seen between the individual slopes of FEV1 and EMGpara against dose 
number (r=0.337, p=0.0591).  This relationship was marginally stronger in 







Figure 20 Baseline to end-of-test percentage changes in FEV1 and EMGpara in 
the whole cohort of 32 adults undergoing methacholine challenge testing.  




4.4.1 Investigation of an alternative baseline 
 
Twenty-one of 32 subjects (65.6%) demonstrated a reduction in EMGpara 
from the measure obtained following saline inhalation to that following the 
first methacholine dose.  The fall in mean (SD) EMGpara for the whole cohort 
approached significance (4.86 (1.74)µV versus 4.45 (1.72)µV, p=0.056).  This 
occurred despite a small but significant fall in mean (SD) FEV1 % predicted 
(96.8 (10.4)% versus 94.1 (10.3)%, p<0.0001). Additional analyses were 
therefore performed to examine the relationship between EMGpara activity 
and FEV1 using the first methacholine dose (0.0625mg.ml-1) as the reference 
point.  Although these analyses would not be acceptable in the context of a 
 124 
clinical methacholine challenge test, controlling for the unexpected fall in 
EMGpara at the first methacholine stage allows more accurate analysis of the 
relationships between the changes in EMGpara and FEV1.  The changes in 
each parameter from 0.0625mg.ml to EOT are shown in Table 8. 
 
The fall in EMGpara activity from saline to 0.0625mg.ml-1 may have been 
related to subject anxiety.  Heart rate taken from the EMGpara trace was used 
to assess subject anxiety.  However, no change in mean (SD) heart rate was 
observed between the diluent and first methacholine stage of the protocol 












(2.12 – 7.91) 
5.86 
(2.37 – 19.60) 
<0.0001 
40.77 




(76.68 – 119.10) 
70.95 
 (37.98 – 100.70) 
<0.0001 
-22.19 






(2.18 – 7.91) 
6.27 
(3.37 – 19.60) 
<0.0001 
40.28 




(76.68 – 119.10) 
67.80 
(37.98 – 92.27) 
<0.0001 
-24.33 






(2.11 – 4.32) 
4.49 
(2.37 – 9.32) 
0.156 
41.26 




(80.70 – 104.0) 
91.43 
(72.98 – 100.70) 
0.078 
-6.77  
(-15.77 – 1.17) 
Table 8 Changes in EMGpara and FEV1 in entire cohort, and responder and non-responder subsets from first methacholine dose 
(0.0625mg.ml-1) to end of test.  Data are expressed as median (range). 
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The median (range) percentage change in EMGpara was significantly greater 
than that observed in FEV1 from the 0.0625mg.ml-1 reference point to EOT 
in both the entire cohort (40.8 (-20.4 – 214.9)% vs -22.2 (-50.5 – 1.2)%, 
p<0.0001) and the responder group (40.3 (1.4 – 214.9) vs -24.3 (-15.2 –         
-50.5), p=0.0013) (Table 8).  A significant relationship between the 
percentage changes in FEV1 and EMGpara was observed in the responder 




Figure 21 Graph showing changes in FEV1 and EMGpara at end of test in 32 
adults undergoing methacholine challenge, using 0.0625mg.ml-1 as baseline.  




In addition, when using 0.0625mg.ml-1 as a reference point, the median 
(range) AUC for EMGpara (72.5 (-81.0 – 543.3) AU) was significantly greater 
than that for FEV1 (25.6 (-4.9 – 62.9) AU, p=0.0007).  AUC FEV1 
demonstrated a moderate but significant correlation with AUC EMGpara 
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(r=0.502, p=0.0034).  Similarly, the median (range) slope of the EMGpara 
against dose number regression was greater than that for FEV1 (12.33 (-1.02 
– 45.50) vs. 6.46 (2.76 – 25.20), p=0.001), and demonstrated a moderate but 
significant correlation (r=0.487, p=0.0136).  These relationships indicate 
that incremental changes in FEV1 and EMGpara are related.  The greater 
overall change, AUC and slope for EMGpara than FEV1 together indicate that 




4.4.2 Individual subject data 
 
Individual plots of FEV1 against EMGpara at each concentration of 
methacholine were constructed for the responder subset (fall in FEV1 
greater than 20%).  The median (range) correlation coefficient of the 
individual subject relationships between FEV1 and EMGpara was -0.57 (-1.00 
– 0.18).  Not all correlations reached statistical significance due to the small 
number of data points included.   
 
If 0.0625mg.ml-1 was used as the reference concentration, the median 
(range) correlation coefficient increased to -0.80 (-1.0 – 0.0).  Visual 
inspection of the plots led to each study subject being categorised into 
groups.  For ease of visualisation, both EMGpara and FEV1 for each subject 
were plotted on the same graph against methacholine dose. 
 
Nine subjects demonstrated a clear relationship between FEV1 and EMGpara, 
with correlation coefficients of -0.8 or greater in all cases (Figure 22 and 
Figure 23). 
 




Nine subjects showed no relationship between FEV1 and EMGpara (Figure 25 
and Figure 26). 
 






Figure 22 Six subjects demonstrating corresponding increases in EMGpara 
with decreases in FEV1 while undergoing methacholine challenge. 
Square symbols represent EMGpara; circles represent FEV1. 
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Figure 23 Three subjects demonstrating corresponding increases in EMGpara 
with decreases in FEV1 while undergoing methacholine challenge. 














Figure 24  Six subjects demonstrating increases in EMGpara prior to 
reductions in FEV1 while undergoing methacholine challenge. 






Figure 25 Six subjects with no apparent relationship between changes in 
EMGpara and FEV1 during methacholine challenge. 




Figure 26 Three subjects with no apparent relationship between changes in 
EMGpara and FEV1 during methacholine challenge. 

















Figure 27 Single subject demonstrating a decrease in FEV1 prior to increase 
in EMGpara during methacholine challenge. 








This study demonstrates that EMGpara can be used to detect an increase in 
respiratory load following chemically induced bronchoconstriction in adults.  
A relationship was observed between changes in FEV1 and EMGpara between 
the first methacholine dose and end of test in the responder subset.  The 
incremental bronchoconstriction induced in the current study offered an 
advantage over the protocol in Chapter Three, where only a single step 
change occurred, allowing a range of degrees of airways obstruction to be 
examined.  The correlations observed between the FEV1-dose and EMGpara-
dose regression lines and between the area under the FEV1 and EMGpara 
dose-response curves further supports a relationship between EMGpara and 
measures of airway calibre.  A wide range of pathophysiological changes 
occurs in response to induced airways obstruction as well as significant 
heterogeneity in individual responses to methacholine challenge testing 
[245, 246].   EMGpara cannot therefore be viewed as a substitute for 
spirometric measures of pulmonary function, but rather reflects the change 
in load on the respiratory system overall.  In this context, the fact that the 
relationship between a measure of global respiratory load provided by 
EMGpara and a unidimensional measure of airway calibre (FEV1) is relatively 
weak was perhaps unsurprising. 
 
 
4.5.1 Critique of the method 
 
Given the aim of this study to assess the agreement between dynamic 
changes in variables, the order in which measurements were performed and 
the time elapsing between each measurement represent limitations of the 
study protocol.  Up to three minutes elapsed between measurement of FEV1 
and EMGpara.  Studies have suggested that the spontaneous resolution of 
methacholine-induced-bronchoconstriction is slow, with recovery times of 
up to two hours reported [247-249].  This provides reassurance that the 
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action of the inhaled methacholine could be expected to be consistent during 
the time over which measurements were made. 
 
The maximal respiratory manoeuvres required for spirometry and for 
delivery of methacholine may have potentially induced changes in 
bronchomotor tone of varying magnitude between asthmatic and non-
asthmatic individuals [250, 251]. The use of the dosimeter technique 
involving maximal inspirations, in combination with the maximal 
inspiratory efforts required for spirometry, have been suggested to produce 
bronchodilation in subjects with mild airway hyperresponsiveness.  The 
effect is reported to be much less pronounced in subjects with moderate or 
severe hyperresponsiveness [252, 253].  Asthmatic subjects also 
demonstrate more rapid airway re-narrowing following a deep inspiration 
[254], with degree of re-narrowing being inversely related to the extent of 
deep inspiration-mediated bronchodilation [255].  While some of the 
subjects in the current study had a formal diagnosis of asthma, others were 
healthy individuals with only mild airway hyperresponsiveness.  A degree of 
heterogeneity in response to deep inspirations may have been expected and 
could have contributed to the variability of results, potentially affecting the 
relationship between EMGpara and FEV1. 
 
To avoid the effect of this variability, a methacholine challenge with EMGpara 
as the sole outcome measure may have been desirable, though this method 
clearly does not allow comparison between EMGpara and other variables.  
The relatively poor between-day reproducibility of methacholine challenge 
tests (+/- 1.5 doubling doses in the absence of any additional confounding 
factors, such as exposure to sensitising agents) would not allow accurate 
comparison of changes in FEV1 and EMGpara measured in isolation on 
different testing occasions.  The use of tidal breathing techniques as 
outcome measures may be more desirable when examining the relationship 
of methacholine-induced changes in pulmonary function to changes in 
EMGpara.  Plethysmographic measurement of airways resistance (Raw) has 
been well documented as an outcome measure for airway challenge testing 
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[256, 257], but performing measurements of Raw at the time intervals 
recommended by international guidelines for methacholine challenge 
testing [226] requires the subject to remain sealed within the 
plethysmograph throughout the challenge test.  In addition, the specialist 
equipment for conducting bronchial challenge tests within a 
plethysmograph was not available in our centre.  Impulse oscillometry (IOS) 
represents an alternative method to measure airways resistance and as the 
measurements are obtained during tidal breathing technique, simultaneous 
measurement of EMGpara would be possible.  Although IOS has been used to 
assess the response to bronchial challenge [258, 259], there is no consensus 
regarding the criteria for a significant response and hence the use of IOS as 
the sole outcome measure for a methacholine challenge test is not 
recommended [226]. 
 
The potential for factors unrelated to the respiratory system to influence the 
EMGpara signal is highlighted by the fall in EMGpara between the saline and 
0.0625mg.ml-1 steps, accompanied by a very small decrease in FEV1.  
Anxiety or the awareness of or focus on breathing by the subject could have 
resulted in increases in the resting respiratory drive.  No change in heart 
rate between the saline and first methacholine dose stages was observed 
however, which would suggest that subjects were not overtly anxious, 
although the use of heart rate to assess anxiety is relatively limited [260, 
261].  While subjects were allowed a period of acclimatisation in the 
laboratory following the application of the EMGpara electrodes, including a 
baseline measurement prior to the administration of the saline diluent, this 
may have been insufficient to allow reproducible values to be obtained. The 
use of the 0.0625mg.ml-1 dose as a reference stage for analysis in the current 
study allows the relationship between relative changes in FEV1 and EMGpara 
to be more closely investigated.  Such an approach would, however, be 
inappropriate for clinical use.  A greater time for acclimatisation to the 
measurement, the introduction of a second saline step that could be used as 
the reference point, and real-time evaluation (even if only qualitative) of the 
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EMGpara signal to ensure stability, prior to obtaining recordings for analysis, 





4.5.2 Relationship of the current findings to previous literature 
 
Sprikkelman et al [190] assessed diaphragm and intercostal surface EMG 
activity in children undergoing histamine challenge testing and 
demonstrated a significant increase in the ratio of the EMG amplitude to that 
obtained at baseline (EMG activity ratio, EMGAR) at the final dose of 
histamine.  No increases were observed in EMG activity at lower histamine 
doses.  The authors reported a correlation coefficient of 0.65 between 
logEMGAR and FEV1 percentage change following the final histamine dose.  
Some subjects in this study did, however, demonstrate EMGAR values of less 
than one, indicating substantial decreases in respiratory muscle activity, as 
well as some individuals showing increases in intercostal and diaphragm 
EMG in the absence of changes in FEV1, in agreement with the findings of the 
current study. 
 
In later work from the same group, Maarsingh et al [194] showed an 
exponential relationship between change in EMGpara and change in FEV1 
during a histamine challenge in asthmatic children, with strong agreement 
between changes in EMGpara and FEV1 (correlation coefficients of 0.79 to 
0.92).  In view of the much weaker correlations observed in the current 
study, the differences between the two studies have been considered in 
detail.   
 
The studies by Maarsingh [194] and Sprikkelman [190] were undertaken 
using ECG signal gating, which allowed automated analysis.  The technique 
removes the cardiac signal and fills the resulting space with an average of 
the EMG activity before and after the removed ECG artefact.  The EMG was 
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expressed as “mean peak-bottom respiratory activity”, which is analogous to 
the mean peak RMS EMGpara value used in this thesis.  Despite the removal of 
the ECG artefact, the method of data analysis is similar and it is therefore 
unlikely that this alternative processing methodology would lead to 
substantially different results. 
 
The use of logEMGAR by Maarsingh et al [194] to describe changes in 
EMGpara activity prevents direct comparison with the current study, 
although relative change can be calculated for comparative purposes.  A fall 
in FEV1 of 30% resulted in a mean logEMGAR of approximately 0.5, 
equivalent to an increase in EMGpara of greater than 200%.  A fall in FEV1 of 
45% was associated with a logEMGAR value of 2, representing a 100-fold 
increase in EMGpara activity.  While the percentage changes indicated by the 
logEMGAR values at the lower levels of bronchoconstriction were similar to 
the EMGpara changes observed in the current study, those occurring at 
greater levels of bronchoconstriction were markedly larger than the current 
results.  In order to obtain changes of these magnitudes, the end of test 
EMGpara activity obtained by Maarsingh et al [194] must either have been 
substantially greater than the values reported in previous studies during 
maximal inspiratory efforts [172, 197], or their baseline values were 
markedly smaller than the level of ambient electrical interference commonly 
encountered in most environments, even when using very high quality 
biomedical amplifiers.  In the absence of raw values for EMGpara from the 
Maarsingh et al study, it is difficult to fully compare their data to that in the 
current study, but 100-fold increases in EMGpara is substantially larger than 
that observed in the present study and other work from this laboratory 
[172, 197]. 
 
Another consideration when comparing the study by Maarsingh et al [194] 
and the current work is the method of analysing the stepwise changes in 
FEV1 and EMGpara.  Maarsingh et al’s study expressed the change in EMGpara 
per 5% decrement in FEV1, presumably through linear interpolation of the 
dose-response curve.  The response to direct airway challenge tests is 
 140 
known to be sigmoidal and since the upper plateau is rarely reached, in 
practice, the curve appears exponential [226].  The appropriateness, 
therefore, of calculating arbitrary 5% steps is unclear.  Subjects may 
demonstrate falls in FEV1 of greater than 5% between consecutive doses of 
the provocant agent, meaning that one stage of the challenge tests would, 
using this methodology, contribute more than one data point to the analysis.  
This may result in inappropriate biasing of the results in favour of a 
relationship.  
 
Maarsingh and colleagues [194] comment that the relationship between 
logEMGAR and FEV1 was linear between 5% and 25% fall in FEV1 from 
baseline.  Inspection of their graphs indicates that the relationship appears 
less strong above this point.  It is not clear, however, whether the reported 
correlation coefficients of 0.79 and 0.92 on test days one and two 
respectively represent the 5%-25% range of FEV1 changes only, or whether 
this is inclusive of all values.  It is therefore difficult to ascertain to what 
extent the results of the current study would be expected to agree with 
those of Maarsingh et al [194], given that fourteen of the 32 subjects in the 
current study demonstrated a decrease in FEV1 in excess of 25%.  
Nonetheless, the findings in the current study of relationships between 
incremental changes in EMGpara and FEV1 (using slope and area under the 
curve analyses) concur with the findings of Maarsingh et al [194] that 




4.5.3 Rationale for results 
 
When the first methacholine dose was used as the reference stage a 
significantly larger percentage change in EMGpara than FEV1 was observed.  
These data are consistent with the results from Chapter Three and the 
suggestion that EMGpara, rather than just reflecting change in airway calibre 
as measured by FEV1, also represents any other changes in pulmonary 
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function occurring as a result of methacholine inhalation.  Lung 
hyperinflation and small airway narrowing may occur during methacholine 
challenge, as well as large airways changes.  The larger AUC for EMGpara 
compared to FEV1 further supports this hypothesis, and unlike using only 
the percentage change from baseline to EOT, which assumes a linear 
relationship between lung function and methacholine dose, takes into 
account the changes that occur at each stage of the challenge test. This was 
further supported by the greater median slope of the regression line of 
EMGpara against dose compared to the FEV1 against dose plot. 
 
Small airways dysfunction can lead to distal airways collapse and 
hyperinflation.  Hyperinflation is frequently reported to occur in patients 
undergoing methacholine challenge testing [262-265].  It has been 
suggested that methacholine induces more extensive small airways changes 
than histamine [266], which may explain in part the stronger relationships 
between FEV1 and EMGpara observed in previous studies [190, 194].  The 
degree of hyperinflation during exercise has been shown to correlate with 
increases in EMGpara in adult patients with cystic fibrosis [172].  The 
presence of lung hyperinflation in some of the subjects in the current study 
may have resulted in additional increases in EMGpara that consequently 
served to weaken the relationship between EMGpara and FEV1.  The increase 
in respiratory load associated with lung hyperinflation may also explain the 
substantial increases in EMGpara (up to 196%) observed in some subjects 
from the non-responder group in whom only modest changes in FEV1 
occurred. 
 
Increased inspiratory flow and tidal volume have been reported in humans, 
as well as increased phrenic nerve activity in dogs, following methacholine 
inhalation, even in the presence of only mild to moderate levels of 
bronchoconstriction [267, 268].  Increases in respiratory rate and duty cycle 
in the absence of changes in tidal volumes or inspiratory flow have also been 
reported following methacholine inhalation [269].  Interestingly, these 
studies have been unable to show any relationship between the ventilatory 
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responses observed and the degree of airways obstruction [270].   
Significant heterogeneity of individual responses to methacholine inhalation 
was also noted.  Given that the magnitude of EMG activity is related to both 
the force generated by the muscle and the rate of development of tension 
within the muscle [182], changes in respiratory pattern will influence 
EMGpara.   The lack of agreement between the findings of previous studies 
and the presence of inter-individual differences within these studies 
supports the premise that different phenotypes may exist and hence simple 
and consistent relationships between bronchoconstriction and peak EMGpara 
per breath may not always be observed. 
 
Similar to the results of previous studies examining changes in ventilatory 
parameters following methacholine challenge [267-270], substantial inter-
individual variability was found in the relationship between changes in FEV1 
and EMGpara in the current study.  Assessing individual subjects’ patterns of 
FEV1 and EMGpara changes allowed a more qualitative assessment of the 
data.  These can be considered in the context of previous data regarding 
pathophysiological changes following airway challenge testing. 
 
As already discussed, a previous study has demonstrated a linear 
relationship between logEMGAR of the parasternal intercostal muscles and 
FEV1 change induced by histamine challenge [194].  The group of subjects in 
the current study in whom a clear relationship was observed between 
EMGpara and FEV1 may represent a similar cohort to the study by Maarsingh 
et al [194] in which individuals responded to the inhaled provocant with 
relatively parallel changes in EMGpara and FEV1. The magnitude of the 
EMGpara change (from 0.0625mg.ml-1) in this group compared to the FEV1 
change (median (range) 67.9 (1.36 – 150.5)% versus -24.1 (-50.5 – -16.8)%) 
suggests that large airways changes are unlikely to account solely for the 
subjects’ changes in NRD, but the close agreement between the two 
parameters would imply that any other changes undetected by spirometry 
are at least occurring simultaneously to those affecting FEV1 values. 
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While FEV1 primarily measures the function of more proximal airways, it 
has been shown previously that asthmatic individuals can demonstrate a 
positive response to methacholine inhalation primarily driven by increases 
in peripheral airways resistance, as opposed to the more widely-reported 
pattern of large airways changes in response to the provocant agent [271, 
272].  The individuals in whom EMGpara appears to increase ahead of 
substantial changes in FEV1 may represent a group in whom changes in 
smaller airways, undetected by spirometry, could have occurred prior to the 
development of overt larger airways obstruction sufficient to cause a 
reduction in FEV1.  Work by Amirav et al [273] in anaesthetised pigs 
exposed to methacholine challenge testing demonstrated heterogeneous 
changes in small and large airways calibre, assessed by high-resolution 
computed tomography (HRCT) scan.  The changes in airway diameter were 
related to respiratory drive, as measured by airway opening pressure, at 
moderate and severe levels of airway narrowing, but not when the degree of 
narrowing was mild. 
 
In the absence of more detailed physiological measurements, the 
mechanisms underlying the patterns of change in the nine subjects in whom 
no relationship existed between EMGpara and FEV1 remain difficult to 
explain. While some of the subjects in this group clearly demonstrate initial 
falls in EMGpara, which may be related to anxiety and/or hyperventilation as 
described above, others show a highly variable pattern of EMGpara activity 
over the course of the challenge test. Perception of bronchoconstriction 
during methacholine challenge has been reported to be much more variable 
in healthy subjects than asthmatics [274], which may contribute to the wide 
range of changes in EMGpara observed in the current study (including within 
the non-responder group).  Measures of NRD relate closely to subjects’ 
perception of breathlessness [172, 198], thus changes in EMGpara may have 
been influenced by perception of the respiratory sensation associated with 
airway obstruction rather than solely due to airway obstruction alone.  It is 
also important to consider that attempting to relate changes in 
unidimensional measures such as FEV1 to EMGpara, a global measure of 
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respiratory load that reflects the combined effects of a broad range of 
pulmonary variables was likely to be unsuccessful. 
 
Also challenging to explain is the one subject in whom a fall in FEV1 
occurred prior to an increase in EMGpara.  This subject, however, highlights 
an important consideration given the population investigated in the current 
study and the magnitude of changes induced by the study protocol.  This 
subject (Figure 27) demonstrated the highest EMGpara value at baseline, 
despite the FEV1 being greater than 110% predicted.  While the decrease in 
FEV1 from baseline to the penultimate dose of methacholine was relatively 
large in absolute terms (660ml), the corresponding %predicted FEV1 
following the penultimate dose was 95.7%, suggesting that the respiratory 
system was not heavily loaded, despite a relatively high EMGpara at baseline.   
The extent of any other changes in pulmonary function other than those in 
large airways was, however, unknown.  The relatively high respiratory drive 
suggested a degree of hyperventilation at baseline, and indeed this subject 
demonstrated a fall in heart rate from 66 to 58 beats per minute from saline 
to 0.0625mg.ml-1 stages, supporting the premise that anxiety may have been 
at least a contributing factor in the high EMGpara at baseline.  The substantial 
decrease in FEV1 induced by the final methacholine dose (to 69.2% 
predicted) was accompanied by a clear increase in EMGpara activity. 
 
Inferences drawn from this single subject are limited in applicability to the 
wider cohort, but these data highlight that the levels of respiratory load to 
which the subjects in the current study were exposed were relatively low.  
The median (range) end of test FEV1 %predicted was only 70.8 (38.0 – 
100.7)%, and the 25th percentile value of 64.1% predicted indicated that few 
subjects experienced severe bronchoconstriction.  Studies in patients with 
CF and COPD [172, 189] have demonstrated significant relationships 
between pulmonary function and NRD using both EMGdi and EMGpara.  The 
patients in these studies had a range of lung disease severities, unlike the 
current cohort of subjects who reported no respiratory symptoms at 
baseline.  Elucidating relationships between variables across relatively low 
 145 
levels of respiratory load makes detection of such relationships more 
challenging.  High dose methacholine challenge testing to induce more 
substantial changes in respiratory load in healthy individuals or recruiting 
subjects with poorer baseline lung function may have helped to overcome 
this problem. 
 
Reilly et al examined changes in NRD both during exercise in healthy 
subjects and adults with cystic fibrosis [172] and also in healthy subjects 
undergoing hypercapnic or negative pressure threshold loading [192].  The 
studies demonstrated different recruitment patterns for the diaphragm and 
parasternal intercostal muscles; EMGpara and EMGdi increased in parallel 
during inspiratory threshold loading but greater increases in EMGdi than 
EMGpara were observed during both hypercapnic ventilation and 
incremental exercise.  A different pattern of costal diaphragm and 
parasternal intercostal muscle EMG activity was also described by 
Maarsingh et al [194] during histamine-induced airflow limitation in 
children.  logEMGAR for diaphragm and parasternal increased linearly from 
baseline until a fall in FEV1 of 25% was reached; thereafter, greater 
variability in the pattern of increase in EMGpara activity was seen, with the 
increase in EMGpara being greater than that in EMGdi.  This is in direct 
contrast to the results of Reilly et al [172, 192].  Sprikkelman et al [190] also 
reported variability in patterns of diaphragm and parasternal intercostal 
muscle activity during histamine challenge, even suggesting that the relative 
contributions of each muscle group could change between consecutive 
doses of the challenge agent.  The different results in these studies indicate 
that relative contributions of the diaphragm and the parasternal intercostal 
muscles to breathing may vary under different circumstances of imposed 
load on the respiratory system.  The current study did not measure EMGdi, 





4.5.4 Relevance to clinical practice 
 
International guidelines for methacholine challenge testing recognise that 
the reliance of the test on spirometry limits the application of this test to 
subjects able to perform spirometry to an acceptable standard, and identify 
the need for alternative test end-points less dependent on subject effort 
[226].  While the lack of consistent relationships between changes in 
EMGpara and FEV1 observed in the current study indicate that EMGpara cannot 
be viewed as a substitute for FEV1 in bronchial challenge testing, the 
significant increase observed in EMGpara in this cohort suggested that the 
technique may be able to detect the increase in respiratory load, indicated 
by the fall in FEV1, induced by methacholine inhalation.  There was also an 
indication that, in some populations at least, the technique may offer 
additional information over and above that obtained by spirometry alone.  
The substantial increases in EMGpara seen in some subjects in the ‘non-
responder’ subset suggested the presence of changes in the respiratory 
load-capacity balance in the absence of significant changes in FEV1, which 
may indicate the potential of EMGpara to enhance diagnostic possibilities, 
though a greater understanding of the driving mechanisms underlying the 






The results contained in this chapter demonstrate that EMGpara can be used 
to detect an increase in respiratory load following chemically induced 
airways obstruction in adults.  After controlling for the increased level of 
EMGpara activity present at baseline, a larger change was observed in EMGpara 
compared to FEV1, supporting the results from Chapter Three.  Using the 
same baseline (0.0625mg.ml-1), a moderate relationship was observed 
between total change in FEV1 and EMGpara.  The lack of a relationship 
between end of test changes in the two variables, however, highlights the 
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complexity of the physiological changes that occur during methacholine 
inhalation.  The following chapter attempts to examine in more details some 
of the physiological changes that occur during bronchial 
hyperresponsiveness testing.  
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5. Chapter Five:  A detailed 
laboratory study of the 
relationships between 
conventional measures of 
pulmonary function and 




Chapter Four demonstrated the ability of EMGpara to detect change in 
respiratory load following methacholine inhalation, but the weak 
relationship observed between changes in FEV1 and EMGpara suggested that 
factors additional to proximal airways obstruction might have influenced 
the changes in EMGpara.  Changes in end-expiratory lung volume (EELV) have 
been demonstrated following methacholine inhalation in previous studies 
[245, 263-265, 267], and lung hyperinflation is known to relate to changes 
in NRD [172].  Changes in small airways resistance would not be detected by 
FEV1 but would influence NRD and have been shown to occur in response to 
methacholine challenge test [259].  The extent of such changes, and their 
relationship with changes in EMGpara, may help to explain the greater change 
in EMGpara than FEV1 observed in Chapter Four, and warranted 
investigation. 
 
A range of changes in different ventilatory parameters has been reported as 
occurring in response to methacholine challenge testing [267-269, 275].  
While the known relationship between rate of change in muscle length and 
EMG activity suggests that changes in inspiratory flow will affect EMGpara 
even in the absence of specific changes in the respiratory load-capacity 
balance, a previous study [276] has demonstrated that there is little 
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influence on the magnitude of respiratory EMG until inspiratory flow 
reaches levels substantially in excess of those observed during tidal 
breathing.  Increases in tidal volume, however, will increase EMGpara 
amplitude, and therefore by expressing EMGpara per breath relative to the 
corresponding tidal volume generated (termed neuroventilatory efficiency 
(NVE), and expressed in ml.µV-1) the potential confounding effects of 
changes in tidal volume can be controlled for.  
 
Despite strong agreement between the two measures, differing magnitudes 
of change in EMGpara and EMGdi have previously been shown in response to 
inspiratory threshold loading [192], hypercapnic loading [192] and exercise 
[172] in adult subjects, and during histamine challenge in asthmatic children 
[194].  The relationship between EMGpara and crural EMGdi has not 
previously been investigated in an asthmatic model of airways obstruction.  
Alterations in the relative recruitment of the diaphragm and parasternal 
intercostal muscles may also assist in explaining the relatively weak 
relationship between changes in FEV1 and EMGpara observed in Chapter 
Four. 
 
In view of the strong relationships previously observed between 
breathlessness scores and measures of NRD in patients with COPD and 
cystic fibrosis [172, 198], despite poor agreement between dyspnoea and 
conventional measures of pulmonary function [33, 277], it was felt that the 
relationship between breathlessness and EMGpara warranted examination 
during induced airflow obstruction.  
 
 
The aims of this study were, therefore: 
 To quantify any changes in end-expiratory lung volume utilising 
measurements of inspiratory capacity and investigate the 
relationship with EMGpara 
 To investigate the utility of neuroventilatory efficiency as an 
alternative measure of NRD 
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 To study the relationship between EMGpara and EMGdi as measures of 
NRD during methacholine-induced airflow obstruction 
 To assess the relationship between NRD and subject perception of 
breathlessness during induced airways obstruction 
 To evaluate the response of the distal airways (using impulse 
oscillometry) to methacholine inhalation, and investigate the 




We hypothesised that: 
 The magnitude of change in EMGpara would be greater in those 
subjects demonstrating hyperinflation than in those without changes 
in end expiratory lung volume 
 Both bronchoconstriction and hyperinflation would be associated 
with a reduction in NVEpara 
 EMGpara would be closely related to subject-reported breathlessness 
 Levels of NRD as measured by EMGpara and EMGdi would be closely 
related 
 Both small and large airways would exhibit changes in resistance in 





Subjects were recruited from staff and students of King’s College Hospital 
and King’s College London, having already undergone Study Two (Chapter 
Four) and demonstrated a positive methacholine challenge test. Ethical 
approval was granted by the King’s College Hospital Research Ethics 
Committee (ref: 09/H0808/100).  Informed, written consent was obtained 






Height was measured using a wall-mounted stadiometer (Harpenden, 
Holtain Ltd, Crymych, UK) and weight with an electronic medical scale (HR 
Person Scale, Marsden Ltd, Henley on Thames, UK). 
 
EMGpara and EMGdi were measured as described in Chapter Two (Methods).  
Briefly, EMGpara was recorded using surface electrodes placed over the 
second intercostal space and EMGdi was measured from the crural 
diaphragm using a multipair oesophageal EMG catheter.  The signal was 
amplified (gain 1,000), band-pass filtered between 10 and 2,000Hz, and a 
50Hz notch filter and a post-acquisition 20Hz digital high-pass filter applied.  
The signal was converted to root-mean-square (RMS) and mean peak RMS 
EMGpara per breath calculated.  Respiratory flow was measured using a 
pneumotachograph and pressure transducer system as described in Chapter 
Two.  
 
Signals were acquired at 10kHz for EMG and at 100Hz for respiratory flow 
using a Powerlab 16SP analogue-to-digital convertor (ADInstruments, 
Sydney, Australia), and displayed on a laptop computer (MacBook Pro, 
Apple, Cupertino, California, USA) running LabChart software (Version 7.2 
ADInstruments Pty, Colorado Springs, Colorado, USA).  Tidal volumes and 
inspiratory capacity were obtained by digital integration of the flow signal. 
 
The methacholine challenge test was performed as described in Chapters 
Two and Four using a portable electronic spirometer-digidoser system 
(KoKo USB spirometer and digidoser, Ferraris Respiratory, Louisville, CO, 
USA) and nebuliser (DeVilbiss 646 characterised nebuliser, Ferraris 
Respiratory, Louisville, CO, USA).  A five-breath dosimeter protocol was 
followed [226], with the duration of both inspiration and expiration fixed at 
five seconds and inspiratory flow limited to 0.5L.sec-1.  A 0.9% saline diluent 
step was followed by methacholine concentrations of 0.0625, 0.25, 1, 4, 8, 16 
 152 
and 32mg.ml-1 (Acetyl-B-Methyl Choline, Nova Laboratories, Wigston, 
Leicestershire). 
 
Impulse oscillometry was measured using the Jaeger Masterscreen PFT 
system, as described in Chapter Two.  Subjects breathed steadily at the FRC 






All subjects underwent measurement of EMGpara, spirometry, inspiratory 
capacity, tidal flow and volume, and breathlessness using the modified Borg 
(mBorg) scale.  Two subsets of participants underwent additional 
measurements: subjects for Part A undertook measurements of EMGdi, while 
subjects for Part B undertook impulse oscillometry. 
 
All participants:  Baseline measurement of EMGpara activity during 3 
minutes of resting tidal breathing was recorded, with flow measured using a 
pneumotachograph attached to a flanged mouthpiece.  Baseline inspiratory 
capacity (IC) and spirometry manoeuvres were then performed. 
 
The methacholine challenge was then performed.  The subjects inhaled 
saline, followed by incremental doses of methacholine (0.0625, 0.25, 1, 4, 8, 
16 and 32mg.ml-1), as described in Chapters Two and Four.  A single 
technically acceptable forced expiratory manoeuvre, allowing measurement 
of both FEV1 and FVC, was performed at both 30 and 90 seconds following 
each delivery, with the lowest value being recorded.  Three technically 
acceptable IC manoeuvres were then performed, with the mean of these 
values being used for analysis. Following this, the subject was instructed to 
breathe in a relaxed manner for the remaining time prior to the next dose 
(approximately 2.5 minutes), and EMGpara was recorded simultaneously 
with tidal flow and volume.  The final minute of this recording was used for 
analysis.  Immediately prior to the next dose of methacholine, the subject 
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was asked to rate their breathlessness using the modified Borg scale 
(mBorg).  The protocol was ceased when the subject demonstrated a 20% or 
greater fall in FEV1, at which point 400μg salbutamol was administered via a 
metered-dose inhaler and spacer.  Spirometry was repeated after 15 
minutes to ensure return to pre-test values.   
 
Changes in FEV1 from the post-diluent stage were plotted against the log-
transformed methacholine concentration.  The provocative concentration of 
methacholine that induced a 20% fall in FEV1 (PC20) was calculated using 
the following equation [226]: 
 
PC20 =  
 
Where: 
C1 = penultimate methacholine concentration 
C2 = final methacholine concentration 
R1 = percent fall in FEV1 after C1 
R2 = percent fall in FEV1 after C2 
 
Percentage changes in EMGpara and IC were also plotted against log 
methacholine concentration.  Linear interpolation of the EMGpara–log 
methacholine dose curve was used to calculate the percentage change in 
EMGpara and IC at PC20. 
 
 
Sub-study A:  This study allowed examination of the relationship between 
EMGpara and EMGdi during induced bronchoconstriction, including any 
differences in relative recruitment patterns.  It also allowed investigation of 
the relationship between EMGdi and conventional measures of pulmonary 
function (FEV1 and IC) during a methacholine challenge test.  Prior to 
commencement of the protocol, an oesophageal multipair electrode to 
measure EMGdi was inserted and positioned using the procedure described 

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in Chapter Three.  There were no differences in study design to that 
described above; EMGdi was recorded simultaneously to EMGpara at all 
points. 
 
Sub-study B:  Impulse oscillometry was performed to examine changes in 
resistance of the distal airways during methacholine-induced 
bronchoconstriction.  EMGpara and IOS were recorded simultaneously at 
baseline, followed by measurements of IC and spirometry.  The protocol for 
the methacholine challenge was followed.  The subject performed a forced 
expiratory manoeuvre at 30 and 90 seconds following the methacholine 
dose, then three IC manoeuvres.  IOS measurements were then performed 
for 90 seconds, during which EMGpara was simultaneously recorded.  Tidal 
volume measurements were extracted from the IOS software and used to 
calculate NVEpara.  The subjects were asked to rate their breathlessness 
using the mBorg scale following the IOS/EMGpara measurement. 
 
 
5.3.1 Additional analyses 
 
Area under the dose-response curve and the slopes of the dose-response 
regression lines were calculated (as described previously (Chapter Four)) to 
assess incremental changes in measured variables at each stage of the 
methacholine challenge test.  As previously, methacholine doses were 
numbered to give a linear scale along the x-axis, and plotted against 
percentage change in each variable. 
 
 
5.3.2 Statistical analysis 
 
Non-parametric statistics were applied as the sample size was <30.  Within-
subject changes were assessed using the Wilcoxon matched pairs test.  
Differences between group medians were assessed with the Mann-Whitney 
test.  Relationships between variables were assessed using the Spearman’s 
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rank correlation. A p value <0.05 was taken as statistically significant.  When 
comparing the magnitude of changes in variables with opposite polarities 
(e.g. increases in EMGpara against decreases in FEV1 or IC), variables 




5.3.2.1 Sample size calculation 
 
No formal sample size calculation was undertaken for this study; the 
subjects represented a convenience sample taken from those who 
demonstrated a positive response to methacholine challenge testing having 




In total 20 subjects undertook this study.  Ten subjects underwent the 
additional measurements of Part A and six subjects underwent Part B; the 
demographic and anthropometric characteristics of the twenty subjects are 
shown in Table 9.  There was no overlap between the subjects for Parts A 
and B of the study.  Subjects’ diagnoses are shown in Table 10. 
 
Changes in EMGpara, FEV1, IC, NVEpara and mBorg from baseline to end of test 
in all 20 subjects are summarised in Table 11.  IC is expressed as both raw 
values and %predicted due to the two thresholds that were investigated for 
determining a significant increase in resting end expiratory lung volume.  All 












(22.01 – 50.78) 
29.23 
(24.13 – 50.78) 
31.57 
(22.01 – 42.83) 
Sex (male: female) 6: 14 4: 6 1: 5 
Height (m) 
1.71 
(1.61 – 1.90) 
1.71 
(1.61 – 1.90) 
1.70 
(1.61 – 1.84) 
Weight (kg) 
68.36 
(56.70 – 91.81) 
71.85 
(56.70 – 91.81) 
64.37 
(62.87 – 84.82) 
BMI (kg m-2) 
24.1 
(20.2 – 32.1) 
24.9 
(20.2 – 32.1) 
23.0 
(21.3 – 26.5) 
Ethnicity (n (%)) 
White: 19 (95%) 
Black: 1 (5%) 
White: 10 (100%) 
White: 5 (83.3%) 




(80.0 – 122.3) 
97.9 
(80.0 – 118.2) 
93.2 
(80.3 – 98.9) 















Asthma (taking medication) 














Asthma (taking medication) 





Table 10 Diagnoses of subjects included in Parts A and B of Study Three.  
Data are shown as n (%). 
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(2.85 – 8.92) 
6.63 
(3.77 – 19.60) 
0.0012 
26.2 
(-21.1 – 144.4) 
FEV1 (%predicted) 
96.86 
(80.00 – 122.30) 
67.50 
(37.98 – 92.27) 
<0.0001 
-28.9 
(-53. 7 – -21.1) 
IC (L) 
2.99 
(2.14 – 4.49) 
2.78 
(1.36 – 4.18) 
0.037 
-7.1 
(-44.7 – 8.7) 
IC (%predicted) 
91.9 
(65.6 – 133.3) 
84.9 
(39.8 – 129.0) 
0.0037 
-7.1 
(-44.7 – 8.7) 
NVEpara (ml.µV-1) 
170.2 
(84.5 – 403.8) 
127.5 
(60.9 – 246.6) 
0.0064 
-18.2 
(-69.1 – 66.2) 
mBorg 
0.0 
(0.0 – 1.0) 
2.0 
(0.0 – 4.0) 
<0.0001 N/A 




No relationships were observed between changes in EMGpara or NVEpara and 
FEV1 or IC.  The changes in FEV1 and IC were also unrelated (r=0.323, 
p=0.614). 
 
Similarly to the results in Chapter Four, a small decrease was observed in 
median (range) EMGpara between saline inhalation (5.37 (2.85 – 8.92)µV) 
and the first methacholine dose (4.59 (2.18 – 7.91)µV), although this did not 
reach statistical significance (p=0.096).  Changes in variables between the 
0.0625mg.ml-1 dose and end of test were therefore assessed (Table 12).  All 
variables continued to demonstrate statistically significant changes.  
However, despite adjusting for the saline inhalation dose, no relationships 
were observed between the changes in EMGpara or NVEpara and FEV1 or IC 
from 0.0625mg.ml-1 to end of test. 
 160 





(2.18 – 7.91) 
6.63 
(3.77 – 19.60) 
<0.0001 
44.3 
(1.36 – 214.9) 
FEV1 (%predicted) 
94.7 
(76.7 – 119.1) 
67.50 
(37.98 – 92.27) 
<0.0001 
-27.7 
(-50.5 – -16.8) 
IC (%predicted) 
89.5 
(65.3 – 141.1) 
84.9 
(39.8 – 129.0) 
0.0037 
 -7.67 
(-45.6 – 16.2) 
NVEpara (ml.µV-1) 
170.0 
(97.5 – 366.7) 
127.5 
(60.9 – 246.6) 
0.0006 
-27.5 
(-67.8 – 46.5) 
mBorg 
0.0 
(0.0 – 2.0) 
2.0 
(0.0 – 4.0) 
<0.0001 N/A 
Table 12 Changes in EMGpara, FEV1, IC, NVEpara and mBorg in 20 adults undergoing methacholine challenge between first methacholine 




Two thresholds for determining significant lung hyperinflation were 
examined: a decrease in inspiratory capacity of ≥300mL or a decrease of 
15% of predicted IC [245].  Using the 300ml threshold, 10 of the 20 subjects 
(50%) were classified as ‘hyperinflators’.  Using the threshold of a decrease 
of 15% predicted IC, five subjects (25%) were defined as hyperinflators.  
The relative changes in FEV1, EMGpara and NVEpara in the hyperinflator and 
non-hyperinflator groups using the two thresholds are shown in Table 13.  
No differences in FEV1, EMGpara or NVEpara were observed between 
















 ΔFEV1 (%) 
-32.5 
(-53.7 – -21.1) 
-23.3 




(-6.86 – 144.4) 
40.1 




(-69.1 – 66.2) 
-16.3 




















(-53.7 – -21.1) 
-26.3 




(-4.7 – 101.9) 
20.9 




(-54.3 – 66.2) 
-16.9 
(-69.1 – 46.2) 
0.691 
Table 13 Changes in FEV1, EMGpara and NVEpara in the hyperinflator and non-hyperinflator subgroups using two cutoff thresholds.  All 
data are shown as median (range). 
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No significant relationships were seen between baseline to end of test 
changes in EMGpara or NVEpara and those in FEV1 or IC in the hyperinflator 






Figure 28 Graph showing baseline to end of test changes in FEV1 and IC.  
Red symbols denote subjects demonstrating significant hyperinflation 
(change in IC of ≥300ml); blue symbols represent those without significant 




Percentage changes in EMGpara and IC at the concentration of methacholine 
inducing a 20% decrease in FEV1 (PC20) were calculated through linear 
interpolation of the log dose-response curve for both parameters.  There 
was no relationship between change in EMGpara and change in IC at PC20 in 
either the whole cohort (r=0.092, p=0.701) or the hyperinflator subset, 
using either the 300ml (r=0.115, p=0.759) or 15% predicted (r=-0.10, 
p=0.95) threshold values for significant hyperinflation. 
 
5.4.1.1 Area under the curve and linear regression analysis 
 
As described above, area under the curve analysis was performed to assess 
the incremental changes in measured variables.  A significant relationship 
was observed between AUC EMGpara and AUC FEV1 when using saline 
(r=0.546, p=0.013) or the 0.0625mg.ml-1 methacholine dose (r=0.577, 
p=0.008) as the baseline value.  A significant relationship between AUC 
NVEpara and AUC FEV1 was also observed (r=0.592, p=0.006) when using the 
0.0625mg.ml-1 methacholine dose as the baseline.  No relationships were 
observed between AUC IC and AUC EMGpara or AUC NVEpara, either in the 
cohort as a whole or the hyperinflator subset (using either threshold value 
for hyperinflation). 
 
The median (range) slopes of the EMGpara-dose and FEV1-dose lines were 
9.18 (-0.86 – 35.70) and 4.97 (2.73 – 17.18) respectively.  The difference 
between slopes did not reach statistical significance (p=0.083), however, a 
significant relationship was observed between the slopes (r=0.462, 
p=0.0405).  No relationship was seen between EMGpara-dose slope and IC-
dose slope, either in the cohort as a whole or in the hyperinflator subgroup 
(using either the 300ml or 15% predicted thresholds).  NVEpara-dose slope 






mBorg score increased significantly from baseline to end of test (Table 11), 
though the magnitude of the median (range) increase (2.0 (0.0 – 4.0) was 
relatively small.  There was no relationship between change in mBorg and 
EMGpara or NVEpara from baseline to end of test, either when using saline or 
the 0.0625mg.ml-1 dose as the reference stage.  A weak relationship was 
observed between change in mBorg and that in IC (r=-0.488, p=0.034).  
There was no relationship between change in mBorg and change in FEV1. 
 
Correlation coefficients for the relationships between EMGpara and mBorg 
and between NVEpara and mBorg were calculated for each subject. The 
median (range) correlation coefficient for individual subjects’ relationships 
between EMGpara and mBorg was 0.70 (0.00 – 1.00).  The median (range) 
correlation coefficient for individual subjects’ relationships between NVEpara 
and mBorg was -0.70 (-0.926 – 0.949). 
 
No significant relationships were observed between changes in mBorg and 
those in EMGdi or NVEdi from baseline to end of test. The median (range) 
correlation coefficients for individual relationships between EMGdi and 




5.4.3 Part A: Diaphragm EMG 
 
In the ten subjects undergoing additional measurement of EMGdi, significant 
changes were observed in all parameters except NVEdi (Table 14). 
 
EMGpara was related to EMGdi both at baseline (r=0.649, p=0.049) and end of 
test (r=0.770, p=0.013).  The percentage changes in EMGdi and EMGpara were, 
however, not related (r=0.188, p=0.607).  There was no significant 
difference between the median (range) percentage changes observed in 
EMGdi and EMGpara (p=0.322). 
 
To assess any relative changes in muscle recruitment and neural respiratory 
drive to each muscle, the ratio of EMGdi to EMGpara activity was calculated.  
No significant difference between median (range) EMGdi to EMGpara activity 
ratio was observed between baseline (3.44 (1.77 – 7.84)) and end of test 
(3.75 (1.99 – 5.97), p=0.432). 
 
Due to the varying number of data points between subjects, individual 
correlation coefficients for the relationship between EMGpara and EMGdi 
were calculated for each subject and the median (range) correlation 
coefficient determined (0.30 (-0.70 – 1.00)).  No individual subject’s 
relationship reached statistical significance. 
 
The percentage changes in EMGdi did not correlate with the changes in FEV1 
(r=-0.042, p=0.918) or mBorg (r=-0.356, p=0.269).  There was no significant 
relationship between percentage changes in EMGdi and IC in the group of ten 
subjects (r=0.564, p=0.096) or those in this subset demonstrating 
hyperinflation (n=7, r=-0.143, p=0.783).  Due to the small numbers, 
comparison between the hyperinflator and non-hyperinflator subgroups 
was not performed.  
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When using the 0.0625mg.ml-1 dose as the reference stage, median (range) 
raw EMGdi was 18.19 (8.40 – 30.91)µV and increased significantly 
(p=0.0059) by 93.27 (-33.03 – 437.10)% to the end of test.   
 
As seen with EMGpara, percentage changes in EMGdi from 0.0625mg.ml-1 to 
end of test were unrelated to changes in FEV1 (r=-0.164, p=0.657), IC 
(r=0.261, p=0.47) or mBorg (r=-0.194, p=0.518). 
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(2.85 – 8.91) 
7.29 
(3.77 – 19.60) 
0.027 
93.11 
(-6.86 – 144.40) 
EMGdi (µV) 
19.42 
(7.31 – 42.32) 
33.77 
(13.51 – 51.56) 
0.027 
61.73 
(-41.85 – 517.20) 
FEV1 (%predicted) 
97.86 
(80.00 – 118.20) 
68.18 
(37.98 – 92.27) 
0.002 
-32.76 
(-53.67 – -21.08) 
IC (%predicted) 
112.10 
(75.11 – 133.30) 
88.47 
(59.10 – 121.60) 
0.0098 
-11.32 
(-28.01 – 6.59) 
NVEpara (ml.µV-1) 
208.00 
(107.70 – 403.8) 
130.7 
(64.74 – 246.6) 
0.027 
-33.26 
(-69.10 – 66.21) 
NVEdi (ml.µV-1) 
48.38 
(24.69 – 145.70) 
32.94 
(23.83 – 65.05) 
0.0645 
-38.11 
(-79.04 – 103.80) 
mBorg 
0.0 
(0.0 – 1.0) 
3.0 
(0.5 – 4.0) 
0.002 N/A 
Table 14 Changes in EMGpara, EMGdi, FEV1, IC, NVEpara, NVEdi and mBorg from baseline to end of test in ten subjects undergoing Part A 
of the study.  Data are expressed as median (range). 
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5.4.4 Part B: Impulse Oscillometry 
 
IOS was measured to evaluate changes in small airways resistance occurring 
in response to methacholine inhalation.  Significant changes were observed 
in EMGpara and FEV1 in the six subjects who undertook the study (Table 15) 
between baseline and end of test.  The fall in NVEpara did not reach statistical 
significance.  The decrease in IC was not significant.  Only two subjects 
demonstrated hyperinflation using the 300ml threshold, and only one if the 
value of 15% predicted was used.  Differences in IOS parameters between 
hyperinflators and non-hyperinflators were not explored due to the small 
numbers. 
 
Significant changes were seen in measures of small airway function (R5Hz, 
Diff R5-R20, and AX) using impulse oscillometry.  The change in R20Hz did 
not reach significance (Table 15).  The percentage increase in R5Hz was 
significantly greater than that in R20Hz (p=0.0313).  No relationships were 
observed between percentage changes in EMGpara or NVEpara and any IOS 
parameters. 
 
No relationships were seen in the dose-response slopes or area under the 
dose-response curves between EMGpara or NVEpara and the IOS parameters 
using either saline or 0.0625mg.ml-1 doses as reference points. 
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Table 15 Changes in EMGpara, FEV1, IC, NVE and IOS parameters from baseline to end of test in six subjects undergoing Part B of the 
study.  All data are presented as median (range).  
 Baseline End of test p value Percentage change 
EMGpara (μV) 
5.58 
(2.97 – 7.38) 
5.95 
(5.56 – 8.79) 
0.0313 
14.44 
(1.41 – 103.9) 
FEV1 (%predicted) 
93.20 
(80.32 – 98.87) 
66.57 
(43.32 – 75.57) 
0.0313 
-24.79 
(-48.45 – -22.28) 
IC (%predicted) 
81.36 
(72.07 – 97.32) 
75.07 
(39.84 – 98.70) 
0.2188 
-4.72 
(-44.72 – 4.53) 
NVEpara (ml.µV-1) 
142.3 
(86.68 – 397.0) 
119.7 
(60.90 – 211.9) 
0.0625 
-16.23 
(-53.23 – 5.75) 
R5Hz (kPa(L.s-1)-1) 
0.40 
(0.26 – 0.48) 
0.61 
(0.37 – 0.70) 
0.0313 
44.23 
(6.67 – 75.68) 
R20Hz (kPa(L.s-1)-1) 
0.29 
(0.16 – 0.39) 
0.35 
(0.20 – 0.41) 
0.0625 
21.76 




(0.07 – 0.19) 
0.26 
(0.08 – 0.38) 
0.0313 
118.30 
(14.29 – 200.00) 
AX (kPa.L-1) 
0.44 
(0.12 – 1.17) 
3.28 
(0.39 – 4.30) 
0.0313 
473.00 




This study has highlighted the complex pathophysiological processes that 
occur during methacholine-induced bronchoconstriction, as well as the 
complexity in the relationships between measures of neural respiratory 
drive and conventional measures of pulmonary function.  The study has 
demonstrated that significant hyperinflation did occur in a proportion of 
subjects following methacholine challenge test, but this did not have a 
simple additive effect on NRD over and above the effect of 
bronchoconstriction.  Significant increases in small airways resistance were 
demonstrated.  Agreement between NRD measured using EMGdi and EMGpara 
was demonstrated, although no relationship demonstrated between the 
relative magnitudes of increase in the activity of each muscle group.  No 
relationships were observed between EMGpara or EMGdi and breathlessness 
as quantified by the mBorg score. 
 
 
5.5.1 Critique of the method 
 
The current study adopted the protocol for standard methacholine challenge 
testing as used clinically but included additional outcome measures to 
quantify and attempt to understand any other pathophysiological changes 
that may have occurred with induced bronchoconstriction.  There are some 
potential weaknesses in the chosen study design. 
 
Other studies that have used methacholine challenge testing to induce 
bronchoconstriction in healthy subjects have used high-dose protocols 
(maximum methacholine dose of 256mg.ml-1) [278, 279], terminating at 
greater degrees of bronchoconstriction (decrease in FEV1 of 50%) [245, 280, 
281].  Such study designs result in a greater number of data points, 
facilitating the analysis of within-subject relationships between variables.  
High concentrations of methacholine were not available for use in the 
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current study and international guidelines were used for methacholine 
challenge testing, although these guidelines are designed to inform clinical, 
rather than research practice.  The current study included some subjects 
with a diagnosis of asthma, who responded at relatively low concentrations 
of methacholine.  The protocol involved the administration of quadrupling 
doses of methacholine at the lower concentrations (0.0625mg.ml-1, 
0.25mg.ml-1, 1mg.ml-1, 4mg.ml-1), with doubling doses used at higher 
concentrations (8mg.ml-1, 16mg.ml-1, 32mg.ml-1) for safety reasons.  Had 
doubling doses been used at the lower concentrations, a greater number of 
data points could have been obtained, enhancing the statistical power of the 
within-subject analyses. 
 
The outcome measure selected in the current study for quantification of 
breathlessness may have been insufficiently sensitive, partly explaining the 
lack of relationship between changes in mBorg score and EMGpara.  The 
changes in mBorg in this study (median (range) change 2.0 (0.0 – 4.0) are 
relatively small, and the ordinal nature of the scale may reduce sensitivity.  
The use of a visual analogue score may have allowed small changes in 
breathlessness to be detected, as such scales are used over a wider range 
than the mBorg, with higher end of test values reported [282, 283].  It is also 
unclear whether “breathlessness” is truly the predominant symptom 
experienced by subjects during methacholine challenge test.  Symptom-
specific scores such as those measuring “chest tightness” demonstrate 
greater changes during methacholine challenge testing than breathlessness 
scores alone [265].  The use of visual analogue scales to quantify “breathing 
discomfort” is also reported in the literature and has been shown to respond 
sensitively to methacholine-induced bronchoconstriction [275]. 
 
Using inspiratory capacity (IC) as a measure of end expiratory lung volume 
may also have limitations.  IC has been shown to demonstrate acceptable 
reproducibility, with intra-class repeatability coefficients of greater than 0.7 
reported [284, 285].  Similar relationships between IC and RV/TLC ratio and 
both EMGpara and EMGdi have also been shown [172], suggesting IC to be an 
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acceptable measure for use in studies of this nature. Nonetheless, it depends 
on the subject’s ability to breathe in a relaxed manner at functional residual 
capacity (FRC), as well as their motivation to inspire fully to TLC [286].  
Appropriate verbal prompting and encouragement was given to ensure both 
of these criteria were met, though greater accuracy may have been achieved 
using plethysmographic measurements of lung volumes.  As discussed 
previously in Chapter Four, body plethysmography would also have allowed 
the measurement of airways resistance.  Specialist equipment is also 
required, however, to conduct methacholine challenge testing within the 
plethysmograph while maintaining the recommended intervals between 
inhalations [226]. 
 
The IC manoeuvres that were performed to examine changes in end-
expiratory lung volume (EELV) may also have had a direct effect on 
bronchomotor tone.  Subjects performed a minimum of five maximal 
inspirations that may have resulted in alterations in airway calibre prior to 
measurement of resting EMGpara.  The magnitude of this effect would 
potentially be greater in healthy than asthmatic subjects, with lesser 
degrees of deep breath-related bronchodilation and greater, more rapid 
airway re-narrowing occurring in asthmatic subjects [250-255].  The 
heterogeneity of the deep breath responses may have acted as a 
confounding factor when attempting to assess relationships between 
variables.  Although the inclusion of subjects with both asymptomatic 
airway hyperresponsiveness or a formal diagnosis of asthma enhanced 
recruitment for the current study, narrower inclusion criteria for future 
studies may help reduce this potential source of variability. 
 
Although recommended [207], performing three IOS measurements and 
reporting the mean value would have  prevented adherence with guidelines 
regarding the timeframe between consecutive doses of methacholine [226].  
Several baseline measurements were performed to ensure that consistent 
values were obtained prior to the methacholine challenge.  In addition, all 
subjects undergoing Part B of this study were experienced in pulmonary 
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function testing and recognised the importance of steady tidal breathing 
during IOS.  It was unlikely, therefore, that any variation in IOS values was 
due to poor technique, but rather represented true changes in airway 
calibre.  The subset of participants undergoing IOS was, however, small, 




5.5.2 Relationship of the current findings to previous literature 
 
The results of the current study indicate the heterogeneous nature of 
pathophysiological changes that occur in obstructive airways disease.  The 
lack of relationship between percentage changes from baseline to end of test 
in FEV1 and IC indicates that hyperinflation can occur independently of the 
degree of large airways obstruction.  This is in agreement with previous 
studies that have demonstrated a lack of relationship between severity of 
bronchoconstriction and extent of change in end expiratory lung volumes 
[263, 287].  It was not possible therefore to determine the relative influence 
of changes in lung volume and/or airway calibre on EMGpara activity. 
 
Lavorini et al [275] examined ventilatory responses to methacholine 
challenge and described consistent increases in EMGpara in all subjects, 
regardless of whether  minute ventilation increased or not.  Similarly, 
changes in NVEpara were observed in the current study, in that NVEpara was 
reduced in some subjects whereas in other subjects it was maintained.  
Although Lavorini et al [275] stated that EMGpara activity was not observed 
at baseline, differences in EMGpara signal acquisition methodology prevent 
further direct comparison between the magnitudes of EMGpara change 
between studies. 
 
Previous data have demonstrated strong agreement between the activity of 
the diaphragm and parasternal intercostal muscles [77, 79, 82, 172, 192].  
The agreement between EMGpara and EMGdi activity in the current study was 
 175 
poor when examined using individual subject correlation coefficients 
(median (range) r value 0.30 (-0.70 – 1.00)).  It is possible, however, that 
these correlation coefficients were of little value in evaluating the 
relationship between diaphragm and parasternal intercostal activity as the 
number of data points available to perform correlation analysis was low for 
most subjects and individual relationships did not reach statistical 
significance (median (range) p value 0.653 (0.058 – 1.00).  Reilly et al [172] 
evaluated change in EMGpara and EMGdi activity measured continuously 
during incremental exercise to exhaustion, by dividing total exercise time 
into deciles.  Similarly, the same author investigated the effects of 
inspiratory threshold loading and hypercapnia on EMGdi and EMGpara [192] 
and exposed all subjects to the same number of incremental loads.  Both 
study designs allowed all subjects’ data to be included in the overall 
analysis.  The nature of the current study does not, however, allow this, 
resulting in variable numbers of data points per subject at discrete time 
points.  Safety considerations precluded exposing all subjects to the same 
number of methacholine doses, as this would result in subjects who 
responded at lower doses being exposed to further, potentially dangerous, 
bronchoconstriction.  Good agreement was, however, observed between 
EMGdi and EMGpara measured both at baseline and end of test. 
 
Previous data have also demonstrated close agreement between changes in 
dyspnoea and changes in NRD (quantified by EMGpara%max or EMGdi%max) 
[172, 198].  The current study demonstrated a wide range of within-subject 
relationships between mBorg and EMGpara (median (range) correlation 
coefficient 0.70 (0.00 – 1.00)), and a similar median but wider range of 
intra-subject agreement between mBorg and EMGdi (0.625 (-1.00 – 1.00)).  
As above, these results should also be interpreted with caution due to the 
small number of data points available for each subject.  The lack of 
significant relationships between baseline to end of test changes in mBorg 
and EMGpara or EMGdi was surprising in view of previous findings of strong 
relationships between these variables [172, 196], although the magnitude of 
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changes in mBorg and the ordinal nature of the scale may not provide 




5.5.3 Rationale for results 
 
We hypothesised that subjects demonstrating hyperinflation in response to 
MCT would show greater changes in EMGpara than those without changes in 
end expiratory lung volume.  This did not occur and no significant 
differences in EMGpara or NVEpara were observed between the hyperinflator 
and non-hyperinflator groups.  The heterogeneity of changes in FEV1 and IC 
across subjects prevented detection of any specific influence of 
hyperinflation on levels of NRD over and above that caused by 
bronchoconstriction.  Changes in airway calibre and end expiratory lung 
volume occurred to different extents within individual subjects as 
demonstrated by the lack of relationship between baseline to end of test 
percentage changes in FEV1 and IC (r=0.248, p=0.492).  The presence of lung 
hyperinflation does not appear to represent a phenotype in whom more 
severe responses to methacholine occur, as the range of percentage changes 
in FEV1 was similar between the hyperinflator and non-hyperinflator 
subgroups. 
 
Changes in EMGpara and IC at the concentration of methacholine inducing a 
20% decrease in FEV1 (PC20) were calculated as a means of examining the 
specific influence of hyperinflation.  Using this method to standardise the 
contribution of bronchoconstriction to EMGpara did not, however, identify 
any relationship between changes in IC and EMGpara.  The median change in 
IC at PC20 was small (-2.96%) and may therefore have been unlikely to 
exert a significant influence on EMGpara.  Previous data from Reilly et al [172] 
demonstrated a relationship between baseline IC and both resting EMGpara 
and resting EMGdi in adults with cystic fibrosis; the strength of the 
relationship was similar to that with FEV1.  Hyperinflation and gas trapping 
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are known to progress with worsening CF lung disease [26, 288, 289], as 
does FEV1 [290]; these may both represent severity of CF lung disease.  The 
simultaneous nature of these changes, however, indicated that IC could not 
definitively be said to exert an independent influence on NRD in the study 
by Reilly et al.  It is also notable that the degree of hyperinflation observed 
in the patients with cystic fibrosis (mean (SD) IC 1.9 (0.5)L) was 
substantially greater than that in the current study (median (range) end of 
test IC 2.78 (1.36 – 4.18)L).  Data regarding the isolated effect of 
hyperinflation on respiratory muscle activity in humans are not currently 
available. 
 
Studies in dogs have suggested that the length-tension relationship of the 
parasternal intercostal muscles is improved at higher lung volumes, and that 
they are able to generate greater force per unit change in length at TLC than 
at FRC [202].  The reduced compliance of the ribcage at higher lung volumes, 
however, means that translation of electrical activity into rib motion and 
lung volume change becomes less efficient [291, 292], potentially offsetting 
these improvements in length-tension relationships.  The ability of the 
diaphragm to generate force is significantly impaired at higher lung volumes 
as a result of substantial flattening of the domes of the hemidiaphragms and 
muscle shortening [293], requiring greater neural drive to effect the same 
change in lung volume.  The relative change in length of the parasternal 
intercostal muscles at higher lung volumes is less than that of the diaphragm 
[73], suggesting that increases in EMGpara may be expected to be less 
pronounced than those in EMGdi in response to hyperinflation.  In the 
current study, no significant difference was found in the magnitude of 
increase in EMGdi and EMGpara, neither was there any significant change in 
the ratio of EMGdi to EMGpara.  The magnitude of hyperinflation (median 
decrease in IC in ten subjects: 11.32%) may have been insufficient to cause 
the diaphragm to become sufficiently shortened and any change in the 
relative neural drive to the diaphragm and parasternal intercostal muscles.  
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Hyperventilation with associated reductions in carbon dioxide partial 
pressures have been observed during methacholine challenge testing in 
asthmatic and non-asthmatic individuals [270, 275, 294].  The systemic 
effects of methacholine have been shown to be minimal at the doses used in 
the current study [295], hence any increases in ventilation were more likely 
to be mediated by a psychogenic mechanism rather than physiological 
demand.  This increase in NRD and ventilation acts as a confounding 
variable when attempting to assess the effect of increases in respiratory 
load on NRD.  While measurement of end tidal CO2 concentrations could 
have provided a method for determining hyperventilation by the subjects, 
the use of NVEpara as a measure of NRD was felt to offer an advantage in the 
assessment of respiratory load. 
 
An increase in tidal volume in the absence of any change in respiratory load 
would require greater activation of the respiratory muscles and hence a 
higher peak EMGpara would be observed.  As previously discussed in Chapter 
Three, measuring the area under the rectified EMGpara curve may provide a 
more sensitive measure of overall respiratory load, this was not possible 
due to technological constraints associated with ECG artefact removal.  
Representing NRD as the ventilatory return for a given neural output (NVE) 
allowed the effect of changes in respiratory pattern to be differentiated from 
alterations in respiratory load.  Any increases in tidal volume, while 
increasing EMG, would result in minimal changes in NVE.  Substantial effects 
would only be expected to occur at much higher lung volume when, due to 
elastic recoil, the chest wall is more difficult to expand. The utility of this 
measure has previously been investigated in assessing readiness for 
extubation [296] and in titrating respiratory support [297] in critical care 
patient populations, as well as in assessing responses to increased 
respiratory load in healthy subjects [192]. 
 
Under conditions of hypercapnia-induced hyperpnoea, significant increases 
in EMGpara and EMGdi have been observed, with minimal change in NVEpara 
or NVEdi [192].  In contrast, at high levels of inspiratory threshold loading 
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(>30% of maximum inspiratory pressures), NVEpara decreased significantly.  
NVEdi, however, was relatively unaffected by the increasing load, possibly as 
a consequence of volitional changes in lung volume to adopt a more 
preferential position on the length-tension curve or as a result of increased 
recruitment of other ribcage musculature (including greater activation of 
the parasternal intercostal muscles).   
 
Changes in tidal volume have previously been documented following MCT, 
although substantial heterogeneity of ventilatory responses was observed 
[267-270, 275].  To minimise the confounding effect of these potentially 
varied responses, NVE was felt to offer an improved method for assessment 
of NRD.  When considered in the context of other reported data, however, it 
appears that the levels of respiratory load imposed may have been 
insufficient to induce substantial effects on NVEpara or NVEdi.  For example, in 
mechanically ventilated adults with a range of pathologies, NVEdi during a 
spontaneous breathing trial was shown to be a sensitive and specific 
predictor of extubation outcome (area under the receiver-operator 
characteristic curve of 0.816) [296].  The optimal NVEdi threshold for 
predicting extubation failure was 25.0ml.µV-1, which is substantially less 
than the end of test NVEdi in the current study (median (range) NVEdi 32.94 
(23.83 – 65.05)ml.µV-1).  The use of NVE to determine the effectiveness of 
respiratory muscle activation may have greater utility in very unwell patient 
populations, where the magnitude of the respiratory load-capacity 
imbalance may precipitate respiratory failure.  NVE may, under such 
circumstances, indicate that the increasing NRD may not be resulting in 
appropriate increases in ventilation.  However, in a healthy population such 
as in the current study, the capacity of the respiratory system to respond to 
(mild to moderate) increases in load is likely to be sufficient and the use of 
NVE as an outcome measure may not offer any advantage above 
measurement of EMGdi or EMGpara alone.  No relationships were observed 
between NVEpara or NVEdi and conventional measures of pulmonary 
function, and the magnitudes of change observed in EMG and NVE for both 
the parasternal intercostal muscles and diaphragm were also similar, 
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suggesting little advantage being gained through the use of NVE as a 
measure of NRD.  
 
Changes in small airways resistance were demonstrated in the subset of 
individuals undergoing Part B of the study.  The percentage changes in 
R5Hz, diff R5-R20, AX, IOS measures of small airways function, were greater 
than that in R20Hz as well as in FEV1, both measures predominantly of 
larger airway calibre.  Although no direct relationship was observed 
between changes in EMGpara and those in the IOS measures of small airways 
function, the data from this small cohort suggest that methacholine 
challenge testing is associated with increases in resistance in small distal 
airways.  The heterogeneity of the changes observed in both small and large 
airways resistance and end expiratory lung volumes seen in both in this and 
previous studies [263, 266, 287] make interpretation of the relative 
contributions of each to the overall change in NRD difficult.  Nonetheless, the 
significantly greater increases in small airways resistance compared to that 
in large airways resistance suggests that distal airways obstruction may 






This study has demonstrated the complexity of the interactions between the 
pathophysiological changes occurring in induced bronchoconstriction.  A 
clear additive effect of hyperinflation in addition to bronchoconstriction on 
the changes in NRD has not been observed; at the degrees of change seen in 
this study, the lack of additional increase in NRD in the hyperinflator group 
may suggest that bronchoconstriction exerts a stronger influence on NRD 
than changes in end expiratory lung volume.  Nonetheless, significant 
changes in small airways resistance, large airways calibre and end 
expiratory lung volume have all been observed and it is likely that all of 
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these changes affect EMGpara.  The extent to which each influences NRD 
cannot be elucidated from the current study.  Weaknesses in the study 
design limit the ability of this study to clarify the relationship between 
EMGpara and EMGdi, as well as the relationship of EMGpara with 
breathlessness, during induced bronchoconstriction. 
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6. Chapter Six: EMGpara in 
paediatric cystic fibrosis  
6.1 Introduction 
 
Cystic fibrosis (CF) is the UK’s most common life-limiting inherited 
condition, with one in every 2,500 live births affected [298].  Pulmonary 
disease is the most common manifestation of CF, with 80-85% of mortality 
attributed to severe lung disease [299, 300].  Repeated endobronchial 
infection and concomitant inflammation in the small airways lead to 
progressive pulmonary destruction and eventual respiratory failure [301, 
302].  While severe lung disease is relatively uncommon in the paediatric 
setting, maintaining lung function during childhood is known to be 
associated with improved pulmonary function, health status and longer 
survival in adulthood [300].  Aggressive treatment of infections and 
exacerbations in the first few years of life are particularly associated with 
improved outcomes [103]. 
  
Although there is no standardised definition of what constitutes an 
exacerbation of CF lung disease, symptoms may include increased cough, 
breathlessness, malaise, low-grade fever, decreased appetite or weight, 
changes in sputum colour or quantity, deterioration in lung function, and 
new findings on chest auscultation [300, 303, 304].  These may be rapid in 
onset or more insidious and hospitalisation for intravenous antibiotics is 
indicated to prevent further disease progression [103, 305, 306].  In 
addition to clinician assessment, spirometry (predominantly FEV1) is 
currently the standard assessment technique used during an acute 
exacerbation to assess changes in lung function and the effects of treatments 
[301, 302, 307, 308].  The volitional nature of spirometry, however, results 
in difficulty obtaining these measures in younger or acutely unwell children 
[308, 309], and makes assessment of treatment efficacy difficult in these 
populations.  Objective measures suitable for assessment of pulmonary 
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function in acutely unwell and/or younger children with CF are lacking.  
EMGpara may offer a non-volitional option for monitoring pulmonary 
function in this population. 
 
The aims of this study were to assess the feasibility of undertaking regular 
measurements of EMGpara in a population of children hospitalised for 
treatment of an exacerbation of CF lung disease, to investigate the changes 
observed in NRD, as measured by EMGpara, over the course of the admission, 
and to explore the relationship between EMGpara and conventional measures 
of pulmonary function.  We hypothesised that EMGpara would gradually 
decrease during the treatment of an exacerbation of CF lung disease.  We 
further hypothesised that the changes in EMGpara would be greater than 





Patients were recruited from the paediatric respiratory ward at King’s 
College Hospital NHS Foundation Trust.  Any child with a diagnosis of cystic 
fibrosis admitted for intravenous antibiotics (for respiratory reasons) was 
eligible for inclusion.  Ethical approval for the study was granted by the 
King’s College Hospital Research Ethics Committee (ref: 09/H0808/100).  







Height was measured using a wall-mounted stadiometer (Harpenden, 
Holtain Ltd, Crymych, UK) and weight with an electronic medical scale (HR 
Person Scale, Marsden Ltd, Henley on Thames, UK). 
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EMGpara was measured as described in Chapter Two (Methods).  Briefly, 
EMGpara was recorded using surface electrodes placed over the second 
intercostal space.  The signal was amplified (gain 1,000), band-pass filtered 
between 10 and 2,000Hz, and a 50Hz notch filter and a post-acquisition 
20Hz digital high-pass filter applied.  The signal was converted to root-
mean-square (RMS) and mean peak RMS EMGpara per breath calculated. 
 
IOS and spirometry were measured as described in Chapter Two, using 
Jaeger Masterscreen IOS and PFT systems respectively, running JLAB 
software version 4.0 (Cardinal Health, Basingstoke, UK).  IOS was performed 
in accordance with ERS guidelines [207], with the mean of three 
reproducible recordings being reported.  Spirometry was performed 
according to ATS/ERS recommendations [14], and the highest value of three 






Patients were studied at the same time on each day of admission.  
Anthropometric and demographic data were collected on the day of 
admission and weekly thereafter.  EMGpara, IOS and spirometry were 
recorded daily during the admission.  Briefly, resting EMGpara was recorded 
for ten minutes, with the final stable minute used to calculate mean peak 
RMS EMGpara per breath.  MaxEMGpara was recorded in those subjects able to 
reliably perform inspiration to total lung capacity (TLC).  IOS followed by 
spirometry were performed after the EMGpara recording, in subjects able to 
comply with such measurements.  As the study was conducted during an 
infective exacerbation where treatment burden is high and patients may 
experience a number of undesirable symptoms such as nausea and fatigue, 
patients and their parents had the option to decline any or all of the 
proposed measurements on any given day.  If daily spirometry 
 185 
measurements were declined, weekly lung function testing was completed 
(as per standard clinical care) and these data used for the study. 
 
 
6.3.3 Additional analyses 
 
Relationships between daily changes of individual parameters within 
patients were examined using area under the curve (AUC) analysis and by 
comparing the slopes of the regression lines. Such analyses have been used 
to assess incremental changes in pulmonary function during airway 
challenge testing [244, 310].  Daily percentage changes were plotted against 
number of days since admission and both the area under the day-response 
curve calculated and linear regression analysis performed.  Regression lines 
were assessed for deviation from linearity using the Wald-Wolfowitz runs 
test.   
 
 
6.3.4 Statistical analysis 
 
Non-parametric statistics were used due to the sample size consisting of 
fewer than 30 subjects.  A p value <0.05 was taken as statistically significant.  
Admission to discharge changes in all measured variables were assessed 
using the Wilcoxon matched pairs test.  The Friedman test was used to 
assess repeated measures within subjects over the first five measurement 
points (as this was equal to the minimum number of data points available in 
the subject with the shortest length of stay, and allowed assessment of acute 
changes in CF lung disease status), with Dunn’s test to correct for multiple 
comparisons.  Spearman’s rank correlation was used to assess relationships 
between variables.  Changes in EMGpara, being generally negative, were 
multiplied by minus one for the comparison of whether the magnitude of 
change in EMGpara was greater than that in FEV1, using the Wilcoxon 
matched pairs test.  AUC and regression line slopes were also compared for 
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6.3.4.1 Sample size calculation 
 
No formal sample size calculation for this study was performed as data are 
not available regarding EMGpara activity in children with CF.  The data from 
the study by Reilly et al [199] in adults with CF were unsuitable to inform 
the sample size for this study due to the progressive nature of the condition, 
and it was not felt appropriate to extrapolate from data obtained in an 
asthmatic population.  Subjects were therefore recruited on a convenience 
basis, according to inpatient admissions during the recruitment period and 






23 children were recruited for the study, from whom twenty complete data 
sets were obtained.  One child declined daily measurements due to the 
severity of their clinical condition, a second withdrew consent after testing 
on the first day having reported discomfort during electrode removal and 
the third was withdrawn due to lack of researcher availability.  The median 
(range) length of stay was 10 (5 – 18) days.  The demographic and 
anthropometric data (as measured on admission) of the twenty participants 





















(1.91 – 15.77) 
12.41 
(4.93 – 15.77) 
12.84 
(7.21 – 15.77) 
Sex 
(male: female) 
5 : 15 5 : 13 4 : 12 
Height (m) 
1.484 




(1.176 – 172.2) 
Weight (kg) 
36.00 
(10.96 – 56.70) 
39.20 
(19.00 – 56.70) 
41.35 




(14.8 – 20.7) 
17.7 
(14.8 – 20.7) 
18.2 





White: 20 (100%) White: 20 (100%) 
Table 16 Demographic and anthropometric characteristics of twenty 
children with CF undergoing measurements of EMGpara during an infective 
exacerbation.  All data are shown as median (range). 
 
 
EMGpara was successfully recorded on median (range) 88.8 (64.3 – 100.0)% 
of admission days.  This was significantly greater than the median (range) 
percentage of days on which spirometry and IOS were obtained: 79.3 (0.0 – 
100.0)%, p=0.012 and 77.5 (0.0 – 100.0)%, p=0.003 respectively.  When the 
patients in whom spirometry and IOS were not attempted or not possible 
(due to age or technique) were excluded, measures of IOS and spirometry 
were still obtained on significantly fewer days (IOS 81.7 (23.5 – 100.0)%, 
p=0.047, spirometry 81.7 (38.9 – 100.0)%, p=0.047) than EMGpara (85.7 




6.4.1 Changes in EMGpara  
 
Median (range) EMGpara decreased in the cohort as a whole from 7.13 (3.19 – 
13.18)μV on admission to 5.60 (2.62 – 13.45)μV at discharge, a median 
(range) percentage change of -14.67 (-54.57 – 29.56)% (p=0.033). 
 
Repeated measures testing of EMGpara on the first five measurements 
indicated a significant change (p=0.015) in median (range) EMGpara from day 
one (7.13 (3.19 – 13.18)µV) to day four (6.45 (2.63 – 13.41)µV) only.  
 
Satisfactory maxEMGpara values were obtained at admission and discharge in 
16 participants.  The change in EMGpara%max was not significant (11.65 
(4.10 – 31.29)% to 10.29 (5.86 – 38.88)%, p=0.632, Table 17).  The median 
(range) within-individual, between-day coefficient of variation of the 
EMGpara%max signal was, however, 29.2 (17.8 – 51.1)%, in contrast to 16.8 
(8.0 – 32.3)% for the raw EMGpara signal (p<0.0001).  The lack of a 
statistically significant change in EMGpara%max was most likely a 
consequence of variability in the maxEMGpara signal.  Correlation analysis 
indicated that the variation of the EMGpara%max signal was strongly related 
to that of the maxEMGpara signal (r=0.678, p=0.002), but not to that of the 
raw EMGpara signal (r=0.179, p=0.478).  There was no significant difference 
(p=0.868) between median (range) maxEMGpara values in all subjects on the 
first five days on which measurements were obtained, indicating that the 
lack of significant difference in EMGpara%max was unlikely to be due to a 
















to day 1) 
Day 1 
7.13 
(3.19 – 13.18) 
N/A 
56.92 
(25.79 – 131.10) 
N/A 
11.65 




(3.67 – 15.67) 
0.143 
46.40 
(24.36 – 90.32) 
0.154 
12.25 




(3.32 – 12.53) 
>0.999 
51.76 
(15.27 – 97.23) 
0.578 
11.25 




(2.63 – 13.41) 
0.015 
54.70 
(21.78 – 150.70) 
>0.999 
10.34 




(2.95 – 13.32) 
0.646 
52.40 
(20.26 – 119.30) 
>0.999 
10.78 
(6.12 – 32.47) 
>0.999 
Table 17 Changes in EMGpara and maxEMGpara from day of admission to days two to five.  Data are expressed as median (range). 
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6.4.2 Changes in pulmonary function 
 
18 children were able to complete spirometry, while 16 were able to 
complete IOS.  Significant increases were seen in FEV1 and FVC, while 
changes in R5Hz approached significance (Table 18). 
 
 
 Admission Discharge p value 
FEV1 (%predicted) 
66.9 
(36.6 – 102.2) 
87.0 




(40.8 – 109.0) 
96.1 




(0.28 – 0.96) 
0.48 




(0.26 – 0.87) 
0.46 




(0.18 – 0.60) 
0.34 




(4.92 – 52.49) 
33.06 




(10.38 – 22.47) 
15.99 




(0.26 – 3.79) 
0.81 
(0.18 – 3.52) 
0.14 
Table 18 Changes in pulmonary function from admission to discharge in 
children with cystic fibrosis.  n=18 for FEV1 and FVC.  n=16 for all other 





6.4.3 Measurements of EMGpara and pulmonary function 
 
In the 18 children in whom spirometry was measured, the median (range) 
percentage change in EMGpara (-16.68 (-54.57 – 29.56)%) was significantly 
greater than that in FEV1 (10.33 (-22.09 – 84.81)%, p=0.0008).  The median 
(range) percentage changes in EMGpara (-10.28 (-34.26 – 66.17)%) and FEV1 
(8.33 (-11.86 – 32.14)%) from the first to the fourth measurement were not 
significantly different (p=0.702). 
 
Plots showing individual subjects’ daily changes in EMGpara and FEV1 are 




Figure 29 Daily changes in EMGpara and FEV1 in subjects 1 to 6 from Study 
Four.  Squares denote EMGpara; triangles denote FEV1. 
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Figure 30 Daily changes in EMGpara and FEV1 in Subjects 7 to 12 from Study 
Four.  Squares denote EMGpara; triangles denote FEV1. 
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Figure 31 Daily changes in EMGpara and FEV1 in Subjects 13 to 18 from 






Figure 32 Daily changes in EMGpara and FEV1 in Subjects 19 and 20 from 




No relationships were observed between percentage changes in EMGpara and 
those in any other measure of pulmonary function, either from admission to 
discharge or acutely between the first and fourth measurements.  The 
relationship between EMGpara at admission and FEV1 at admission 
approached significance (r=-0.445, p=0.064, Figure 33).  The change in 
EMGpara was related to FEV1 on admission (r=0.490, p=0.039, Figure 34), 
with a greater fall in EMGpara being observed in subjects with lower FEV1 
%predicted on admission.  The length of stay was inversely related to 
severity of lung function impairment on admission, as indicated by FEV1 
%predicted (r=-0.47, p=0.039).  No relationship was seen between change 







Figure 33 Relationship between FEV1 and EMGpara on admission in 18 








Figure 34 Relationship between FEV1 on admission and change in EMGpara 




There was no significant difference in the median (range) AUC for EMGpara 
and FEV1 (30.02 (-504.1 – 349.3) AU vs. 60.9 (1.0 – 627.5) AU, p=0.167).  
There was no significant relationship observed between AUC EMGpara and 
AUC for any spirometric parameters.  The only IOS parameter exhibiting a 
significant relationship with AUC EMGpara was the AUC for frequency 
dependence of resistance (ΔR5-20, r=0.547, p=0.031).  
 
 
To examine the nature of the progressive change in different measures, the 
slopes of the changes in individual parameters per day of admission were 
calculated.  No relationship was observed between the slopes for EMGpara 
and FEV1 or FVC.  The only IOS parameter demonstrating a significant 
relationship with EMGpara was X5Hz (r=0.741, p=0.0015).  There was no 
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significant difference in the median (range) slopes of the regression lines for 
EMGpara and FEV1 (0.447 (-3.293 – 7.997) vs. 1.067 (0.131 – 7.071), 
p=0.495), indicating that improvements in disease status were not seen 








This study has demonstrated the feasibility of obtaining EMGpara 
measurements in children hospitalised for an infective exacerbation of CF 
lung disease.  EMGpara fell during the resolution of the acute respiratory 
episode, suggesting a reduction in respiratory load, as indicated by the 
increase in FEV1.  Changes in EMGpara were not, however, related to changes 
in spirometry and IOS.  The study also demonstrated that EMGpara as a 
measure of disease severity is applicable both to a wider age range and on a 
greater percentage of admission days than conventional measures of 
pulmonary function (spirometry and IOS).   
 
 
6.5.1 Critique of method 
 
The feasibility of obtaining measurements on each day of admission was 
limited by a number of factors, including patients’ willingness to co-operate, 
clinical procedures, deterioration in clinical condition, and planned home 
leave.  The greater acceptability of EMGpara compared to conventional 
pulmonary function measures, particularly spirometry, resulted in EMGpara 
data being recorded on some days in the absence of other measures of 
pulmonary function.  When the relationships between daily changes in 
EMGpara and other measures of pulmonary function were analysed, only days 
on which both values were available were used, resulting in some data 
points being excluded.  While for the majority of subjects, this only resulted 
in a relatively small number of missing or unused data points, one subject 
only performed spirometry, IOS and EMGpara measurements on four of 
seventeen admission days (23.5%).  These missing data points resulted in 
reduced statistical power with which to evaluate relationships between 
daily changes in the different outcome measures.  The short length of stay in 
some subjects (due to these subjects being discharged to complete the 
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course of intravenous antibiotics at their local hospital or at home) also 
reduced the number of data points. 
 
Maximal manoeuvres were attempted in all subjects to allow the EMGpara 
signal to be expressed as a percentage of maximum (EMGpara%max), as in 
previous studies [172, 192, 197-199].  Only 16 subjects were able or willing 
to perform these manoeuvres at both admission and discharge, highlighting 
the limitations of using this method for expressing EMGpara.  While it has 
been suggested that the use of EMGpara%max allows more accurate inter-
individual comparison [172, 189, 192, 197, 198, 311], the data in Chapter 
Seven suggest that the raw signal might be equally useful.  Data are not 
available regarding the day-to-day variability of the raw EMGpara signal in 
clinically stable children with CF, which would be of benefit in interpreting 
the significance of the changes observed in the current study and would 
allow the determination of a threshold for a significant change in EMGpara. 
 
Using EMGpara%max may also potentially minimise the influence of slight 
variations in electrode placement [172, 192, 197, 198] that underlies the 
poor reproducibility commonly reported when using surface EMG 
measurements.  This was felt to be an important consideration in the 
current study, given that repeated measurements were obtained over many 
days.  The significantly greater between-day CV in EMGpara%max when 
compared to the raw EMGpara signal in this cohort, as well as the strong 
relationship between the variability of the EMGpara%max and maxEMGpara 
values, suggests that it is the variability of the maximum EMGpara signal that 
reduces the utility of EMGpara%max.  As a result of undertaking airway 
clearance techniques involving deep inspirations, children with CF are 
familiar with performing volitional inspiratory efforts from a relatively 
young age [304].  It was, therefore, felt that most subjects in this study 
would be likely to be able to reliably perform inspirations to TLC.  Despite 
technically acceptable maxEMGpara signals being obtained in sixteen of the 
twenty subjects, the between-day variability of these measures suggests that 
there may have been either contamination of the signal from other chest 
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wall musculature, influences on signal amplitude by the speed at which the 
inhalation was performed, or that submaximal efforts may have been 
performed on some occasions.  It is not possible to ascertain whether 
changes in the subjects’ clinical condition influenced this variability without 
knowing the variability of maxEMGpara values in clinically stable children 
with CF, though no consistent change in maxEMGpara was seen on repeated 
measures testing. 
 
In addition to the variability potentially introduced by variations in 
electrode placement, the longitudinal study design also allows the results to 
be influenced by a variety of other factors.  Individual patients’ 
measurements were performed at the same time of day and were planned 
around scheduled clinical interventions.  Timetabling of all planned 
activities, including time for schoolwork, clinical interventions and meals, is 
standard clinical practice at King’s College Hospital for all inpatients with 
CF.  Where possible, the interval between study measurements and 
treatments such as nebulised mucolytics, bronchodilators or antibiotics and 
airway clearance activities (including exercise) was standardised.  Patients 
and/or their parents engaged well in ensuring the interval between 
measurements and clinical treatment was maintained, hence minimising 
their influence on the results.  
 
No additional data regarding patients’ symptoms or clinician assessment of 
clinical status were obtained in the current study.  Many of the available 
patient- or parent-reported outcome measures (PROs) validated for use in 
children with CF have a recall period too long to be sensitive to acute 
changes in disease status, such as those occurring during treatment for an 
infective exacerbation.  There is also no single PRO suitable for use across 
the age spectrum included in this study [312].  Similarly, although some 
dyspnoea scales have been shown to demonstrate responsiveness to clinical 
change in children with CF [313-315], none of these were suitable for use in 
the younger children included in the current study.  Future studies could 
include a simple visual analogue scale or global rating of change 
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questionnaire to ascertain daily change in patient- or parent-perceived 
health status, as well as clinician opinion of clinical improvement or 
deterioration.  Inclusion of such a measure would enable the relationship to 
EMGpara to be assessed, particularly in view of the strong relationships 
previously described between measures of NRD and patient perception of 
breathlessness [172, 189]. 
 
 
6.5.2 Discussion of findings 
 
The significant decrease in EMGpara from admission to discharge suggests 
that the technique can detect change in respiratory load with clinical 
improvement, though no correlation with the change in other measures of 
lung function was observed.  These data are in agreement with data from 
Reilly et al [199], who found a significant decrease in EMGpara activity from 
admission to discharge in adults hospitalised with an acute exacerbation of 
CF lung disease.  The adult CF patients showed much greater impairment of 
lung function (mean (SD) FEV1 %predicted 41 (17)%) compared to the 
children in the current study (median (range) 66.9 (36.6 – 102.2%).  The 
improvement in FEV1 in the adult patients was also much greater (mean 
(SD) percentage change 39 (30)% vs. median (range) percentage increase of 
10.3 (-7.1 – 84.8)% in the current cohort).  This greater change in FEV1 was 
mirrored by a greater fall in EMGpara in the adult patients (mean (SD) change 
in EMGpara -38 (19)%) compared to the current study (median (range) 
change -14.7 (-54.6 – 29.6)%).  Such differences were to be expected due to 
the progressive nature of CF lung disease and the increasing severity of 
acute exacerbations with worsening of pulmonary function.  The results 
from the current study further support this with the relationship between 
FEV1 on admission and the magnitude of the significant decrease in EMGpara, 
suggesting greatest change in those with more severe lung disease.  In 
agreement with the current study, however, Reilly et al found no 
relationship between the percentage changes in FEV1 and EMGpara. 
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A similar study by Murphy et al [198] in patients hospitalised with an acute 
exacerbation of COPD, demonstrated a significant fall in EMGpara%max but 
no relationship between changes in spirometric parameters and those in 
EMGpara%max.  The authors did not comment specifically on this lack of 
agreement.  Maarsingh et al [186] assessed change in respiratory muscle 
EMG activity in infants and toddlers undergoing inpatient hospital 
treatment for acute wheezing illnesses and demonstrated a significant fall in 
both EMGpara and surface EMGdi.  These changes correlated with falls in the 
Clinical Asthma Score, a validated scale for assessing severity of respiratory 
disease in pre-school children [316].  Due to the age of the children included, 
the authors did not compare changes in EMG activity to any other objective 
measures of pulmonary function.  Nonetheless, the results of the current 
study can be said to be broadly in agreement with the results obtained by 
Murphy et al [198] and Maarsingh et al [186], despite the studies having 
been conducted in very different clinical populations.   
 
Patients with CF have higher resting energy expenditure than healthy 
individuals due to the presence of chronic inflammation and infection [317], 
which increase further with an acute exacerbation of CF lung disease.  Amin 
et al demonstrated reductions in resting energy expenditure in patients with 
CF following commencement of mucolytic therapy [318].  This reduction in 
metabolic demand is also likely to result in reduced respiratory drive, 
reflected in EMGpara changes but not in spirometry or oscillometry, and is a 
potential confounder when using this technique in acute CF lung disease, 
and may have influenced the lack of relationship between EMGpara in this 
and previous studies in acutely unwell populations. 
 
Patients with a range of lung disease severities (as quantified by FEV1), 
ranging from significant impairment (below 40% predicted) to greater than 
100% predicted were included in this study.  This further supports the 
applicability of the technique in all disease severities.  That the measure can 
be obtained in hospitalised children as young as 23 months of age also 
indicates that the technique may have potential for use as a clinical tool to 
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monitor clinical improvement in children in whom objective measures of 
pulmonary function are currently lacking.  The withdrawal by one subject 
due to the severity of their clinical condition was not due to poor 
acceptability of EMGpara to patients with severe disease, but moreover that 
the additional measures against which the EMGpara values were to be 
compared were too arduous for the patient to perform. 
 
The trend towards a relationship between EMGpara and FEV1 on admission 
indicates that EMGpara may have potential as a marker of disease severity, as 
has been suggested in previous studies in adult CF and asthma patients 
[172, 197].  Although FEV1 is currently used as the primary indicator of lung 
disease severity in individuals with CF, small airways obstruction and 
hyperinflation also contribute significantly to the severity of CF lung disease 
and are not detected by FEV1.  EMGpara is likely to be sensitive to such 
changes, which will influence the relationship between EMGpara and FEV1.  
The predominance of small airways disease in younger children may explain 
the weaker relationship observed in the current study when compared to 
previous data [172]. 
 
The population included in this study was heterogeneous, with a range of 
ages and lung disease severities.  While this offers an advantage in terms of 
demonstrating the applicability of EMGpara in a range of clinical 
circumstances, the range of disease presentations resulted in varied 
treatment regimes and differing response patterns. Individual CF patients 
may be infected or colonised with a number of different pathogens, and with 
varying bacterial loads [300], which may lead to different degrees of 
involvement of airways throughout the bronchial tree.  The pathogens may 
also demonstrate different susceptibility to antibiotic treatment, with 
resultant variations in reversibility of lung function impairment [319].  No 
record was kept of the organisms cultured on bronchoalveolar lavage or 
sputum sample in the subjects included in the current study, nor of 
medications administered.  It was felt unlikely that any meaningful analysis 
using these data could have been conducted in a cohort of this size.  
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Heterogeneous changes in pulmonary function measures have previously 
been demonstrated with resolution of acute exacerbations of CF [320], 
suggesting that relationships between unidimensional measures of 
pulmonary function (such as FEV1 and measures of airways resistance) and 
EMGpara, a composite measure of respiratory load-capacity balance, may not 
have been found.  This heterogeneity may also contribute to the wide range 
of changes observed in EMGpara (-54.57 – 29.56%). 
 
The greater number of days on which EMGpara could be measured, as well as 
the younger age in which EMGpara could be obtained in comparison to 
conventional measures of lung function, supports the acceptability of this 
measure under a wider range of circumstances than current standard 
measures.  Some subjects were unable to perform spirometry to a 
technically acceptable standard due to age, comprehension or fatigue.  
Patients’ willingness to perform spirometry and IOS was limited in several 
instances by nausea, a common side effect of many of the frequently-used 
antibiotics in patients with CF [321].  Although IOS is a tidal breathing 
technique and therefore thought to be suitable for children unable to 
perform spirometry [259, 322], four subjects in the current study were 
nonetheless unable to perform this measure to a satisfactory standard.  This 
is in comparison to only two subjects who were unable to perform 
spirometry.  This was due either to unwillingness to breathe through a 
mouthpiece or an inability to adopt a sufficiently stable tidal breathing 
pattern in the presence of the imposed oscillations.  EMGpara clearly offers an 
advantage in this respect due to the completely non-volitional nature of the 
measure.  Although some subjects initially demonstrated an awareness of 
the EMGpara measurement and altered their breathing pattern as a result, the 
provision of DVDs and/or books was sufficient distraction to allow the 
adoption of a stable tidal breathing pattern within only a few minutes. 
 
The significantly greater change observed in EMGpara than FEV1 supports the 
initial hypothesis and suggests that EMGpara may be more sensitive to the 
range of pathophysiological changes that occur during treatment of an acute 
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exacerbation of CF lung disease, though EMGpara may also demonstrate 
greater variability (as suggested by the large range of percentage changes in 
EMGpara from admission to discharge).  The complexity of CF lung disease 
results in heterogeneous changes throughout the lung fields, including 
chronic bacterial infection, airway wall thickening and mucous plugging.  
This subsequently leads to inflammation in both proximal and distal 
airways, which further impairs local host-defence mechanisms and 
facilitates further infection and inflammation.  This ongoing vicious cycle 
leads to bronchiectasis and gas trapping, resulting in impairment of gas 
exchange and ultimately respiratory failure [300].  While FEV1 mainly 
reflects obstruction in the more proximal airways, EMGpara was likely to 
reflect changes occurring throughout the bronchial tree and lung 
parenchyma. 
 
The lack of a relationship between changes in FEV1 and EMGpara may be 
partly a result of the predominance of smaller airways disease and distal gas 
trapping in early CF lung disease.  Impulse oscillometry was used in the 
current study to allow measurement of small airways resistance, though 
statistically significant changes in these measures were not seen.  The 
change in resistance at 5Hz approached significance (p=0.051), although the 
changes in other measures of small airways function (ΔR5-R20, AX, RF) 
were not significant.  No relationships were observed between admission to 
discharge changes in EMGpara and any of the IOS parameters, although in the 
absence of statistically significant changes in these measures, this is perhaps 
unsurprising. 
 
Data obtained from CT scanning provide insight into the nature of the 
changes occurring in CF lung disease.  Peripheral bronchiectasis, air 
trapping, airway wall thickening and mucous plugging can be identified 
using CT in young children, adolescents and adults with both stable CF and 
during acute exacerbations [289, 323-325].  While bronchiectasis, airway 
wall thickening and gas trapping showed little reversibility with clinical 
resolution of an acute exacerbation, mucous plugging improved significantly 
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[324].  FEV1 %predicted and FEF25-75% demonstrated weak or no 
correlations with the changes seen in CT scores [323, 324].  In a longitudinal 
study evaluating changes in CT scores and pulmonary function over several 
years in a cohort of children with CF, de Jong et al [289] demonstrated more 
rapid deterioration in CT scores than in spirometric values.  In their cohort, 
not only was there no agreement between changes in CT score and 
spirometry, but also in over half of subjects discordance in the direction of 
the changes was seen, with FEV1, FVC and FEV1/FVC ratio improving in the 
presence of worsening CT scores in some subjects. 
 
The lack of a relationship between changes in FEV1 and EMGpara may have 
been a result of changes in other aspects of lung function.  Mucous plugging 
can lead to reabsorption atelectasis and reductions in lung compliance 
[149].  The multiple therapies instituted, including intensive airway 
clearance therapy and mucolytic, bronchodilator and antibiotic medications, 
may have resolved mucous plugging present at admission and while the 
studies cited above indicate that this may not result in improvements in 
spirometric parameters, the associated improvements in lung compliance 
may have resulted in a reduction in the respiratory drive.  Few data are 
available regarding the specific effect of resolution of atelectasis on 
oscillometric airways resistance, though one study demonstrated minimal 
change in resistance at 5Hz following alveolar recruitment manoeuvres in a 






The reduction in EMGpara observed in this cohort of children hospitalised for 
acute exacerbations of CF lung disease may be related to changes in a 
variety of physiological parameters, both directly and indirectly related to 
respiratory system mechanics.  The heterogeneity of CF lung disease and 
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associated treatment response may explain the lack of relationship between 
the changes observed.  EMGpara nonetheless demonstrates promise as a 
measure of respiratory load in the paediatric CF population, having 
demonstrated greater applicability than conventional measures of 
pulmonary function. 
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For a technique to be of benefit in assessing disease severity in patient 
populations, normative data from a cohort of healthy individuals must be 
available for comparative purposes.  Previous studies investigating EMGpara 
in adult populations have used small groups of healthy controls to provide 
comparative data. Given the substantial maturational changes that occur in 
the lungs and ribcage throughout childhood and into adolescence, it is not 
known whether the level of NRD in healthy children would be the same as 
that observed in adults.  Studying a large cohort of healthy children reduces 
the potential bias resulting from heterogeneity of growth and development. 
 
To allow comparison between subjects and different testing occasions, the 
raw EMGpara signal can be normalised by expressing it as a percentage of the 
value obtained during a maximal inspiratory effort (EMGpara%max).  Reilly 
et al reported the mean EMGpara%max to be 5.8% in a group of 15 young 
healthy adults [172], while Steier et al showed a similar mean EMGpara%max 
of 4.9% in 12 healthy subjects [197].  Normalising EMGpara to a percentage of 
maximum, however, limits the use of such measures of NRD in young 
children unable to perform maximal inspiratory efforts.  The ability to 
produce maximal volitional efforts is a basic requirement of many existing 
objective measures of pulmonary function and represents the main 
limitation in younger children.  Reilly et al [172] reported a mean (SD) value 
for the raw (non-normalised) EMGpara of 4.8 (2.0)μV.  The low inter-
individual variability in the EMGpara signal may, therefore, render 
normalising EMGpara when comparing between subjects unnecessary.   
 
The aim of this study was, therefore, to investigate the utility of the raw 
EMGpara signal in a large cohort of healthy children and develop a reference 
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range for NRD in healthy children, expressed both as μV and EMGpara%max.  
The study also investigated the effect of growth and maturation on 
respiratory drive.  The repeatability and reproducibility of the EMGpara 
signal were also assessed.  Finally, these data were compared to the EMGpara 






Healthy children were recruited from siblings of children attending for 
clinical pulmonary function testing or participation in clinical research and 
from friends and relatives of research staff and students.  Children were 
eligible for inclusion if no history of current or previous respiratory ill 
health was reported by their parent/guardian.  Any child with a previous 
hospitalisation for a respiratory cause, a diagnosis of any chronic 
respiratory condition, or a history of recurrent GP visits for infant wheeze or 
lower respiratory tract infections, was excluded from participation.  Any 
child in whom cough or coryzal symptoms were noted at the time of study 
was also excluded. 
 
Ethical approval for the study was granted by the King’s College Hospital 
Research Ethics Committee (ref: 09/H0808/100).  Informed, written 
consent was obtained from parents or guardians of all participants. 
 
The children recruited for this study represented a convenience sample; no 




Children attended for testing on one occasion.  Demographic and 
anthropometric data were collected and ten minutes of EMGpara was 
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recorded during resting tidal breathing as previously described (Chapter 
Two).  Briefly, EMGpara was recorded using surface electrodes placed over 
the second intercostal space.  The signal was amplified (gain 1,000), band-
pass filtered between 10 and 2,000Hz, and a 50Hz notch filter and a post-
acquisition 20Hz digital high-pass filter applied.  The signal was converted 
to root-mean-square (RMS) and mean peak RMS EMGpara per breath 
calculated. 
 
The EMGpara value from final minute of the recording was reported as the 
EMGpara for each subject.  The EMGpara from minute three onwards was 
analysed to calculate the inter-minute variability of EMGpara.  In those 
children able to comply with the manoeuvre, inspirations to total lung 
capacity (TLC) were also performed to obtain a measure of maximum 
EMGpara (maxEMGpara), and the resting EMGpara expressed as EMGpara%max. 
 
EMGpara measurement was repeated within the same testing session in ten 
subjects to obtain data regarding measurement repeatability.  In those 
subjects, the electrodes were removed following the first recording and a 
new measurement performed following a break of between ten minutes and 
one hour.  Repeatability data could not be obtained from larger numbers of 
subjects for pragmatic reasons – many subjects attended with at least one 
sibling and parents were often not willing to remain in the laboratory for a 
sufficient time period to allow repeat measurements to be taken.   
 
In order to assess whether any differences in EMGpara between older and 
younger children were due to differences in electrode size relative to the 
size of the muscle, EMGpara was measured in six paediatric and six adult 
subjects using electrodes of two different diameters (diameter of electrode 
active area 9mm and 19mm).  The two sizes of electrode were of identical 
construction and supplied by the same manufacturer (Blue Sensor R, Ambu, 






7.3.1 Statistical analysis 
 
Where the sample size exceeded 30 subjects, data were tested for normality 
using the D’Agostino Pearson omnibus test.  As no data were normally 
distributed, all data were expressed as median (range).  A p value <0.05 was 
taken as statistically significant.  Spearman’s rank correlation was used to 
assess relationships between variables.  Linear regression analysis was 
performed with the Wald-Wolfowitz runs test applied to assess for deviation 
from linearity. 
 
Non-parametric statistical testing was performed on the repeated measures 
due to the small number of subjects.  Agreement between repeated 
measures was assessed using the Spearman’s rank correlation, Bland-
Altman analysis, and the Wilcoxon matched pairs test.  Differences between 




7.4.1 EMGpara in healthy children 
 
Of the 87 children studied, 81 acceptable data sets were obtained.  Six data 
sets were rejected, due to either movement artefact or unstable tidal 
breathing pattern.  Subject demographic and anthropometric characteristics 










Age (years) 9.63 (1.17 – 17.33) 
Height (m) 1.373 (0.800 – 1.846) 
Weight (kg) 32.35 (10.80 – 97.00) 
BMI (kg m-2) 17.0 (13.8 – 35.5) 
BMI-for-age percentile 64.4 (3.5 – 100.0) 
Ethnicity (n (%)) White: 49  (60.5%) 
Black: 22  (27.2%) 
Asian: 4  (4.9%) 
Mixed: 6  (7.4%) 
Table 19 Anthropometric and demographic characteristics of healthy 




Seventeen of the 81 subjects (21.0%) were classified as overweight or 
obese, defined by BMI-for-age >+1SD in children aged 5-19 years, or BMI-
for-age >97th percentile in children aged 0-5 years.  Of these, five were 
classified as obese (BMI-for-age >+2SD).  The median (range) BMI in these 
seventeen children was (24.0 (18.2 – 35.5)kg.m-2), equivalent to a median 















Maximal values of EMGpara were obtained in 54 children.  The resting 
EMGpara, maxEMGpara and EMGpara%max are summarised in Table 20. 
 
Mean peak RMS EMGpara per breath (μV) 
(n=81) 
4.76 
(1.93 – 14.92) 
Maximum EMGpara (μV) 
(n=54) 
58.19 
(22.63 – 253.25) 
EMGpara %max (%) 
(n=54) 
7.04 
(3.46 – 14.43) 
Table 20 Resting and maximal EMGpara values in healthy children.  All data 





The median (range) age of children who could reliably perform the 
maximum EMGpara manoeuvre was significantly higher than those who could 
not (10.26 (2.00 -16.35) vs. 4.47 (1.17 – 17.33) yrs, p=0.007). 
 
Significant negative correlations were found between age (r=-0.644, 
p<0.0001, Figure 35), weight (r=-0.648, p<0.0001, Figure 36), and height 
(r=-0.632, p<0.0001, Figure 37) and EMGpara.  No significant relationships 
were observed between EMGpara%max and age, height or weight (p>0.2).  
MaxEMGpara demonstrated a weak relationship with age (r=-0.358, p=0.008). 
 
If those subjects in whom maxEMGpara was not successfully obtained were 
excluded, the relationships between EMGpara and age, height and weight 
weakened marginally but remained highly significant:  r=-0.587, -0.574 and 
-0.612 respectively (all p<0.0001). 
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EMGpara and maxEMGpara were also related to BMI (r=-0.583 and -0.556 
respectively, both p<0.0001), suggesting attenuation of the signal by adipose 
tissue.  When age-related changes in BMI were accounted for by the use of 
BMI-for-age percentile, the correlations were weaker but remained 
significant (r=-0.242, p=0.029 and r=-0.490, p<0.0001 for EMGpara and 
maxEMGpara respectively). 
 
The relationship between age and respiratory drive, as assessed by 
measurement of P0.1, has been described previously using a power function 
[174].  When assessed for deviation from linearity, the relationships 
between EMGpara and age, height or weight were best fit using linear 














Figure 37 Correlation of EMGpara and height. 
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7.4.2 Variability of EMGpara  
 
The inter-subject coefficient of variation for the raw EMGpara signal was 
45.1%.  Due to the influence of age on the EMGpara signal, subjects were 
divided into two-year age subgroups and inter-subject coefficient of 
variation calculated (Table 21). 
 
Age (years) 


















































(1.93 – 14.92) 
45.1 
Table 21 Raw EMGpara values and inter-subject coefficient of variation of 
resting signal according to subject age.  EMGpara data are expressed as 




The inter-subject variability in EMGpara%max was also assessed and 
compared to that for the raw EMGpara signal, excluding subjects in whom 
maxEMGpara was not recorded successfully.  Despite a trend towards a lower 
inter-subject coefficient of variation for the raw EMGpara signal, there was no 
statistically significant difference in the median (range) inter-subject 
coefficient of variation for EMGpara (28.07 (7.09 – 51.91)%) and 
EMGpara%max (36.40 (30.69 – 86.72)%, p=0.25) when assessed in two-year 
age subgroups.  When taking the 54 subjects as a single group, the values for 
inter-subject coefficient of variation for EMGpara and EMGpara%max were 





















































Table 22 Inter-subject coefficient of variation for raw EMGpara and 




Stable recordings of a sufficient duration to calculate within-subject inter-
minute coefficient of variation were obtained in 55 children.  Inter-minute 
coefficient of variation was examined in the entire cohort and in two-year 
age subgroups (Table 23).  When assessed using correlation analysis, the 














































Table 23 Within-individual, inter-minute coefficient of variation of the raw 











7.4.3 Repeatability of EMGpara 
 
The characteristics of the ten subjects in whom repeat measurements of 




(3.97 – 13.10) 
Height (m) 
1.314 
(1.050 – 1.619) 
Weight (kg) 
27.65 
(16.00 – 63.00) 
BMI (kg.m-2) 
15.6 
(14.0 – 24.0) 
BMI-for-age percentile 
37.6 
(15.7 – 99.8) 
Table 24 Demographic and anthropometric characteristics of ten subjects 
undergoing repeat measurements of EMGpara. 
 
 
There was no significant difference between the values for EMGpara obtained 
from the two measurements (4.58 (2.91 – 8.48)µV versus 5.11 (2.88 – 
7.82)µV, p=0.32).  Bland-Altman analysis showed a small bias of -0.37μV 
(towards a higher second measurement), with 95% limits of agreement of -
2.11 – 1.38μV (Figure 38).  The two measurements were significantly 








Figure 38 Bland-Altman plot of repeat measures of EMGpara in ten children. 
Dashed line shows bias (-0.37μV); dotted lines 95% limits of agreement (-
2.11 – 1.38μV). 
 
 
Six of the subjects who underwent repeat measurements were able to 
successfully perform maximal inspiratory efforts.  The median (range) 
EMGpara%max from the first and second measurements was 8.85 (5.17 – 
13.08)% and 9.59 (4.77 – 12.78)% respectively (p=0.438).  The median 
(range) raw EMGpara in these six subjects was 4.65 (3.65 – 8.48)µV and 5.51 
(2.88 – 7.82)µV from the first and second measurements (p=0.688).  There 
was a strong significant correlation between the EMGpara%max (r= 0.886, 
p=0.033) obtained from the two measurements in these six subjects, 
although the relationship between the two raw EMGpara measurements in 
these six individuals did not reach significance (r=0.771, p=0.103).  The 
Bland-Altman analysis indicated a bias of -0.63%max for EMGpara%max and 
-0.25µV for EMGpara between measurements (Figure 39 and Figure 40), 




Figure 39 Bland-Altman plot of repeat measures of EMGpara%max in six 
children.  Dashed line shows bias (-0.63%max) and dotted lines 95% limits 






Figure 40 Bland-Altman plot of repeat measures of EMGpara in six children 
in whom maxEMGpara values could be obtained.  Dashed line shows bias (-
0.25µV) and dotted lines 95% limits of agreement (-2.31 – 1.81µV). 
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7.4.4 Effect of electrode size 
 
The demographic and anthropometric characteristics of the six children and 
six older children and adults in whom EMGpara was measured on a single 
occasion with two different sized electrodes are shown in Table 25. 
 
 Young children (n=6) 




(3.20 – 8.07) 
21.34 
(16.53 – 31.24) 
Height (m) 
1.107 
(0.931 – 1.261) 
1.65 
(1.58 – 1.72) 
Weight (kg) 
18.65 
(12.90 – 24.50) 
54.00 
(48.00 – 62.00) 
BMI (kg.m-2) 
15.6 
(14.6 – 17.1) 
20.2 
(17.9 – 21.6) 
Table 25 Demographic and anthropometric characteristics of subjects in 
whom EMGpara was measured with electrodes of different sizes.  Data are 
expressed as median (range). 
 
 
No significant difference was found in resting peak RMS EMGpara per breath 
when electrodes of two different sizes were used (p=0.38) (Table 26).  The 
median (range) EMGpara value was not significantly different between the 
19mm and 9mm electrodes in either the young (7.24 (3.10 – 8.62)µV vs. 5.74 
(2.95 – 9.35)µV, p=0.313) or older (5.13 (3.43 – 8.80) vs. 5.23 (3.21 – 




 Mean peak RMS EMGpara per breath (μV) 
 19mm electrode 9mm electrode 
Subject 1 8.62 6.30 
Subject 2 8.46 7.48 
Subject 3 6.33 5.18 
Subject 4 8.14 9.35 
Subject 5 3.10 2.95 
Subject 6 5.48 4.22 
Subject 7 5.27 5.52 
Subject 8 3.43 3.21 
Subject 9 4.87 4.70 
Subject 10 5.00 4.93 
Subject 11 6.39 6.35 
Subject 12 8.80 10.31 
 
All subjects (median) 5.91 5.35 
Table 26 Values of EMGpara recorded using electrodes of two different sizes 






There was a strong correlation between the values of EMGpara measured 
with the two electrode sizes in the twelve subjects (r=0.895, p=0.0002, 
Figure 41).  In the younger children alone, the correlation did not reach 
significance (r=0.771, p=0.103).  In the six older children and adults, the 









Bland-Altman analysis was performed to assess the agreement between the 
measures of EMGpara from each electrode size (Figure 42).  A bias of 0.26μV 
was found towards a higher value from the larger, 19mm electrode, though 
the 95% limits of agreement were relatively wide and did include zero (-
1.77 – 2.30μV). 
 
Bland-Altman analyses of the younger children indicated a bias of 0.74µV 
with 95% limits of agreement of -1.58 – 3.06µV.  In the older children and 
adults, the bias was -0.21µV with 95% limits of agreement -1.50 – 1.08µV. 
 
MaxEMGpara was recorded in the six older subjects.  Median (range) 
maxEMGpara was not significantly different when measured with 19mm vs. 
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9mm electrodes (123.6 (59.7 – 146.4)µV vs. 114.9 (52.7 – 150.6)µV, 
p=0.125). 
 
Correlation analysis indicated an inverse relationship between age and the 
difference between the EMGpara measured with the two electrode sizes in 
twelve subjects (r=-0.643, p=0.028), indicating closer agreement between 





Figure 42 Bland-Altman plot of EMGpara recorded with 19mm and 9mm 
electrodes in twelve subjects. 
Dashed line shows bias (0.26μV); dotted lines 95% limits of agreement (-





7.4.5 Comparison to data from patient populations 
 
The data from the control subjects was compared to those obtained from the 
children with asthma and CF in Chapters Three and Six respectively.  As the 
control subjects were not recruited to provide a cohort matched to the 
patients, average values were taken of all control subjects with ages within ± 
six months of each patient.  The mean age and EMGpara value was calculated 
and then compared to the value obtained for each patient.  Comparisons 
were made for both the pre- and post-bronchodilator values (for the 
paediatric asthma study) and admission and discharge values (in the CF 
study) against the control value. 
 
In the 53 children with asthma, median (range) EMGpara pre-bronchodilator 
was significantly greater (8.36 (1.37 – 20.11)µV) than in controls (5.48 (2.83 
– 8.35)µV, p<0.0001).  Despite significant reductions, the post-
bronchodilator median (range) EMGpara remained significantly higher than 
in controls (6.30 (1.42 – 20.57)µV, p=0.037, Figure 43). 
 
The median (range) percentage difference between EMGpara in children with 
asthma and healthy subjects was 67.47 (-82.83 – 573.30)% pre-






Figure 43 Difference between EMGpara in healthy subjects and children with 
asthma pre- and post-bronchodilator (BD).  Lines denote median and inter-




Median (range) EMGpara was higher in patients with CF at hospital admission 
(7.13 (3.19 – 13.18)µV) compared to healthy controls (4.40 (3.65 – 8.19)µV, 
p=0.018), but was not significantly different to controls at discharge (5.60 
(2.62 – 13.45)µV, p=0.433, Figure 44).  A retrospective power calculation 
showed that the data from the 20 children with CF and matched control 
sample were significantly underpowered to detect such a difference, 
achieving only 24% power at the 5% level, though 81% power was achieved 




The median (range) percentage difference between EMGpara in children with 
CF and healthy subjects was 25.97 (-23.59 – 215.70)% at hospital admission 
and 15.28 (-37.25 – 89.94)% on discharge. 
 
 
Figure 44 Difference between EMGpara in healthy subjects and children with 




Correlation analysis indicated that, at hospital admission, the difference in 
EMGpara between the controls and patients was related to the degree of lung 
function impairment, as quantified by FEV1 %predicted: r=-0.678, p=0.002.  
Such relationships were not observed at hospital discharge (r=0.086, 
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p=0.735) or in the children with asthma, either pre-bronchodilator (r=-




This study demonstrates the feasibility of obtaining EMGpara in healthy 
children and provides normative data for comparative purposes.  Significant 
relationships between EMGpara and age, height and weight were observed, 
highlighting that a single reference value for EMGpara cannot be applied to 
children of all ages.  The EMGpara values in healthy children were 
significantly lower than those in children with asthma pre- and post-
bronchodilator, and lower than those in children with CF at hospital 
admission. 
 
Although children of a range of ages were studied and despite the 
requirement to remain still during the recording of EMGpara, only six of 87 
(6.9%) datasets were rejected due to movement artefact.  Maximal EMGpara, 
however, was obtained in only 54 of the 81 successful recordings (66.7%) 
emphasising the difficulty of obtaining the maximal manoeuvres required to 
normalise EMGpara.  Obtaining a maximal volitional manoeuvre when testing 
skeletal muscle strength in children is difficult [327].  The children who 
were unable to reliably perform a maximal inspiratory effort were 
significantly younger than those in whom maxEMGpara was successfully 
obtained, although it should be noted that the upper age in both groups was 
similar (17.33 vs. 16.35 years).  Although these older children were able to 
perform the manoeuvres required, the maximal EMGpara values were felt to 
have been contaminated by activity of other adjacent muscles and were 
consequently rejected.  This was particularly notable in children with more 
developed chest wall musculature.  It is not possible to confidently eliminate 
the possibility of EMGpara signal contamination during maximal inspiratory 
efforts from any of the subjects through the use of surface EMG 
measurements alone; this would necessitate comparison of signals obtained 
simultaneously from needle and surface electrodes.  Future studies could 
examine the magnitude of EMGpara responses obtained during maximal and 
graded submaximal inspiratory efforts. 
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The values for raw EMGpara activity reported from this cohort of children are 
broadly in agreement with adult data, although demonstrate a much larger 
degree of variability.  EMGpara%max values, however, were somewhat higher 
(7.04 (3.46 – 14.43)%) than those reported in healthy adult subjects.  Reilly 
et al [172] reported a mean (SD) raw value of EMGpara of 4.8 (2.0)μV in 
healthy adults during resting breathing, equivalent to 5.8 (3.0)% of 
maximum.  Similarly, Steier et al [197] described mean (SD) EMGpara%max 
values of 4.9 (3.2)%, although raw values of EMGpara were not reported.  The 
higher overall EMGpara%max values observed in the current study are 
consistent with previous data showing increased respiratory drive as 
measured using P0.1 as age decreases [174]. 
 
Although the standard deviations of the EMGpara%max values given by Reilly 
et al and Steier et al were not wide in numerical terms, the data from these 
two studies give coefficients of variation (CV) of 51.7 and 65.3% 
respectively.  The lower inter-subject CV for EMGpara%max (37.8%) in the 
current study may partly be a reflection of the larger sample size (n=54), 
compared to those in the studies by Reilly et al (n=15) [172] and Steier et al 
(n=12) [197].   
 
The ability of adult subjects to perform reliable repeatable maximal 
manoeuvres allows the EMGpara signal to be normalised to maxEMGpara.  
Normalisation provides a means to control for variation in electrode 
placement within a subject on different measurement occasions as well as to 
allow comparison between individuals.  Such manoeuvres cannot, however, 
be obtained in all children.  In the current study the between-subject CV for 
the raw EMGpara signal across the whole group was 45.1%, indicating that 
this measure was not substantially more variable between subjects than 
EMGpara%max (37.8%).  The between subject CV of the raw EMGpara signal in 
the 54 subjects in whom EMGpara%max could be measured was 41.1%, 
suggesting that subject groups unable to perform maximal manoeuvres do 
not demonstrate substantially higher variability in their EMGpara signal, 
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supporting the use of the raw EMGpara signal in subject groups unable to 
perform maximal manoeuvres.  Slightly lower inter-subject variability is 
reported in paediatric populations for other measures of pulmonary 
function, such as Rint (27%) [328], impulse oscillometry (33-38%) and 
spirometry (32-35%) [322], though this may be a reflection of larger sample 
sizes and narrower age ranges in these other studies. 
 
To evaluate the inter-subject variability of the raw EMGpara signal free of the 
confounding influence of the relationships observed between EMGpara and 
age/height/weight, subjects were divided into two-year subgroups and the 
between-subject CV for EMGpara within each subgroup calculated.  No 
significant difference was found in the between-subject coefficient of 
variation for the raw EMGpara and EMGpara%max signals, indicating that the 
raw EMGpara signal may demonstrate acceptable variability to merit its 
consideration as a method for quantifying NRD without the need to 
normalise the signal. 
 
The data regarding signal variability from both raw EMGpara and 
EMGpara%max from the current study and previous work, as indicated 
above, suggest that EMGpara%max may not confer additional advantages 
when compared to the raw signal alone in reducing inter-individual 
variability.  The within-occasion repeatability measures of EMGpara and 
EMGpara%max allow the influence of small differences in electrode position 
on the EMGpara signal within individuals to be assessed.  The bias of -0.37µV 
obtained from the ten subjects who underwent repeat measurements was 
felt to be acceptable.  The 95% limits of agreement are, however, relatively 
wide when considered in the context of the magnitude of the values 
obtained for raw EMGpara.  If repeated measurements are to be taken from 
the same subject on different occasions, as in Chapter Six, then the 
repeatability of the measurement must be considered.  The bias and 95% 
limits of agreement were, however, greater for EMGpara%max in the six 
subjects in whom repeated measures were performed, suggesting that raw 
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EMGpara may represent a more reproducible measure than EMGpara%max in 
a paediatric cohort. 
 
The current data indicated an inverse relationship between age, height or 
weight and EMGpara but not EMGpara%max.  The inverse relationship 
observed between maxEMGpara and age was, however, weaker than that 
between resting EMGpara and age, which may have been the result of greater 
variability in the maximal manoeuvre and hence the maxEMGpara signal.  
 
Interference from adjacent muscles can pose a significant problem in the 
measurement and interpretation of surface EMG.  Cross-talk from other 
muscles was unlikely to be a problem when recording the EMG from the 
parasternal intercostal muscles during resting tidal breathing in a healthy 
subject, due to the absence of active overlying musculature.  During maximal 
efforts, however, the accessory muscles of respiration located in close 
proximity to the parasternal intercostal muscles such as the pectoralis 
major muscle may have been recruited, and contaminated the EMGpara 
signal.  In an attempt to eliminate accessory muscle use subjects were 
instructed to perform maximal inspiratory efforts without moving or 
bracing the upper limbs.  Such manoeuvres are, however, difficult for a child 
to perform without the actions that would normally facilitate a maximal 
effort.  A number of maximal efforts were rejected from signal analysis 
based on the appearance of the EMG signal that suggested the EMG activity 
was not purely from the parasternal intercostal muscles.  As stated above, 
the variability of the maxEMGpara signal was greater than that in the resting 
EMGpara signal, despite efforts to exclude contaminated signals, suggesting 
potentially greater signal contamination from cross-talk during forced 
inspiratory efforts. 
 
A standard 19mm diameter electrode was used to record EMGpara in all 
children regardless of age.  In younger subjects, thoracic size and hence 
parasternal intercostal muscle size will be smaller in relation to the size of 
the electrode.  It could be postulated that the magnitude of the EMG signal 
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would have been directly proportional to electrode size, as in younger 
children the active area will cover a greater proportion of the muscle and 
hence sample from a larger number of motor units.   
 
A surface electrode can be viewed as an arrangement of point electrodes 
and its net potential is equivalent to the mean rather than the sum of the 
potentials produced by each single electrode [329].  Electrode size in theory, 
therefore, has little or no influence on the amplitude of the EMG signal [329, 
330].  This assumption, however, is based on mathematical modelling and 
has not previously been confirmed in vivo.  It is possible that, while the 
electrode size does not directly influence signal amplitude from the 
parasternal muscles, the physically smaller thoracic size in young children 
would place the electrodes in closer proximity to the accessory respiratory 
muscles, potentially resulting in greater signal contamination when 
compared to adults.  This was tested by obtaining measurements of EMGpara 
in twelve healthy individuals (six young children, three older children and 
three adults) using electrodes of two different diameters.   
 
Measuring EMGpara with electrodes of two sizes showed a bias toward a 
slightly higher value for EMGpara measured using a larger electrode.  There 
was, however, no significant difference between the values obtained with 
the two electrode sizes and the 95% limits of agreement obtained from 
Bland-Altman analysis were relatively wide.  There was closer agreement 
between the measurements of EMGpara from the two sizes of electrode in the 
older than in the younger subjects.  The bias in the older subjects in fact 
demonstrated a tendency towards higher values from the smaller electrode.  
The bias and 95% limits of agreement were similar to those shown in the 
ten subjects who underwent repeat measurements, suggesting that the 
difference in EMGpara values when measured with the two electrode sizes 
may represent simply the variability of the measure.  Bland-Altman analysis 
also showed a tendency towards poorer agreement between values at 
higher levels of EMGpara activity.  Correlation analysis showed an inverse 
relationship between age and the difference in the measurements from the 
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two electrode sizes, indicating greater differences in younger children.  A 
similar rather than a weaker relationship between maxEMGpara and age (or 
height/weight) than between resting EMGpara and age might have been 
expected if the change in NRD with age or growth was due to relative 
electrode-to-muscle size.  Under circumstances of maximal muscle 
activation, it would be expected that any influence of electrode size on signal 
amplitude would be accentuated.  In addition, maxEMGpara was also not 
significantly different when measured with two electrode sizes. 
 
Gaultier et al [174] demonstrated an inverse relationship between age and 
respiratory drive, measured as P0.1.  The reduction in NRD that occurs with 
increasing age could be due to maturational changes in the respiratory 
system, including ribcage ossification [48, 49], increases in length of the 
abdominal hydrostatic column [48], and lung growth and maturation [37-
40, 42-47].  It is likely that the substantial increases in airway diameter, and 
concomitant reductions in airways resistance, occurring with growth has 
the greatest influence on the changes observed in EMGpara with increasing 
age. 
 
When considering whether the raw EMGpara signal or EMGpara%max should 
be used in future studies, it should be noted that reliance on a normalised 
signal requires the subject to be able to reliably perform a maximal 
inspiratory effort, thus limiting the applicability of the measure.  The upper 
limit of the range of EMGpara%max values obtained in the current study 
(14.43%max) is markedly greater than those reported in adult subjects 
[172, 197], suggesting that true maxEMGpara may not have been attained in 
all subjects in the current study during inspiratory efforts.  All recordings of 
maxEMGpara manoeuvres were assessed for consistency, with the 
manoeuvre repeated at least three times, and subjects were given both a 
practical demonstration and verbal encouragement to promote 
performance of the optimal technique.  Nonetheless, true maxima can be 
difficult to obtain in many populations, not least children [327, 331], and 
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reproducibility may not be an indication of maximality when performing 
maximal respiratory efforts [332]. 
 
The effect of differences in BMI is important when considering the use of 
surface EMGpara.  Subcutaneous adipose tissue acts as a low-pass filter and 
decreases the amplitude of the resultant EMG signal [333].  The results from 
the current study indicated relationships between both EMGpara and 
maxEMGpara and BMI.  As the change in BMI during childhood is non linear 
[334], BMI-for-age percentile was calculated for all children to eliminate the 
effect of age.  The strength of the relationships between EMGpara and BMI-
for-age was weaker but remained significant, with the EMG signal amplitude 
decreasing with increasing adiposity.  Neural respiratory drive, measured 
using EMG of the diaphragm (EMGdi), has previously been shown to be 
increased in obesity [311].  The use of oesophageal EMGdi eliminates the 
filtering effects of adipose tissue and thus represents a more accurate 
representation of the effect of increased BMI on NRD.  The increases in 
respiratory load, and hence respiratory drive and respiratory muscle EMG, 
will be attenuated when using surface EMG techniques due to the filtering 
effect of the subcutaneous fat.  In the current study, 17 of the 81 subjects 
(21.0%) were classified as overweight, with five of these classified as obese.  
Steier et al [311] examined the influence of obesity on EMGdi in a cohort of 
adult patients with a mean (SD) BMI of 42.8 (8.6)kg.m-2; in contrast, the 
maximum BMI in the current study was 35.5kg.m-2.  The median (range) 
BMI (24.0 (18.2 – 35.5)kg.m-2) in the 17 overweight subjects in the current 
study may not have been sufficient to cause a substantial increase in 
respiratory load and hence NRD.  The relationship between EMGpara and BMI 
in the current study may be, therefore, a result of signal filtering rather than 
physiological alterations, though this remains an important consideration 





7.5.1 Difference between healthy subjects and patients 
 
EMGpara values in the patient groups studied in Chapters Three and Five are 
significantly higher than those obtained from healthy controls in the current 
study.  EMGpara remained higher in children with asthma than in healthy 
subjects even following bronchodilator administration.  Although no 
difference was seen in EMGpara in children with CF at hospital discharge 
when compared to healthy controls, the sample size was too small to 
achieve sufficient statistical power.  The relationship observed between the 
severity of airways obstruction (as quantified by FEV1) and the difference 
between EMGpara in healthy children and patients with CF on admission 
further supports the utility of EMGpara as a measure of disease severity. 
 
The use of a large cohort of healthy subjects allowed values from individual 
patients to be compared to average values calculated from a number of 
healthy subjects aged within six months of that of the patient.  Six months 
was chosen as a timeframe during which major maturational differences 
were unlikely to be present.  Despite the statistically significant difference 
between the groups, an overlap is noted, with some patients demonstrating 
lower EMGpara activity than the comparative healthy values; the greatest 
difference was EMGpara activity 82.83% lower in a patient with asthma than 
in the matched healthy data.  Determining the ability of EMGpara to 
discriminate between healthy children and patients with respiratory disease 
is also confounded by the fact that patients with very mild disease were 
included in both Chapter Three and Chapter Six.  The overlap between 
groups may reflect an inability of EMGpara to detect the small increases in 
respiratory load associated with mild disease.  It would also be preferable to 
obtain normative data from a larger cohort such that age-specific reference 
ranges could be developed and EMGpara expressed as a percentage of 
predicted values or z-scores.  It is recommended that reference data sets 
comprise a minimum of 300 subjects in order to avoid significant effects of 





7.6 Conclusions  
 
The aims of the study were to produce normative data for EMGpara for 
comparative purposes, and to investigate the utility of the raw EMGpara 
signal.  It is clear that use of the raw signal allows the technique to be 
applied to a wider range of subjects than relying on a value of EMGpara%max.  
The inter- and intra-individual variability of the EMGpara signal also appears 
to be less than that for EMGpara%max.  Significant relationships between age, 
height and weight and raw EMGpara values indicate that a single reference 
value for EMGpara cannot be applied to all age groups.  While the lack of a 
significant bias between measures of EMGpara obtained using different 
electrode sizes suggests that the relationships are physiological, rather than 
technical, the small sample size from which to draw conclusions means that 
this remains to be fully clarified.  EMGpara is significantly higher in children 
with asthma and CF than in healthy children, lending further support to the 
use of this measure to assess respiratory disease in children. 
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8. Chapter Eight: Discussion 
The importance of accurate measurement of pulmonary function in 
quantifying respiratory disease severity, progression and response to 
treatment is well documented [11, 303].  Spirometry is currently the 
technique used most commonly in assessing lung disease, though the 
requirement for the subject to perform complex, maximal, volitional 
respiratory efforts limits the applicability of this technique in a range of 
patient populations, including younger children and those patients with 
more severe disease [14, 31, 113].  Alteration of the respiratory load-
capacity balance that occurs in lung disease and the resultant increase in the 
neural output from brainstem respiratory centres can be quantified via the 
electromyogram of selected inspiratory muscles.  The parasternal 
intercostal muscles, as obligate muscles of inspiration, easily accessed with 
surface EMG techniques, represent a clear choice for assessment of neural 
respiratory drive. 
 
The data within this thesis have demonstrated EMGpara to be a feasible 
technique in the paediatric setting, in a range of ages and clinical conditions.  
EMGpara changes in response to a variety of interventions that alter the load-
capacity balance of the respiratory system.  Exploration of the relationship 
between EMGpara and existing measures of pulmonary function has indicated 
that such relationships are likely to be complex.  While previous work has 
compared measures of neural respiratory drive to spirometry on a single 
occasion as a marker of disease severity [172, 196, 197, 214], the work 
contained within this thesis has expanded the understanding of the 
relationship between dynamic changes in EMGpara and conventional 
measures of pulmonary function. 
 
Previous data examining the use of EMGpara have expressed it relative to 
either a baseline measurement obtained from the same patient (the 
logarithm of the EMG activity ratio (logEMGAR)) [185-187, 194, 195, 336], 
or to the signal obtained during a maximal volitional effort (EMGpara%max) 
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[172, 192, 198, 199].  The former method limits the application to 
assessment of within-subject change, while the latter cannot be used in 
subjects unable to comply with maximal inspiratory efforts.  The studies 
within this thesis have utilised the raw EMGpara signal, expressed in 
microvolts (µV), in healthy children and in a range of presentations of 
obstructive lung disease, and the data suggest this to be an acceptable 
method of expressing the EMGpara signal, therefore allowing EMGpara to be 
applied to a wider range of subjects and scenarios than would be possible 
with the previous methods (logEMGAR or EMGpara%max). 
 
 
8.1 Response to change 
 
Chapter Three demonstrated the ability of EMGpara to detect change in 
respiratory load in asthmatic children following a relatively simple 
intervention, administration of a β2 agonist to reverse bronchoconstriction.  
This was demonstrated both in children over the age of five, who were able 
to complete spirometry, and in children of pre-school age.  Similarly, 
significant change in EMGpara was demonstrated in children with cystic 
fibrosis undergoing inpatient treatment for an exacerbation of CF lung 
disease.  In both of these studies, the EMGpara technique was shown to be 
feasible in children unable to complete existing standard measures of lung 
function, including those as young as eight months of age.  Although other 
measures of pulmonary function are available for use in very young children 
and infants [236], the techniques may require adaptation, making 
longitudinal interpretation of the results challenging.  For example, while 
infant lung function testing (including the rapid thoraco-abdominal 
compression technique and infant plethysmography) is comparable to 
spirometry, the child must be sedated during the procedure [236].  
Similarly, while spirometry in children between the ages of three and five 
years of age may be feasible in greater than 50% of subjects [111], the small 
lung volumes and large airway size relative to lung volume results in 
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expiratory times less than one second.  In younger children, FEV0.5 and 
FEV0.75 are therefore used [119], making longitudinal interpretation of 
spirometry values more complex when transitioning to the use of FEV1.  In 
contrast, the EMGpara technique is consistent regardless of age, disease 
severity or cognitive ability, meaning results can be continuously 
interpreted throughout life. 
 
Inter-minute variability of the EMGpara signal was also evaluated in a subset 
of children with asthma, allowing the development of a threshold for 
statistically significant change in EMGpara to be determined.  This 
methodology was based on previous work using the within-subject 
variability to develop a threshold for significant bronchodilator reversibility 
based on FEV1 [217].  Applying the method used to determine a threshold 
for significant change in FEV1, where each measurement is a discrete value 
obtained from the best of three maximal expiratory efforts, to EMGpara, 
which may be a continuous recording of any duration, may be somewhat 
problematic.  It may be of benefit to examine in future studies the 
relationship between inter-minute variability and other aspects of signal 
variability.  Future studies may also need to expand on this to develop a 
minimal clinically important difference in EMGpara by anchoring against 
other outcome measures [337].  Nevertheless, knowledge of the variability 
of the measure represents an important early step in potentially moving this 
technique towards clinical use.  Inter-minute variability of the EMGpara signal 
was also assessed in the large cohort of healthy children included in Chapter 
Seven, and was shown to be similar to that observed in the children with 
asthma (8.95% compared to 9.24%), suggesting little difference in within-





8.2 Relationship with conventional measures of pulmonary 
function 
 
While previous studies have shown clear relationships between measures of 
NRD (both EMGdi and EMGpara) and conventional measures of pulmonary 
function [172, 189, 194], the studies contained within this thesis did not 
observe consistent relationships between changes in spirometry, 
oscillometry or end expiratory lung volume and those in EMGpara.  In Chapter 
Three, no relationship was observed between changes in FEV1 and EMGpara 
in 33 children over the age of five years undergoing bronchodilator 
reversibility testing.  EMGpara was also shown to be poorly predictive of a 
significant (≥12%) increase in FEV1 following β2 agonist administration.  
Similarly, in the subset of twelve subjects in whom impulse oscillometry was 
measured, no relationship was observed between changes in IOS 
parameters and changes in EMGpara.  These results were reflected in those 
from Chapter Six, with no relationship between the admission to discharge 
changes in EMGpara and spirometric or oscillometric parameters.  There was 
a relationship observed, however, between the change in EMGpara and the 
FEV1 on admission, indicating that those children with the greatest lung 
function impairment experienced the greatest reduction in respiratory load.  
There was also a trend observed towards a relationship between EMGpara 
and FEV1 on admission, though this did not reach significance. 
 
To investigate further the relationship between conventional measures of 
pulmonary function and EMGpara in an asthmatic phenotype, incremental 
changes in spirometry and EMGpara were induced using methacholine 
challenge testing. Chemically induced bronchoconstriction may differ 
somewhat from the spontaneous airways obstruction occurring in asthma.  
Pragmatic reasons also necessitated the use of adult subjects in this study, 
thus caution must be exercised in using the results to inform and explain 
those obtained in asthmatic children with spontaneous bronchoconstriction.  
 
A moderate correlation was observed between incremental changes in FEV1 
and those in EMGpara from the first methacholine dose to end of test, as 
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assessed by area under the curve analysis.  The magnitude of the change in 
EMGpara was significantly greater than that in FEV1, when examined from 
first methacholine dose to end of test both using overall percentage change 
and area under the curve analysis.  The percentage change in EMGpara was 
also greater than that in FEV1 in both children with cystic fibrosis and those 
with asthma, though the difference did not reach significance in the 
asthmatic group.  These data indicated that factors additional to the larger 
airways obstruction measured by FEV1 may be responsible for the changes 
in EMGpara observed in airways obstruction.   
 
Hyperinflation is known to be present in a range of obstructive lung diseases 
and may occur in the absence of overt airways obstruction as quantified by 
FEV1 [288].  Hyperinflation has previously been shown to relate to increases 
in NRD [172, 189], though the relationship between dynamic changes in end 
expiratory lung volumes and EMGpara has not previously been reported.  
Significant small airways obstruction has also been demonstrated in, among 
other diseases, asthma [30] and cystic fibrosis [31, 338], and may contribute 
to respiratory load and hence EMGpara.  Chapter Five was therefore designed 
to investigate in depth the pathophysiological changes occurring during 
induced bronchoconstriction, and to relate these to the changes in EMGpara. 
 
The results of Chapter Five indicated, however, that evaluating the relative 
influences of small and large airways obstruction and end expiratory lung 
volume on EMGpara is made difficult by the simultaneous and heterogeneous 
nature of these changes.  Subjects demonstrated differing degrees of change 
in each parameter; isolating the effect of changes in each parameter was 
therefore not possible with the sample size used.  The study was able to 
demonstrate clear changes occurring in small airways resistance and end 
expiratory lung volume, in addition to the changes previously observed in 
FEV1 in Chapter Four.  Although clear relationships have not been 
demonstrated between these measures and EMGpara, the presence of such 
changes nonetheless suggests that these may well be factors in determining 
the magnitude of changes in EMGpara.  Formulating a study design that 
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allows the influence of such measures to be evaluated in isolation is likely to 
be difficult; larger studies that allow multiple regression analysis to be 
undertaken are likely to represent the best method, although the current 
reliance on manual analysis of the EMGpara data makes such studies 
formidable. 
 
The lack of strong and/or consistent relationships between EMGpara and 
conventional measures of pulmonary function in the studies included within 
this thesis must also be considered in the context of the populations studied, 
most of which had markedly less pulmonary function impairment compared 
to previous studies.  Reilly et al [172] included patients with CF with a mean 
(SD) FEV1 of 53.5 (24) %predicted.  Similarly, Jolley et al [189] showed 
relationships between EMGdi and FEV1, inspiratory capacity and vital 
capacity in 30 subjects with COPD with a mean (SD) FEV1 of 34.8 (13.9) 
%predicted.  Jolley et al also described the relationship between EMGdi and 
FEV1, IC or VC to be curvilinear.  It may be that the majority of the subjects 
included in this thesis, due to their milder disease, are situated on the flatter 
portion of the FEV1-EMG curve. 
 
The most likely factor underlying the lack of relationship between 
conventional pulmonary function measures and EMGpara, however, is the 
consideration that such measures are unidimensional, assessing only a 
single aspect of respiratory physiology.  EMGpara can be considered likely to 
provide a composite measure of the overall load-capacity balance of the 
respiratory system, thus reflecting in a single measure all of the 
pathophysiological changes in obstructive lung disease.  FEV1 is a measure 
of obstruction in predominantly proximal airways, and is therefore 
relatively insensitive to the substantial airflow limitation in smaller, more 
distal airways, such as occurs in asthma [30] and early CF lung disease [31].  
Changes in small airways function have been demonstrated in the studies 
contained within this thesis, in addition to significant changes in FEV1 and, 
in Chapter Five, end expiratory lung volume.  These changes may occur to 
differing extents within individual subjects, resulting in a lack of direct 
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relationships between individual measures and EMGpara.  The 
multidimensional nature of EMGpara, however, represents the major 
advantage of this measure over existing techniques, and the lack of 
relationship between the different variables should not, perhaps, be viewed 
as a major weakness of the EMGpara technique. 
The studies within Chapters Four and Five, in which an expected fall in 
EMGpara was observed between the saline and first methacholine inhalations 
in adults undergoing bronchial challenge testing, indicate another potential 
weakness of the EMGpara technique.  Although EMGpara appears to have clear 
potential as a marker of respiratory load, it is strictly a measure of 
respiratory muscle activity and can therefore be influenced by higher 
centres as well as by the metabolic drive to breathe.  We hypothesised that 
anxiety may have been the reason for the fall in EMGpara observed between 
the saline and first methacholine step in Chapters Four and Five and this is 
an important consideration for future studies.  Subjects should be given 
sufficient time to acclimatise to the environment and familiarise themselves 
with the equipment before data acquisition begins, and may benefit from 
distraction, as was provided for the paediatric subjects.  Simultaneous 
measurements of end tidal CO2 may assist in screening for the presence of 
hyperventilation, though the behaviour of EMGpara during hypocapnic 
ventilation has not been investigated to date. 
 
 
8.3 Technical and methodological considerations 
 
Chapter Seven provided normative data regarding levels of EMGpara activity 
in children over a range of ages.  While the cohort is insufficient in size to 
develop true reference values, it nonetheless represents a much larger 
cohort of healthy subjects than have been measured previously [172, 192, 
197, 198].  This large data set has provided insight into the changes in 
EMGpara that occur with growth and development, emphasising that a single 
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reference value cannot be applied to all children.  The reduction in EMGpara 
activity with increasing age is likely to be multifactorial, related to changes 
in chest wall configuration, muscle development and maturation of lung 
tissue and vasculature [41-43, 48, 55], and mirrors the reduction in 
respiratory drive as quantified using P0.1 shown in previous work [174].  A 
small sub-study was performed to evaluate whether the differences in 
EMGpara signal magnitude may have been due to the relative muscle to 
electrode size; the results of this small laboratory study provide in vivo 
support for previous modelling data suggesting that electrode size does not 
affect signal magnitude [329]. 
 
The data from Chapter Seven also indicate that the raw EMGpara signal 
demonstrates acceptable reproducibility when compared to EMGpara%max. 
Although in the healthy subjects, the difference in inter-subject variability of 
the raw EMGpara and EMGpara%max signals did not reach statistical 
significance, the data in Chapter Six showed significantly greater variability 
in the EMGpara%max signal.  This variability was influenced predominantly 
by variation in maxEMGpara.  Although previous studies have suggested that, 
in order to successfully interpret EMGpara data obtained on different 
occasions, the EMGpara signal must be normalised to that obtained during a 
maximal manoeuvre (EMGpara%max) to account for differences in electrode 
placement and relative skin to muscle geometry [172, 192, 198, 199], the 
data contained within this thesis would appear to contradict this.   
 
Given these data regarding the increased variability of EMGpara%max, as 
well as the apparent utility of the raw EMGpara signal, it would appear that 
the raw EMGpara signal warrants further investigation.  EMGpara can be used 
for within-occasion assessment of change without requiring normalisation 
(for example during assessment of bronchodilator response, or in airway 
challenge testing), but in order to allow assessment of disease severity or 
longitudinal monitoring of individual subjects, further data will be required 
regarding the reproducibility of the resting EMGpara signal.  That a significant 
difference was seen between raw EMGpara from children with asthma or CF 
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and age-matched data from healthy subjects supports further investigation 
of the raw signal.  Furthermore, the use of raw EMGpara allows the technique 
to be applied to a much wider range of individuals.  The substantial number 
of healthy children in whom maxEMGpara could not be obtained (27 of 81 
children), including children able to perform the manoeuvre but only with 
levels of signal contamination deemed unacceptable, as well as younger 
children, highlights the weakness of relying on maximal volitional efforts for 
the measurement of EMGpara.  Similarly, 20% of the subjects included in 
Chapter Six were unable to consistently perform maximal manoeuvres to a 
satisfactory standard.  The use of the raw EMGpara signal therefore would 
allow the clinical application of this technique not only to very young 
children and infants, but also to individuals with significant cognitive 
impairment, including children with severe developmental delay who may 
develop respiratory diseases such as bronchiectasis [339], and sedated 
patients in critical care environments.  Indeed, the Neurally Adjusted 
Ventilatory Assist (NAVA) technology already in use clinically utilises the 
raw EMGdi signal [340].  One major consideration when using the raw 
EMGpara signal is the effect of chest wall adiposity on the magnitude of the 
signal (as observed in Chapter Seven); with increasing obesity in the 
paediatric population [341, 342], this is likely to be an important matter and 
warrants further attention. 
 
8.4 General critique of the method 
 
Although the sample sizes within the clinical studies included within this 
thesis were larger than those in many previous studies, some studies, or 
subanalyses therein, remained underpowered, therefore limiting the 
conclusions that can be drawn from the data.  Larger sample sizes were not 
feasible for a number of reasons, primarily the time required for analysis of 
the EMGpara signal.  Development of automated analysis algorithms may 
facilitate larger studies. 
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The patient populations studied in Chapters Three and Six had relatively 
mild and/or well controlled respiratory disease, which may have impacted 
on the ability to detect relationships between variables.  Similarly, the 
magnitude of respiratory load induced by the methacholine challenge test 
was relatively small due to most of the subjects having normal or even 
supra-normal lung function at baseline. 
 
Inter-rater reproducibility of the EMGpara signal analysis was not assessed 
during the undertaking of these studies.  Although good inter-rater 
reliability has previously been demonstrated for respiratory EMG [172], this 
has not been assessed as part of the work undertaken within this thesis. 
 
8.5 Future work 
 
The successful use of EMGpara in the studies contained within this thesis in 
younger children who were unable to perform conventional measures of 
pulmonary function suggests that this population represents the first in 
which EMGpara should be explored clinically.  The data from Chapter Three 
demonstrated a fall in EMGpara occurring following administration of 
bronchodilator in pre-school children with asthma or wheeze.  
Bronchodilator reversibility testing is used in older children and adults as a 
marker of asthma control and can help to guide decisions regarding the 
need for medication changes.  To build on the data from Chapter Three, the 
utility of EMGpara-based bronchodilator reversibility testing in predicting 
treatment outcome in children with pre-school wheeze commenced on 
preventer medication could be evaluated.  We would hypothesise that 
children with a significant reduction in EMGpara following bronchodilator 
administration would be more likely to benefit from inhaled corticosteroids, 
and we propose a study design whereby the ability of the EMGpara 
reversibility test to predict clinical improvement would be evaluated using 
receiver-operator characteristic analysis. 
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The data from Chapter Six indicate that EMGpara may have promise in 
monitoring patients hospitalised with an acute respiratory illness.  This 
thesis has demonstrated that EMGpara can be undertaken in subjects who are 
either unable to perform conventional measures of pulmonary function.  
Infants with bronchiolitis represent such a group.  One-third of all infants 
are thought to develop bronchiolitis within the first year of life, and 
approximately nine percent of these will require hospitalisation, although 
this rate is higher in infants with pre-existing medical conditions [2, 343].  
Rapid clinical deterioration can occur in some infants and EMGpara may 
represent a method for identifying this deterioration, thereby allowing 
earlier escalation of care and possibly improving outcomes. 
 
The non-volitional nature of the technique also holds promise in areas such 
as intensive care.  Neurally adjusted ventilatory assist (NAVA), whereby the 
delivered ventilatory support is titrated according to the magnitude of the 
EMGdi signal [340], has been in clinical use for a number of years.  However, 
NAVA utilise the EMG signal from the diaphragm and therefore necessitates 
the use of an oesophageal catheter, and can only be used in conjunction with 
the NAVA ventilator, limiting flexibility and applicability of the technique.  
Accurately predicting extubation outcome and optimising weaning of 
ventilatory support present significant and important clinical problems in 
paediatrics [344].  As a marker of respiratory load relative to capacity, 
EMGpara may have potential in informing decisions regarding ventilator 
weaning and readiness for extubation, as well as guiding the need for post-
extubation respiratory support.  The non-invasive nature of the technique 
and independence from any other equipment makes it well suited to brief 
measurements rather than the ongoing monitoring offered by the NAVA 
system.  Future studies should evaluate the feasibility of performing EMGpara 
measurements within the paediatric intensive care environment, as well as 
the response of the EMGpara signal to changes in ventilatory support, with a 
view to considering the technique as a potential predictor of extubation 







The data within this thesis have demonstrated that EMGpara is sensitive to 
change in respiratory load in a range of clinical scenarios.  It is a feasible tool 
for use in populations in whom assessment of pulmonary function has, to 
date, been difficult to objectively assess.  Although conducted in adult, rather 
than paediatric populations, the data obtained during methacholine 
challenge testing highlights the complexity of the pathophysiological 
changes occurring in obstructive lung disease and may help to explain the 
lack of clear relationships observed between EMGpara and existing 
conventional measures of pulmonary function in the paediatric studies.  
Technical aspects of EMGpara signal acquisition have been explored and, 
together with differences observed between the EMGpara signals obtained 
from healthy children and those with asthma and CF, the use of the raw 
EMGpara signal has been supported, opening up the use of this technique to 
virtually any patient population. 
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